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Background 
Although recognized for centuries, the association between tuberculosis (TB) and 
diabetes mellitus (DM) was forgotten with the discovery of efficient treatments. In the 
last decade, the prevalence of DM has dramatically increased, particularly in low- and 
middle-income countries experiencing a high burden of TB, leading to a new interest 
in this association. DM increases TB risk while TB, as an infectious disease, leads to 
hyperglycemia. The relationship between TB and DM has been poorly studied in Sub-
Saharan Africa, where the high incidence of TB is associated with HIV infection. 
Concentration of vitamin D is inversely associated with TB and DM, and it has been 
suggested that low vitamin D could mediate some of the association between TB and 
DM. DM affects the immune response to TB, but the precise mechanisms underlying 
this association are not clear.  
To address this issue of high public health relevance, we undertook a project on the 
association between TB, DM and HIV in Tanzania. The project had three major 
components: 
(1) Assessing the association of TB and its outcome with the presence and persistence 
of hyperglycemia in Tanzania, using three different DM screening tests. 
(2) Describing the association between vitamin D, TB and DM. 
(3) Studying the immunological features underlying TB and DM comorbidity in sub-
Saharan Africa and testing the hypothesis of delayed adaptive immune response with 
increasing glycemia. 
The overall aim of the project was to improve knowledge on the dynamic interaction 
between TB and DM in an African setting with high HIV prevalence by integrating a 
longitudinal component into the case-control study.  
Methods 
A case-control study with longitudinal follow-up of cases was conducted in Dar es 
Salaam. Consecutive adults with new active TB were included and followed up for five 
months after the start of anti-TB treatment. Healthy controls, matched by age and sex 
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to TB cases, were recruited among volunteering adults accompanying patients to the 
outpatient departments of the same hospitals. Exclusion criteria were a biological 
relationship to TB case, TB history, symptoms or signs of TB, other acute infection or 
major trauma within the last three months. All underwent 25-hydroxyvitamin D 
(25(OH)D) measurement and DM screening tests (fasting glucose (FCG), 2-hour 
capillary glucose after standard oral glucose tolerance test (2h-CG) and glycated 
hemoglobin (HbA1c)) at enrolment and TB patients were again tested after five months 
of TB treatment. Data on the outcome of TB (treatment failure, death, lost to follow-up) 
were collected. 
For the nested immunological study, four groups of HIV negative patients were 
included: i) active TB without DM, ii) active TB with DM, iii) latent TB patients without 
DM and iv) latent TB patients with DM. Latent TB patients were selected among the 
healthy volunteering adults, as well as among diabetic patients attending the DM clinic 
in the participating hospitals. Exclusion criteria for groups iii and iv were past TB history 
and symptoms or signs of active TB. Peripheral blood mononuclear cells were 
stimulated with Mycobacterium tuberculosis (Mtb)-specific peptide pools and live 
Mycobacterium bovis BCG and then analysed by polychromatic flow cytometry for Th1, 
Th2, Th9 and Th17 cytokine production. Cell culture supernatants were analysed by 
Luminex® for 34 cytokines and chemokines. 
Findings 
At enrolement, DM prevalence was significantly higher among TB patients (N=539; 
FCG>7mmol/L: 4.5%, 2-hCG>11mmol/L: 6.8% and HbA1c>6.5%: 9.3%) compared to 
controls (N=496; 1.2%, 3.1% and 2.2%). However, the association between 
hyperglycemia and TB disappeared after TB treatment (aOR(95% CI) at enrolment vs 
follow-up: FCG 9.6(3.7-24.7) vs 2.4(0.7-8.7); 2-hCG 6.6(4.0-11.1) vs 1.6(0.8-2.9); 
HbA1c 4.2(2.9-6.0) vs 1.4(0.9-2.0)). FCG hyperglycemia at enrolment was associated 
with TB treatment failure or death (aOR(95%CI) 3.3(1.2-9.3). 
The prevalence of 25(OH)D insufficiency (25(OH)D<75nmol/l) was not statistically 
different between TB patients and controls (25.8% versus 31.0%; p=0.22). But the 
association between 25(OH)D insufficiency and TB was modified by hyperglycemia 
(pinteraction=0.01). Patient with vitamin D insufficiency were only at higher risk for TB in 
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the presence of underlying hyperglycemia. The OR (95%CI) for TB risk in patients with 
vitamin D insufficiency and hyperglycemia was 4.94(1.16-21.0) versus 0.68(0.39-1.17) 
for patients with vitamin D insufficiency and normoglycemia  where normoglycemia and 
normal vitamin D were the reference category.  
Patients with active TB and DM had a lower frequency of INF-γ CD4+ T cells and a 
lower proportion of CD4+ T cells producing both TNF-α and IFN-γ after live M. bovis 
BCG but not after Mtb-specific peptide pool stimulation, compared to normoglycemic 
TB patients. A negative correlation between INF-γ or TNF-α CD4+ T cell frequency and 
increasing glycemia was observed in the context of live M. bovis BCG stimulation only.  
Conclusions 
Transient hyperglycemia is frequent during TB, and DM needs confirmation after TB 
treatment. However, DM screening at TB diagnosis gives the opportunity to detect 
patients at risk of adverse outcome. 
25(OH)D insufficiency seams to increase the risk of TB only if associated with 
hyperglycemia. DM patients living in high TB burden settings might benefit from 
preventive vitamin D supplementation. 
The immunological findings suggest that DM might affect Mtb-specific CD4+ T cell 
immune responses at the level of reduced antigen processing and presentation, a 
defect that could be compensated by metformin. 
The results of the study are of public health and clinical utility. First, they lend support 
to the integration of care between TB and DM programs. Second, they imply that, at 
the time of TB diagnosis, patients should be screened for hyperglycemia using cost-
effective fasting glucose tests. Treatment of hyperglycemia should be initiated to 
improve TB outcome. Third, before initiation of long-term DM treatment, DM diagnosis 
must be confirmed after the resolution of TB. Finally, in the absence of evidence for a 
strong contribution of DM to TB risk in this African setting with high HIV prevalence, 
DM patients should not be screened for TB with expensive test. DM physicians and 
patients should rather be trained for recognizing TB symptoms and signs as a cost-
effective way to recognize TB early. 
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Zusammenfassung 
Hintergrund 
Obwohl die Verknüpfung zwischen Tuberkulose (TB) und Diabetes mellitus (DM) seit 
langem bekannt ist, wurde sie doch mit der Entdeckung von wirksamen Therapien 
vergessen.  In Ländern mit hohen Anzahlen von Tuberkulosefällen, also vor allem in 
den Ländern mittleren und niedrigen Einkommens, stieg die Prävalenz von DM in den 
letzten Jahren stark an und das Interesse an der vergessenen Verknüpfung wurde neu 
geweckt. DM erhöht das Risiko für Erkrankung an TB, und TB wiederum, als 
Infektionskrankheit,  führt zu hohen Blutzuckerwerten. Das Verhältnis zwischen TB und 
DM wurde bisher wenig in Afrika südlich der Sahara erforscht. In dieser Region beruht 
die hohe Prävalenz von TB vor allem auf HIV Infektion.  Die Plasmakonzentration von 
Vitamin D ist invers mit TB und DM korreliert; es wurde also stipuliert, dass Vitamin-D 
Mangel teilweise für die Verbindung von TB und DM verantwortlich sein könnte. DM 
beeinflusst die Immunantwort auf TB Infektion, aber der genaue Mechanismus ist 
bisher unklar. Um diesen wichtigen Fragen nachzugehen, erforschte unser Projekt den 
Zusammenhang   zwischen TB, DM, und HIV in Tansania. Das Projekt bestand aus 
den folgenden drei Hauptteilen: 
(1) Die Erforschung des Zusammenhangs zwischen TB-Infektion /-Outcome  und 
erhöhten Blutzuckerwerten (einmalig oder anhaltend) mit Hilfe von drei 
verschiedenen DM Screening Tests.  
(2) Die Beschreibung des Zusammenhangs zwischen Vitamin D, TB und DM 
(3) Die Untersuchung der immunologischen Merkmale, die der TB-DM-
Komorbidität in Afrika südlich der Sahara unterliegen. Dabei testeten wir auch 
die Hypothese, dass zu hohe Blutzuckerwerte zu einer verzögerten 
angepassten Immunreaktion (delayed adapative immune response) führen. 
Das Hauptziel dieses Projektes war, im afrikanischen Kontext mit hoher HIV-Prävalenz 
die dynamische Interaktion zwischen TB und DM, durch die Integration einer 
Längsschnitt-Studien Komponente in eine Fall-Kontroll-Studie, weiter zu beleuchten.   
 
Methoden 
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Wir führten eine Fall-Kontroll-Studie mit Längsschnitt Follow-Up in Dar es Salaam 
durch. Erwachsene mit TB-Neuinfektion wurden konsekutiv in eine fünf-monatige 
Langzeitstudie aufgenommen. Anfangspunkt war hierbei der Start der TB-Behandlung.  
Gleichalterige und gleichgeschlechtliche, gesunde Kontrollen wurden unter freiwilligen 
Angehörigen rekrutiert, die PatientInnen zur Krankenhausambulanz begleiteten. 
Ausschlusskriterien für Kontrollen waren: Blutsverwandtschaft zu den Fällen, TB-
Krankengeschichte, Anzeichen von TB–Infektion sowie andere Infektionen oder ein 
schwerwiegender Unfall in den letzten drei Monaten. Bei allen Teilnehmern wurde bei 
Studienaufnahme 25(OH)Vitamin D3 Messung und Screening für DM durchgeführt 
(Nüchtern-Blutzucker (FCG), Zweistunden-Blutzucker nach Standard 
Glukosetoleranz-Test (2h-CG) und Glykohämoglobin (HbA1c)). Bei den TB 
PatientInnen wurden die gleichen Messungen nach 5 Monaten TB-Behandlung 
wiederholt, sowie Daten zum TB-Behandlungsergebnis erhoben (Therapieversagen, 
Tod, „lost to follow-up“).  
Für die immunologische, „Nested“ Fall-Kontroll-Studie, schlossen wir HIV-negative 
PatientInnengruppen mit vier verschiedenen Merkmalskombinationen ein: i) aktive TB 
ohne DM, ii) aktive TB mit DM, iii) latente TB ohne DM und iv) latente TB mit DM. Die 
latenten TB-PatientInnen rekrutierten unter gesunden Freiwilligen und unter 
DiabetespatientInnen, die die Diabetesklinik der teilnehmenden Krankenhäuser 
besuchten. Ausschlusskriterien für die Gruppen iii und iv waren: TB-Infektion in der 
Krankengschichte, und Anzeichen einer aktiven TB-Infektion. Mononukleäre Zellen 
des peripheren Blutes wurden dann mit Mycobacterium tuberculosis(Mtb)-spezifischen 
Peptid-Pools sowie lebend Mycobacterium bovis-BCG stimuliert und dann auf Th1-, 
Th2-, Th9- and Th17- Zytokinproduktion mittels polychromatischer 
Durchflusszytometrie untersucht. Desweiteren wurden in Zellkultur-Überstände 34 
Zytokine und Chemokine mittels Luminex® bestimmt.  
Ergebnisse 
Zum Zeitpunkt der Rekrutierung war die Prävalenz von DM signifikant höher bei TB-
PatientInnen (N=539; FCG>7mmol/L: 4.5%, 2-hCG>11mmol/L: 6.8% and 
HbA1c>6.5%: 9.3%) verglichen mit Kontrollen (N=496; 1.2%, 3.1% and 2.2%). In der 
Langzeitstudie bei TB-PatientInnen, verschwand diese Verbindung zwischen erhöhten 
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Blutzuckerwerten und nach fünfmonatiger TB-Therapie: FCG 9.6(3.7-24.7) vs 2.4(0.7-
8.7); 2-hCG 6.6(4.0-11.1) vs 1.6(0.8-2.9); HbA1c 4.2(2.9-6.0) vs 1.4(0.9-2.0)). Erhöhter 
FCG zum Zeitpunkt der Rekrutierung war hier auch mit Therapieversagen und Tod 
assoziiert (aOR(95%CI) 3.3(1.2-9.3). 
Die Prävalenz von 25(OH)Vitamin D3-Mangel (25(OH)D<75nmol/l) war nicht 
signifikant unterschiedlich zwischen TB-PatientInnen und Kontrollen (25.8 versus 
31.0%; p=0.22). Jedoch wurde die Assoziation zwischen 25(OH)Vitamin D3-Mangel 
und TB durch Hyperglykämie modifiziert (pinteraction=0.01):  PatientInnen mit 
25(OH)Vitamin D3-Mangel hatten nur dann ein erhöhtes TB-Infektionsrisiko, wenn 
gleichzeitig Hyperglykämie vorlag: Die OR (95% CI) für TB-Infektion waren: 4.94(1.16-
21.0) für PatientInnen Hyperglykämie und Vitamin-D Mangel, 0.68 (0.39-1.17) für 
PatientInnen mit Normoglykämie und Vitamin-D Mangel, jeweils verglichen zu 
PatientInnen mit Normoglykämie als und normalen Vitamin-D Werten. Nach 
Stimulierung mit lebend M. bovis- BCG, aber nicht mit Mtb-spezifischen Peptid-Pool, 
hatten PatientInnen mit aktiver TB und DM, im Vergleich zu PatientIennen ohne TB 
und Normoglykämie, weniger  INF-γ CD4+ T-Zellen  und einen niedrigeres Prozent an 
TNF-α- und IFN-γ-produzierenden CD4+ T-Zellen.  Nach Stimulierung mit lebend M. 
bovis- BCG stellten wir eine negative Korrelation zwischen INF-γ- TNF-α CD4+ T-Zell 
Häufigkeit und ansteigenden Blutzuckerwerten.   
Schlussfolgerung 
Vorübergehend erhöhte Blutzuckerwerte kommen häufig bei TB-Infektion vor. Eine 
DM-Diagnose muss daher nach Therapiebeginn nochmals bestätigt werden. Jedoch 
bietet DM-Screening bei TB Diagnosestellung die Möglichkeit, PatientInnen mit 
erhöhtem Riskiko für Komplikationen zu identifizieren.  
25(OH)Vitamin D3-Mangel, wenn mit Hyperglykämie kombiniert, erscheint das Risiko 
für TB-Infektion zu erhöhen. DM PatientInnen, in deren Umfeld ein hohes TB-
Übertragungsrisiko herrscht, könnten also eine Vit-D Nahrungsergänzung 
zugutekommen.  
Die immunologischen Ergebnisse legen nahe, dass DM die Mtb-spezifische CD4+ T-
Zell Immunantwort beeinflusst, nämlich über eine verminderte Antigenprozessierung 
und –präsentation. Dieser Defekt könnte durch Metformin kompensiert werden. 
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Die Ergebnisse dieser Studie sind von klinischer Bedeutung und von Relevanz für das 
öffentliche Gesundheitswesen. Zum ersten befürworten sie die Vernetzung von TB-
und DM-Therapieprogrammen. Des Weiteren sollten TB PatientInnen bei 
Therapiebeginn, mit Hilfe der kosteneffizienten Nüchtenblutzuckermessung, auf 
Hyperglykämie untersucht werden. Eventuelle Hyperglykämie sollte dann behandelt 
werden, um die TB-Therapieergebnisse zu verbessern. Darüber hinaus sollte eine 
definitive DM Diagnose, und somit die Indikation zur Langzeitbehandlung, erst nach 
Abschluss der TB-Behandlung gestellt werden. Schliesslich, da es keine Evidenz dafür 
gibt, dass DM signifikant das TB-Ansteckungsrisiko im afrikanischen Kontext mit hoher 
HIV-Prävalenz erhöht, sollten DM PatientInnen nicht systematisch mit teuren 
Testvefahren auf TB untersucht werden. Als kosteneffizientere Massnahme sollten 
vielmehr DM behandelnde Ärzte in der Erkennung von klinischen TB Anzeichen 
ausgebildet werden.  
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Muhtasari 
Historia 
Ingawa unajulikana kwa karne nyingi, uhusiano kati ya kifua kikuu na kisukari 
ulisahaulika tangu ugunduzi wa tiba fanisi.  Kwa kipindi cha karne iliopita, kiwango cha 
ugonjwa wa kisukari kimeongezeka kwa kasi, hususani katika nchi zenye kipato cha 
chini na kati zikikumbwa na kiwango kikubwa cha kifua kikuu, na kuleta fikra mpya 
katika uhusiano huu. Kisukari huongeza hatari ya kupata kifua kikuu, huku kifua kikuu 
kama ugonjwa ambukizi , huleta hali ya kuongezeka kiwango cha sukari katika damu. 
Uhusiano kati ya kifua kikuu na kisukari haujachunguzwa vizuri katika nchi za kusini 
mwa Afrika, ambapo kiwango kikubwa cha kifua kikuu kinahusiana na maambukizi ya 
VVU. Kiwango cha vitamin D kimehusishwa na kifua kikuu na kisukari, na imefikiriwa 
kuwa kiwango kidogo cha vitamin D kunaweza elezea baadhi ya uhusiano kati ya kifua 
kikuu na kisukari. Kisukari kinaathiri kinga dhidi ya kifua kikuu, lakini njia haswa 
inayosababisha hili haijajulikana vizuri bado. 
Ili kukabiliana na suala hili lenye umuhimu wa juu katika afya ya umma, tulifanya 
uchunguzi kuangalia uhusiano kati ya kifua kikuu, kisukari na maambukizi ya VVU 
Tanzania. Uchunguzi ulikuwa una maeneo makuu matatu: 
Kutathmini uhusiano wa kifua kikuu na matokeo yake katika uwepo na usugu wa 
kiwango cha juu cha sukari katika damu Tanzania, tukitumia vipimo vitatu tofauti vya 
kuchunguza kisukari 
Kuelezea uhusiano kati ya vitamini D, kifua kikuu na kisukari 
Kuchunguza misingi ya kinga pale ambapo kifua kikuu na kisukari hutokea kwa pamoja 
katika nchi za kusini mwa Sahara na kupima dhana ya kuchelewa kujitokeza kwa kinga 
kiwango cha sukari kiongezekapo katika damu 
Kwa ujumla, lengo la utafiti huu lilikuwa ni kuboresha maarifa juu ya muingiliano wa 
nguvu kati ya kifua kikuu na kisukari katika mazingira ya Africa yenye kiwango kikubwa 
cha maambukizi ya Ukimwi kwa kuingiza mfumo endelevu katika tafiti za kulinganisha 
mgonjwa (kesi) na mtu mwenye sifa zote sawa na mgonjwa isipokuwa ugonjwa 
wenyewe (kontrol). 
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Mbinu 
Uchunguzi wa kesi na kontrol, uliokuwa ukiwafuatilia kesi ulifanyika Dar es Salaam. 
Wagonjwa wapya ambao ni watu wazima waliogundulika wana ugonjwa wa kifua kikuu 
waliingizwa katika utafiti na kufuatiliwa kwa kipindi cha miezi mitano baada ya kuanza 
matibabu ya kifua kikuu.  Kontrol wenye afya nzuri waliofanana kwa umri na jinsia na 
kesi za kifua kikuu na waliojitolea kuingia katika utafiti, walichaguliwa miongoni mwa 
watu wazima waliowasindikiza wagonjwa wasiolazwa kupata huduma za hospitali. 
Wafuato hawakuingizwa katika utafiti; waliokuwa na uhusiano wa kibiolojia na kesi 
(mgonjwa wa kifua kikuu), waliowahi kuugua ugonjwa wa kifua kikuu, wenye dalili au 
viashiria vya ugonjwa wa kifua kikuu, na wenye magonjwa mengine ya dharura au 
waliohusika na ajali kubwa katika kipindi cha miezi mitatu iliopita. Wote walifanyiwa 
vipimo vha 25-hydroxyvitamini (25(OH)D) na uchunguzi wa kisukari (kipimo cha sukari  
wakiwa wamefunga kula – fasting glucose FCG),  kipimo cha kuangalia kiwango cha 
sukari masaa mawili baada ya kunywa sukari  iliyopimwa kwa kiwango maalum (2h-
CG)  na kipimo cha kuangalia kiwango cha sukari katika chembe chembe nyekundu 
za damu  (HbA1c) katika hudhurio la kwanza, huku wagonjwa wa kifua kikuu 
wakipimwa tena miezi 5 baada ya kuanza tiba ya kifua kikuu. Matokea ya ugonjwa wa 
kifua kikuu (waliofeli tiba, waliokufa, waliopotea) yalikusanywa. 
Katika utafiti wa kuangalia kinga, uliofanyika ndani ya utafiti huu, wagonjwa wa kifua 
kikuu wasiokuwa na maambukizi ya virusi vya ukimwi waligawanywa kulingana na 
kuwepo au kutokuwepo kwa kisukari na maambukizi ya kifua kikuu. Hawa 
waliochaguliwa miongoni mwa watu wazima wenye afya nzuri waliojitolea kushiriki 
katika utafiti pamoja na wagonjwa wa kisukari waliokuwa wakihudhuria kliniki ya 
kisukari miongoni mwa hospitali zilizohusika na utafiti. Wafuato hawakuingizwa katika 
utafiti; waliokuwa na maambukizi ya ukimwi, waliowahi kuugua kifua kikuu na wenye 
dalili au viashiria vya ugonjwa wa kifua kikuu. Seli za damu (PBMCs) zilifanyiwa 
uchunguzi kwa kuzichochea na vijidudu vya Mycobacterium tuberculosis (Mtb) na 
vijidudu hai vya Mycobacterium bovis BCG na kuchunguzwa kwa kutumia kipimo cha 
polymorphic flow cytometry kuangalia uzalishaji wa cytokini Th1, Th2, Th9 na Th17. 
Seli zilizooteshwa zilichunguzwa kwa kutumia kipimo cha Luminex kuangalia cytokini 
34 na kemokini. 
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Matokeo 
Wakati wa ugunduzi wa ugonjwa wa kifua kikuu, uwingi wa kisukari ulikuwa juu zaidi 
kati ya wagonjwa wa kifua kikuu (N=539; FCG>7mmol/L:4.5%, 2-
hCG>11mmol/L:6.8% na HbA1c>6.5%:9.3%) ukilinganisha na kontroli (N=496; 1.2%, 
3.1% na 2.2%). Hata hivyo, uhusiano kati ya kiwango cha juu cha sukari na kifua kikuu 
ulitoweka baada ya matibabu ya kifua kikuu (aOR(95% CI) wakati wa kujiandikisha 
katika utafiti huu na kipindi cha mahudhurio ya ufuatiliaji FCG 9.6(3.7-24.7) vs 2.4(0.7-
8.7); 2-hCG 6.6(4.0-11.1) vs 1.6(0.8-2.9); HbA1c 4.2(2.9-6.0) vs 1.4(0.9-2.0). Kiwango 
cha juu cha sukari wakati wa kujiandikisha katika utafiti huu kulihusiana na kufeli kwa 
matibabu ya kikua kikuu au kifo (aOR(95%CI) 3.3(1.2-9.3). 
Kiwango cha upungufu wa vitamini D (25(OH)D<75nmol/l) haukua tofauti kitakwimu 
kati ya wagonjwa wa kifua kikuu na wasio na kifua kikuu (25.8 versus 31.0%; p=0.22). 
Lakini uhusiano kati ya upungufu wa vitamini D  na kifua kikuu ulibadilika kiwango cha 
sukari kilipokuwa juu (pinteraction=0.01). Upungufu wa vitamini D ulihusiana na hatari ya 
kifua kikuu pale ambapo kiwango cha sukari kilikuwa juu katika damu (OR(95%CI): 
4.94(1.16-21.0)), lakini si wakati kiwango cha sukari katika damu kiwapo kawaida 
(OR(95%CI): 0.68(0.39-1.17)) ukifananisha na washiriki wasiokuwa na kiwango cha 
juu cha sukari na upungufu wa vitamini D. 
Wagonjwa wenye ugonjwa wa kifua kikuu walikuwa na uwingi mdogo zaidi wa seli za 
INF-γ CD4+T na kiasi kidogo zaidi cha seli za  CD4+ T zinazotengeneza TNF-α na IFN-
γ baada ya kuchochea na  vijidudu hai vya M. bovis BCG lakini sio baada ya kuchochea 
na  Mtb. Uusiano hasi kati ya uwingi wa seli za INF-γ au TNF-α CD4+T na kuongezeka 
kwa kiwango cha sukari katika damu ulionekana tu wakati wa kuchochea na vijidudu 
hai M. bovisBCG. 
Hitimisho 
Kuongezeka kwa kisuakari katika damu kwa muda mfupi kunajitokeza mara kwa  mara 
wakati wa kifua kikuu, na ugonjwa wa kisukari unahitaji uthibitisho baada ya tiba ya 
kifua kikuu. Hata hivyo, uchunguzi wa kisukari wakati wa ugunduzi wa kifua kikuu 
unatoa fursa ya kugundua wagonjwa wenye hatari ya kupata matokeo mabaya. 
Upungufu wa 25(OH)D unaelekea kuongeza hatari ya kifua kikuu  kama tu ukihusiana 
na kiwango cha juu cha sukari katika damu. Wagonjwa wa kisukari wanaoishi katika 
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mazingira yenye kiwango cha juu cha maambukizi ya kifua kikuu wanaweza pata faida 
kwa kupatiwa nyongeza ya vitamini D. Matokeo ya utafiti wa kinga unaashiria kwamba 
kisukari kinaweza athiri kinga ya CD4+ T inayojitokeza kwa Mtb tu katika kiwango cha 
kupungua kwa usindikaji na uonekanaji wa antijeni, kasoro inayoweza fidiwa na dawa 
ya metformin. 
Matokeo ya utafiti huu ni katika matumizi ya afya ya umma na tiba. Kwanza, yanatoa 
msaada katika ushirikiano wa programu za  huduma za kifua kikuu na kisukari. Pili, 
huashiria kwamba, wakati wa ugunduzi wa kifua kikuu, wagonjwa hupaswa kufanyiwa 
uchunguzi wa kiwango cha sukari kwa kutumia vipimo vha gharama nafuu vha kupima 
sukari baada ya kufunga kula. Matibabu ya kiwango cha juu cha sukari yanatakiwa 
yaanzishwe ili kuboresha matokea ya kifua kikuu. Tatu, kabla ya kuanzisha matibabu 
ya muda mrefu ya kisukari, ugunduzi wa kisukari lazima uhakikiwe baada ya kupona 
ugonjwa wa kifua kikuu. Na mwisho, kukosekana kwa uhusiano wa nguvu kati ya 
kisukari na hatari ya kifua kikuu katika mazingira haya ya Africa yenye uwingi wa juu 
wa maambukizi ya virusi vya ukimwi, wagonjwa wa kisukari hawapaswi kufanyiwa 
uchunguzi wa kisukari kwa kutumia vipimo vya gharama ya juu. Madaktari wa kisukari 
pamoja na wagonjwa wapatiwe mafunzo ya kugundua dalili na viashiria vya kifua kikuu 
kama njia ya gharama nafuu ya kugundua kifua kikuu mapema. 
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1 Introduction 
Non-communicable diseases (NCD) are chronic diseases that are not passed from 
person to person contrary to communicable diseases which are acute or chronic 
infections. There are four main groups of NCDs: cardiovascular diseases, cancers, 
chronic respiratory diseases and diabetes mellitus (DM). As a result of economic 
transition and resulting increase in life expectancy, globalization and rapid urbanization 
leading to lifestyle changes, NCDs are increasing worldwide and are the leading cause 
of death globally (68%) with three quarter of them occurring in low- and middle-income 
countries. The rising burden of these NCDs is one of the major health and development 
challenges of the 21st century, particularly for low- and middle-income countries. At the 
same time, socioeconomic and environmental factors, international travel and 
migration increase the spread of communicable infectious diseases. Non-
communicable and communicable diseases increasingly co-occur geographically and 
interact with each other. Interactions between non-communicable and communicable 
diseases have been recognized for centuries but the interest in this association 
disappeared with the discovery of effective treatment for both types of diseases such 
as antibiotic and antidiabetic drugs. The importance of these interactions is reemerging 
as a consequence of the NCD increase, particularly in low- and middle-income 
countries. The reciprocal link between infections and DM is well known. On the one 
hand, stress related to inflammation as a result of infection induces hyperglycemia and 
on the other hand, DM with chronic hyperglycemia weakens the immune system and 
increases susceptibility to infections and also worsens their outcome. Most data are 
from developed countries which do not experience the same variety of infectious 
diseases than developing countries. There is a need to improve knowledge on the 
consequences of the NCD increase in low- and middle-income countries. 
This PhD work focused on two diseases which depict well how a convergence of 
different type of illnesses can become a threat beyond the effect of each of them 
separately. DM is one of the most common NCDs, it is on the rise all over the world 
and is emerging in Africa. We studied its interrelation with tuberculosis (TB) in a 
longitudinal manner.  
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1.1 Diabetes Mellitus 
DM is a chronic metabolic illness mainly characterized by hyperglycemia which leads 
to long-term complications (microvascular disease, such as nephropathy, retinopathy, 
neuropathy, and macrovascular disease, such as cardiovascular disease and stroke). 
Different types of DM have been described. Type 2 DM accounts for over 90% of DM 
cases in the United States, Canada, Europe as well as in sub-Saharan Africa (ADA, 
2014, Hall et al., 2011). Type 2 DM results from a progressive insulin secretion defect 
on the background of insulin resistance and more commonly occurs with adult-onset 
and in association with obesity and physical inactivity. Type 1 DM accounts for another 
5 to 10% in high-income countries and usually affects children or young adults. It 
results from autoimmune pancreatic β-cell destruction, leading to absolute insulin 
deficiency and, therefore, to an absolute requirement for insulin therapy. Type 1 DM is 
rare in sub-Saharan Africa, probably because these people die as a consequence of 
lack of insulin access (Hall et al., 2011, Swai et al., 1993). Gestational DM occurs 
during pregnancy and can lead to serious health risks to the mother and her infant 
(IDF, 2013). The remainder DM are due to other causes such as genetic defects, 
pancreas diseases, endocrinopathies and drugs side effects (e.g. Lamivudine, 
protease inhibitors and efavirenz, currently used in HIV treatment) (Paula et al., 2013).  
Type 2 DM is increasing rapidly worldwide as a consequence of energy- and 
carbohydrate-rich diets and increasingly sedentary lifestyles (2014). A higher 
prevalence of dysglycemia is observed in the HIV-infected population. On top of 
antiretroviral drugs side effects, HIV-specific mechanisms include immune dysfunction 
with increased inflammatory response leading to a higher prevalence of metabolic 
syndrome, dyslipidemia and dysglycemia (Paula et al., 2013). 
Currently, the global DM prevalence is estimated at 8.3% (387 million people, most of 
them aged between 40 and 59) and is expected to rise beyond 592 million in less than 
25 years. The regional DM prevalence in Africa is estimated at 5.1%, and is expected 
to double by 2035. The African region has the highest proportion of undiagnosed DM 
(63%), and in this region DM accounts for 8.6% of all deaths (IDF, 2013, Shaw et al., 
2010). In sub-Saharan Africa, differences in DM prevalence have been reported 
between urban and rural areas and between ethnic communities, with the highest 
prevalence reported within the Indian community in Tanzania (7.1-9.1%) and the 
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lowest prevalence in indigenous black populations (1.1-5.3%) (Idemyor, 2010, 
Ramaiya et al., 1995, Stevenson et al., 2007b, Unwin et al., 2010). 
1.2 Tuberculosis 
TB is caused by an intracellular bacteria belonging to the Mycobacterium tuberculosis 
(Mtb) complex and is transmitted from person to person though infectious particles 
which are aerosolized by coughing or talking. In the majority of cases, the infection is 
either eradicated by the host response or contained as a latent infection with a 10% 
lifetime risk of reactivation and development of clinical TB (13 per 1000 person-years) 
(Frieden et al., 2003). Factors associated with progression to active TB comprise 
extremes of age, malnutrition, smoking, DM and immunosuppression, HIV infection 
being the strongest risk factor (20-fold to 40-fold increase). The most common clinical 
presentation of active TB is lung infection, extrapulmonary disease (lymph node, 
central nervous system, bone, joint, genitourinary system) accounting for around 20% 
of disease in HIV-negative patients (Frieden et al., 2003).  
In 2000, the stop TB partnership, an international body involved in the fight against TB, 
set a strategic plan linked to the millennium development goals with the targets to 
reduce the global burden of TB disease by 50% relative to 1990 levels by 2015 and to 
eliminate TB by 2050. As a consequence, the global burden of disease is decreasing, 
but not fast enough. TB elimination is challenged by the duet TB/HIV and by multidrug-
resistant TB (MDR-TB, caused by Mtb strains resistant to at least two of the most 
powerful first-line anti-TB drugs, isoniazide and rifampicine). TB remains a global 
health problem with 9.6 million of people who developed TB in 2014, 12% of them 
being HIV infected Almost three-quarters of these HIV-positive cases are in Africa, 
where 32% of TB patients are screened positive for HIV (WHO, 2015). Resistant TB is 
arising due to improper use of antibiotics during TB treatment, particularly in areas with 
week TB control programs. Globally, MDR-TB is detected in 3.3% of new TB cases 
and 20% of those previously treated for TB (WHO, 2015). In most African countries, 
levels of drug resistance among new cases remain low (<3%). 
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1.3 Association between tuberculosis and diabetes 
The last decade has experienced a global increase of DM, particularly in developing 
countries with a high TB burden. The convergence of these two ongoing epidemics 
has a potentially strong impact on TB surveillance and treatment (Stevenson et al., 
2007b). Two systematic reviews of the medical literature alerted the scientific 
community in 2007 and 2008, showing that DM doubles or triples the risk of TB 
compared with people without DM (Jeon and Murray, 2008, Stevenson et al., 2007a). 
The World Health Organization (WHO) and the International Union against TB and 
Lung Disease (The Union) established a framework which aims to guide national 
programs to establish a coordinated response to DM and TB in 2011 (Maurice, 2011). 
However, the prevalence of DM among patients with TB varies according to the setting. 
The highest proportion of people with DM among TB patients was observed in the 
Western Pacific (37%) and in India (25-32%) (Gupta et al., 2011, Viney et al., 2015, 
Viswanathan et al., 2012). In Africa, DM prevalence is generally lower than in other 
continents, to some degree also as a result of underdiagnosis. In contrast, both TB and 
HIV are very common on the African continent (Figure 1-1). 
 
Figure 1-1. Worldwide incidence of TB in 2011 (A), prevalence of HIV in 2011 (B) and DM in adults in 2008 
(C) (Adapted from (Marais et al., 2013)). 
Up to date, only four studies examined the association between the two diseases in 
sub-Saharan Africa. In Mwanza, Tanzania, DM prevalence was 16.7% among TB 
patients versus 9.4% in the control group. Interestingly, the association depended on 
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HIV status with an association only among HIV uninfected patients (Faurholt-Jepsen 
et al., 2011). In Uganda, DM prevalence was 8.5% among admitted TB patients and 
HIV infection was a protective factor against DM (Kibirige et al., 2013). Two additional 
studies, one in Benin and the other in Guinea-Bissau found a very low DM prevalence 
among patients with TB (1.9-2.8%) but did not analyze the interaction with HIV (Ade et 
al., 2015, Haraldsdottir et al., 2015). No study observed a synergistic 
immunosuppressive effect of HIV and DM on the incidence of active TB and the results 
point to the predominant effect of HIV on TB risk in African settings. However, the 
complex interplay between immunosuppression linked to HIV and DM cannot be 
analyzed cross-sectionally and needs further investigations.   
DM was also associated with an increased risk of failure and death during TB treatment 
(Baker et al., 2011). Sputum culture conversion rate after two to three months of TB 
therapy has been analyzed in different settings among diabetics and showed 
conflicting results (Alisjahbana et al., 2007, Dooley et al., 2009, Tatar et al., 2009). 
Several cross-sectional studies conducted in different settings showed an association 
between MDR-TB and DM but none of them was conducted in Africa (Fisher-Hoch et 
al., 2008, Gomez-Gomez et al., 2015, Magee et al., 2015, Rifat et al., 2014). 
For decades, DM screening has been based on plasma glucose criteria. As an 
infectious disease, TB can increase insulin resistance and lead to stress-induced 
hyperglycemia and to an overdiagnosis of DM during the acute phase of the disease 
(Gearhart and Parbhoo, 2006). The American Diabetes Association (ADA) and WHO 
recommend now the use of glycated haemoglobin (Hba1c) for diagnosing DM (ADA, 
2014, WHO, 2011a). Hba1c has several advantages over plasma glucose including 
greater convenience, since fasting is not required, and less day-to-day perturbations 
during periods of stress and illness. The half-life of Hba1c is also much longer than that 
of glucose, and reflects blood glucose concentrations over the course of about 3 
months. Hba1c measurement could therefore be a more reliable tool for diagnosing 
preexisting DM during acute TB and to assess the impact of DM on the risk and 
prognosis of active TB. Indeed, the normalization of glycemic status during TB 
treatment has already been described in small study samples (n=20-50) using oral 
glucose tolerance tests (Oluboyo and Erasmus, 1990, Singh et al., 1984).  
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1.4 Vitamin D as a potential link between tuberculosis and diabetes 
Vitamin D is generated in the skin after sun exposure and the dietary source of vitamin 
D is limited. Vitamin D deficiency was first described as the cause of rickets and 
osteomalacia. The importance of sufficient vitamin D level for musculoskeletal health 
is now well recognized. However, the vitamin D receptor is expressed in most cells in 
the body and a wide variety of vitamin D associated health outcomes have been 
described (Rosen, 2011). An inverse association between type 2 DM and poor vitamin 
D status has been described in several cross-sectional and prospective studies and in 
a meta-analysis of 21 prospective studies (Song et al., 2013). Several studies have 
also shown an association between low level of vitamin D and TB (Martineau, 2012). 
Indeed, vitamin D boosts the antimicrobial activity of human macrophages against Mtb, 
modulates adaptive response and affects pancreatic β-cell function (Hawn et al., 
2015). In monocytes, activation of Toll-like receptors (TLRs; pathogen recognition 
receptors) by mycobacteria induces expression of an enzyme which converts vitamin 
D into the bioactive form 1,25(OH)2D and upregulates vitamin D receptor. Then, 
vitamin D stimulates the receptor to induce cathelicidin expression which has both 
immunoregulatory and direct antimicrobial activity (Hawn et al., 2015, Schauber et al., 
2007). The association of vitamin D with both, TB and DM, suggests that vitamin D 
deficiency could mediate some of the association between TB and DM (Handel and 
Ramagopalan, 2010). A cross-sectional Indian study confirmed the association 
between vitamin D deficiency, TB and DM while another study conducted in China did 
not show any association (Chaudhary et al., 2013, Zhan and Jiang, 2015). 
Large trials of adjunctive vitamin D therapy during TB treatment have failed to show a 
significant acceleration of sputum culture conversion despite demonstration of 
enhanced resolution of inflammatory markers (Coussens et al., 2012, Daley et al., 
2015, Martineau et al., 2011b). Particular sub-groups of patients with lower levels of 
vitamin D, such as diabetic patients, may have a clinical benefit of vitamin D 
supplementation for TB treatment and prevention (Davies and Martineau, 2015).  
Up to date, no longitudinal study has described the interplay between vitamin D 
concentrations, DM status and TB (Figure 1-2).  
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Figure 1-2. Complex interaction between TB, DM, HIV and vitamin D deficiency. 
Figure 1-2 underlines the importance of a longitudinal analysis of these comorbidities 
as the causal relationship can be bidirectional. Our longitudinal study will explore the 
interplay of DM and TB in Tanzania, a setting with high HIV and TB prevalence. The 
present study will evaluate the role of low vitamin D level in the association between 
TB and DM. It will also assess the optimal method and timing of screening for DM in 
TB patients. By this way, it could improve the management of both, TB and DM and 
lead to the development of new recommendations regarding DM screening and 
management in this population. 
1.5 Diabetes and immune response to Tuberculosis 
DM is known to increase susceptibility to bacterial, fungal and viral infections through 
reduced innate and adaptive immune response, particularly in patients suffering from 
chronic hyperglycemia. Regarding innate response, polymorphonuclear cells and 
macrophages have impaired performance in the presence of hyperglycemia with 
decreased mobilization, chemotaxis, phagocytic activity and cytokine expression 
(Schuetz et al., 2011). Some studies demonstrated impaired T-cell functions 
characterized both by an aberrant regulation in the interplay between anti-inflammatory 
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and pro-inflammatory cytokines, as well as functional defects in the antigen-presenting 
cell compartment (Geerlings and Hoepelman, 1999, Schuetz et al., 2011). The 
negative effect of DM on immune responses could explain the higher co-morbidity with 
TB since it is well established that macrophages and CD4+ T helper type 1 lymphocytes 
play a major role in the immune defense mechanisms against TB. 
The pathophysiological mechanisms linking the two diseases are poorly understood. 
The effect of DM on immunity has been primarily attributed to hyperglycemia, but there 
is also a potential contribution of other factors associated to DM such as older age, 
obesity, vitamin D deficiency and other co-morbidities (Restrepo and Schlesinger, 
2013).  
The main port of entry of TB is the lung where alveolar macrophages phagocyte the 
bacilli. Dissemination of the bacteria to the draining lymph nodes activates naive T-
cells which proliferate and become effector cells. These effector cells migrate from the 
lymph node to the lung in the granuloma. They mediate immune protection by 
activating infected macrophages with the induction of oxygen radicals and nitric oxide 
to combat the intra-cellular localized Mtb. A dynamic balance between bacterial 
persistence and host defence develops within an inflammatory lesion, the granuloma 
(Cooper, 2009). 
CD4+ T helper type 1 (Th1) lymphocytes largely mediate resistance to mycobacterial 
infections through cytokine production (e.g. interleukin-2 [IL-2], interferon-γ [IFN-γ], 
tumor necrosis factor-alfa [TNF-α]), whereas CD4+ T helper type 2 (Th2) lymphocytes 
and their cytokines (interleukin-4 [IL-4], interleukin-10 [IL-10]) correlate with disease 
susceptibility in TB (Dooley and Chaisson, 2009, Flynn and Chan, 2001, Al-Attiyah and 
Mustafa, 2009). CD4+ T helper type 17 (Th17) lymphocytes, producing e.g. Il-17a, are 
critical for the enhancement of memory responses again Mtb and excessive activation 
of this pathway has been associated with metabolic diseases such as DM (Pappu et 
al., 2011). Specific chemokines (e.g. MIP-1beta/CCL4) produced during Mtb infection 
and recruiting CD4+ Th1 cells for granuloma formation, are present at higher levels in 
diabetic patients (Bala et al., 2011, Vesosky et al., 2010).  
The immunological consequences of DM co-morbidity on TB specific adaptive 
immunity have been evaluated in different human studies but a defect in protective 
immunity has not yet been identified (Martinez and Kornfeld, 2014). A higher 
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production of Th1 cytokines following tuberculin-purified protein derivative stimulation 
among patients with active TB with DM compared to patients without DM has been 
reported but not reproduced in an Indonesian setting (Kumar et al., 2013b, Restrepo 
et al., 2008, Stalenhoef et al., 2008). Mice studies provided interesting data showing a 
delayed but unimpaired cellular immune response to Mtb among mice with DM 
(Martinez et al., 2014, Vallerskog et al., 2010). 
The present study will describe the immunological features underlying TB and DM 
comorbidity in sub-Saharan Africa and test the hypothesis of delayed adaptive immune 
response in humans. We performed a broad phenotypic and functional 
characterisation of T cells in subjects with active or latent Mtb infection stratified by 
their diabetic status following stimulation with either live M. bovis BCG or Mtb-specific 
peptide pools that respectively requires or not antigen processing or presentation. 
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2 Goal and Objectives 
2.1 Goal 
The goal of the present project was to improve knowledge on the interplay between 
communicable and non-communicable diseases focusing on DM and TB comorbidity 
in an African setting with high HIV prevalence.  
2.2 Objectives 
2.2.1 Objective 1 
To assess the association of TB and its outcome with the presence and persistence of 
hyperglycemia in Tanzania, using three different DM screening tests. 
2.2.2 Objective 2 
To analyse the modifying effect of a low level of vitamin D on the association between 
DM and TB.  
2.2.3 Objective 3 
To study the immunological features underlying TB and DM comorbidity in sub-
Saharan Africa and to test the hypothesis of delayed adaptive immune response with 
increasing glycemia. 
 
 
 
 12 
 
 
 
 
 
 
 
Study setting and Methods 
13 
 
3 Study setting and Methods 
3.1 Study site and Setting 
3.1.1 Study site 
The field work of the present project took place in Dar es Salaam, the economic capital 
of the United Republic of Tanzania (Figure 3-1). 
 
Figure 3-1. Study site. (Adapted from: http://www.lib.utexas.edu/maps/africa/tanzania_pol_2003.pdf). 
Study setting and Methods 
14 
 
Located in East Africa, Tanzania is a low income country with a Gross National Income 
per capita of 930$ (World-Bank, 2015). In 2014, the population of Tanzania was 51.82 
million and more than 70% of the population lived in rural areas. Life expectancy at 
birth has been constantly increasing during the last decade and was 61 years in 2013 
(World-Bank, 2015) (Figure 3-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Life expectancy at birth in Tanzania and Sub-Saharan Africa (developing countries only). 
(Adapted from: http://data.worldbank.org/indicator/SP.DYN.LE00.IN/countries/TZ-ZF?display=graph). 
Dar es Salaam is the economic capital of the country, located on the East coast. It is 
the largest city in Tanzania with 4.4 million inhabitants in 2012 (PHC, 2012). It is among 
the ten fastest growing cities in the world with an annual growth rate of 5.6% and 70% 
of its population living in informal habitations (Figure 3-3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3. Rapidly 
growing Dar es Salaam. (Adapted from: Wikipedia) 
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The administrative structure divides Dar es Salaam into three districts or municipalities, 
Kinondoni, Ilala, and Temeke, from North to South. Each district is further divided in 
wards and subwards. Three District Medical Offices are in charge of the management 
of the health facilities (one district hospital, health centers and dispensaries) that are 
located in their district. 
Tanzania has a high burden of TB with an incidence of 327:100’000 population in 2014. 
The number of estimated new TB cases in 2014 according to WHO was 63’000. The 
HIV prevalence in incident TB cases was estimated to be 35% (WHO, 2015). Dar es 
Salaam is the major contributor to TB incidence with 21.8% of the new TB patients 
diagnosed here (NTLP, 2013a).  
The prevalence rate of DM in Tanzania is estimated at being between 1 and 9% 
depending on setting, with the highest rates reported within the Indian community and 
in urban settings (Aspray et al., 2000, Kolling et al., 2010, McLarty et al., 1989, 
Ramaiya et al., 1995, Swai et al., 1990, Unwin et al., 2010). The last WHO report 
reported a prevalence of 5% (WHO, 2014a). 
3.1.2 Study setting 
The study took place in Kinondoni district, the biggest district of Dar es Salaam. Patient 
recruitment was located in different health facilities from this district: Mwananyamala 
hospital (referral hospital), Sinza hospital (district hospital), Magomeni healthcare 
center and Tandale dispensary (Figure 3-4).  
 
 
 
 
 
 
 
 
 
Figure 3-4. Participating Healthcare centers in Kinondoni District, Dar es Salaam. 
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3.2 Methods 
3.2.1 Evaluation of the association of TB and its outcome with the presence and 
persistence of hyperglycemia 
Study design 
Case-control study with longitudinal follow-up of cases. 
Study population 
Consecutive adults with new active TB diagnosed in the participating hospitals in Dar 
es Salaam were included and followed up for five months after the start of anti-TB 
treatment. TB diagnosis was based on sputum smear microscopy, chest X-ray 
findings, clinical evidence of TB and decision by the clinician to treat with a full-course 
of anti-TB therapy (2013b). Healthy controls were recruited among volunteering adults 
accompanying patients, other than the one included in the study, to the outpatient 
departments of the same hospitals and living in Kinondoni District. We used frequency 
matching on sex and age (10-year age groups) to select the controls. Exclusion criteria 
were a biological relationship to TB case, TB history, symptoms or signs of TB, other 
acute infection or major trauma within the last three months. 
Measurements 
All underwent DM screening tests (fasting capillary glucose (FCG), 2-hour capillary 
glucose after standard oral glucose tolerance test (2h-CG) and glycated hemoglobin 
(HbA1c)) at enrolment and TB patients were again tested after 5-month of TB 
treatment. Every abnormal glycemic (FCG ≥5.6 mmol/l; 2-hCG ≥7.8 mmol/l) or HbA1c 
value (HbA1c ≥5.7% (39 mmol/mol)) was confirmed by repeat testing two to five days 
later. Data on the outcome of TB (treatment failure, death, lost to follow-up) were 
collected. 
Outcomes 
Description of the longitudinal course of hyperglycemia in TB patients. 
Assessment of the association of TB with hyperglycemia at baseline and 5-months 
follow-up. 
Assessment of the association between TB outcome and hyperglycemia at baseline. 
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3.2.2 Description of the association between low vitamin D and TB and its dependence 
on DM 
Study design 
Case-control study with longitudinal follow-up of cases. 
This study was part of the study on the association between TB and DM described 
previously. 
Study population 
Consecutive adults with active TB and healthy volunteers were included as described 
above. TB patients were followed up for five months after the start of anti-TB treatment.  
Measurements 
All underwent DM screening tests (FCG, 2-hCG and HbA1c) and total 25 
hydroxyvitamin D (25(OH)D) measurement at enrolment and after TB treatment for TB 
patients. Data on the outcome of TB were collected. 
Outcomes 
Assessment of the association of TB with 25(OH)D level at baseline and 5-months 
follow-up and its dependence on DM. 
Assessment of the association between TB outcome and 25(OH)D level at baseline. 
3.2.3 Phenotypic and functional characterisation of T cells in subjects with active or 
latent TB stratified by their diabetic status following stimulation with either 
whole-mycobacteria or peptide pools to test the hypothesis of delayed adaptive 
immune response 
Study design 
Ex-vivo immunological TB case control study. 
Study population 
Active TB patients (Xpert MTB/RIF positive in sputum) HIV negative were recruited 
in the participating hospitals in Dar es Salaam and stratified according to their DM 
status.  
Latent TB patients. Healthy volunteering adults and diabetic patients attending the 
DM clinic in the participating hospitals were included if they were latently infected with 
Mtb, HIV negative, had no past TB history and no symptoms or signs of active TB. 
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Exclusion criteria were pregnancy and first week of lactation, any kind of 
immunosuppression during the last 6 months and severe anemia. 
DM status. The presence of DM was defined as repeated measurements of the three 
DM screening tests: ≥7.0 mmol/l for FCG, ≥11.1 mmol/l for 2-hCG and ≥6.5% for 
HbA1c and/or in the presence of history and treatment for DM. The three tests had to 
be in the DM range in order to avoid as much as possible patients with stress 
hyperglycemia. The absence of DM was defined as FCG<6.1 mmol/l and 2-hCG<7.8 
mmol/l. Patients with pre-DM were excluded. The capillary glucose values were 
confirmed by plasma testing (Cobas Integra 400 plus).  
Measurements 
All underwent DM screening tests (FCG, 2h-CG and HbA1c) at enrolment. Peripheral 
blood mononuclear cells were stimulated with peptide pools and live Mycobacterium 
bovis BCG and analysed by polychromatic flow cytometry for Th1, Th2, Th9 and Th17 
cytokine production. Cell culture supernatants were analysed by Luminex for 34 
cytokines and chemokines. 
Outcomes 
Comparison of the frequencies of CD4+ T cells producing cytokines after live M. bovis 
BCG vaccine and Mtb-specific peptide pool stimulation between the four study groups 
(active TB or latent TB patients stratified by their DM status). 
Comparison of frequencies of CD4+ T cells producing cytokines according to fasting 
glycemia. 
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4.1 Abstract 
Background 
Diabetes mellitus (DM) increases tuberculosis (TB) risk while TB, as an infectious 
disease, leads to hyperglycemia. We compared hyperglycemia screening strategies in 
controls and TB patients in Dar es Salaam, Tanzania. 
Methods 
Consecutive adults with TB and sex and age-matched volunteers were included in a 
case-control study between July 2012-June 2014. All underwent DM screening tests 
(fasting (FCG), 2-hour capillary glucose (2-hCG) and glycated hemoglobin (HbA1c) at 
enrolment and cases again after TB treatment. Association of TB and its outcome with 
hyperglycemia were assessed using logistic regression adjusted for sex-age-body 
mass index-HIV-socioeconomic status. TB patients with newly-diagnosed DM were not 
treated for hyperglycemia. 
Results 
At enrolment, DM prevalence was significantly higher among TB patients (N=539; 
FCG>7mmol/L:4.5%, 2-hCG>11mmol/L:6.8% and HbA1c>6.5%:9.3%) compared to 
controls (N=496; 1.2%, 3.1% and 2.2%). Association between hyperglycemia and TB 
disappeared after TB treatment (aOR(95% CI) at enrolment vs follow-up: FCG 9.6(3.7-
24.7) vs 2.4(0.7-8.7); 2-hCG 6.6(4.0-11.1) vs 1.6(0.8-2.9); HbA1c 4.2(2.9-6.0) vs 
1.4(0.9-2.0)). FCG hyperglycemia at enrolment was associated with TB treatment 
failure or death (aOR(95%CI) 3.3(1.2-9.3). 
Conclusions 
Transient hyperglycemia is frequent during TB and DM needs confirmation after TB 
treatment. DM screening at TB diagnosis gives the opportunity to detect patients at 
risk of adverse outcome. 
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4.2 Background 
Interest in the comorbidity between tuberculosis (TB) and diabetes mellitus (DM) has 
reemerged due to the global increase of DM and its potential impact on TB control. DM 
doubles or triples the incidence of active TB and increases the risk of TB treatment 
failure and death (Baker et al., 2011, Jeon and Murray, 2008, Stevenson et al., 2007b). 
A framework was developed to guide national programs in their response to DM and 
TB (2011b). The prevalence of DM among TB patients differs between countries (16-
45%). Sub-Saharan Africa has the highest rate of undiagnosed DM, is expecting the 
sharpest increase in DM by 2035, has a high TB burden, and the highest rate of TB 
and HIV coinfection (Shaw et al., 2010, WHO, 2014b). Two studies in Tanzania and 
Uganda confirmed the cross-sectional TB-DM association in the presence of high HIV 
prevalence (Faurholt-Jepsen et al., 2011, Kibirige et al., 2013). Unexpectedly, HIV 
seamed to protect against DM. The impact of HIV infection on the TB-DM association 
needs further investigations as HIV increases metabolic risk, but can also lower body 
mass index (Paula et al., 2013). 
When and how best diagnose DM in the presence of infections is challenging. As an 
infectious disease, TB increases insulin resistance and stress-induced hyperglycemia 
which may lead to over-diagnosis of DM during the acute phase of TB (Dungan et al., 
2009). Screening of DM is based on blood glucose criteria, and, lately, on the use of 
glycated hemoglobin (HbA1c) with its advantage of not requiring fasting and exhibiting 
less day-to-day variations during periods of stress and illness due to its half-life of 120 
days (2014, WHO, 2006, WHO, 2011a). Few small studies have examined the 
longitudinal course of glycemia during TB treatment, but none was conducted on the 
African continent or compared the performance of different DM screening tests over 
time within the same study population (Jawad et al., 1995, Oluboyo and Erasmus, 
1990, Singh et al., 1984, Tabarsi et al., 2014). 
We examined the association of TB and its outcome with the presence and persistence 
of hyperglycemia in Tanzania, using three different DM screening tests.  
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4.3 Methods 
Study design and setting 
TB patients were recruited between June 2012 and December 2013 and followed up 
for a median time of five months (IQR 4.7-6.1) after the start of anti-TB treatment. 
Controls were recruited between December 2012 and September 2013 and did not 
have follow-up visits. The study was carried out in Kinondoni, the most populated 
District of Dar es Salaam. Patients were recruited in Mwananyamala Regional Hospital 
and connected health facilities (Sinza Hospital, Magomeni Health Centre, Tandale 
Dispensary).  
Study participants 
Cases  
Consecutive adult patients (age ≥ 18 years; living in Kinondoni District) presenting in 
the participating hospitals with new active TB diagnosed by the National TB and 
Leprosy Control Programme (NTLP) were screened for study inclusion.  
TB diagnosis was based on sputum smear microscopy, chest X-ray findings, clinical 
evidence of TB and decision by the clinician to treat with a full-course of anti-TB therapy 
(2013). TB patients were classified as pulmonary smear-positive, smear-negative or 
extrapulmonary. TB patients were treated for 6 months with a standard regimen or 
longer if necessary (2013, WHO, 2010). Sputum microscopy was repeated at months 
two-three and five by NTLP to evaluate the response to treatment in pulmonary smear-
positive TB patients (2013, WHO, 2010). TB treatment outcome was defined according 
to WHO guidelines as treatment success (cure, treatment completed) or adverse 
outcome (failure, death, lost to follow-up) (WHO, 2010). 
Controls  
We used frequency matching on sex and age (10-year age groups) to select controls 
among adults accompanying patients, other than the one included in the study, to the 
outpatient departments and living in Kinondoni District. Exclusion criteria were a 
biological relationship to case, TB history, symptoms or signs of TB, other acute 
infection or major trauma within the last three months.  
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Study procedures 
Data collection 
Information on demographic characteristics, health history (DM, high blood pressure 
(BP), TB and HIV) and symptoms (type and duration), SES (indicators of education, 
occupation, wealth using factor analysis), smoking (ever daily smoking), and alcohol 
misuse (≥three drinks per day or ≥six drinks per occasion (WHO, 2001a)) was obtained 
during an in-person interview. Clinical examination and screening for hyperglycemia 
were performed on the day of the interview. Body mass index (BMI) was calculated as 
measured weight divided by measured height squared (kg/m2).  BP was measured and 
defined according to WHO (WHO, 2013). Data were entered directly into an open data 
kit (ODK) in a personal digital assistant with real-time error, range and consistency 
checks (Hartung et al., December 2010). 
Laboratory and chest X-ray investigations 
Chest X-rays, performed in every TB patient, were read by an experienced radiologist. 
Participants were screened for HIV infection according to the national algorithm using 
first a rapid immune-chromatographic test (Alere DetermineTM HIV-1/2) and for 
confirmation a second rapid test (Trinity Biotech Uni-goldTM Recombigen® HIV-1/2). In 
case of HIV diagnosis, cART was started by NTLP according to national guidelines 
(2013). Complete blood count was performed (Sysmex XS-800i automated 
hematology analyzer). Anemia was defined as hemoglobin <13 g/dl in men and <12 
g/dl in women (WHO, 2001b).  
Hyperglycemia screening and DM diagnosis  
Blood glucose testing was conducted between 8 and 11 am after an overnight fast of 
≥8 hours (fasting capillary glucose-FCG; GlucoPlusTM, Diabcare); two-hours capillary 
glucose (2-hCG; standard 75-gram OGTT); glycated hemoglobin HbA1c (venipuncture 
whole blood; immuno-assay certified by the National Glycohemoglobin Standardization 
Program and insensitive to hemoglobinopathies (Tina-quant HbA1c Gen. 2 Cobas 
Integra 400, Roche Diagnostics)) (NGSP, NGSP). Testing for DM was performed at 
enrolment in both controls and TB patients (45% screened after start of TB treatment 
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(median (IQR) of 2 days (1-4)), and repeated in TB patients after a median of five 
months of anti-TB treatment (67% screened under TB treatment).    
DM is generally a chronic and permanent condition, however, for the sake of clarity, 
we refer to DM when repeated measurements are ≥7.0 mmol/l for FCG, ≥11.1 mmol/l 
for 2-hCG or ≥6.5% for HbA1c and/or in the presence of history and treatment for DM 
according to the standard ADA and WHO criteria (2014, WHO, 2006, WHO, 2011a). 
Pre-diabetes (pre-DM) was defined according to WHO: 6.1≤FCG<7 mmol/l; 7.8≤2-
hCG<11.1 mmol/l; 5.7≤HbA1c<6.5% (39≤HbA1c<48 mmol/mol) (WHO, 2006, WHO, 
2011a). Hyperglycemia refers to patients with pre-DM or DM. Every abnormal glycemic 
(FCG ≥5.6 mmol/l; 2-hCG ≥7.8 mmol/l) or HbA1c value (HbA1c ≥5.7% (39 mmol/mol))) 
was confirmed by repeat testing two to five days later. 2-hCG testing was omitted if 
FCG was ≥11.1 mmol/l. Participants diagnosed with DM were referred to the local DM 
clinic, but none was started on DM treatment. 
Data analysis 
Case-control study at enrolment 
TB patients and controls with complete glucose status data (FCG, 2-hCG and HbA1c) 
at enrolment were included in the cross-sectional analysis (Figure 4-1). Characteristics 
of TB patients were compared to controls (+/-HIV stratification) and differences were 
tested with Wilcoxon-Mann-Whitney and chi-square tests. The independent 
association of pre-DM and DM with TB status was evaluated by logistic regression (+/-
HIV stratification) for every DM screening test independently. Covariates included in 
the final models were age, sex, BMI, SES and HIV status (non-stratified analysis only). 
Lifestyle variables were not included in the models as they had no influence on the 
reported association. Additional sensitivity analysis excluded patients previously 
known and treated for DM. 
Longitudinal course of hyperglycemia in TB patients 
Longitudinal analysis of  changes in blood glucose  over follow-up of a median of five 
months of TB treatment was restricted to patients with complete DM screening data at 
enrolment and follow-up (Figure 4-1). Baseline characteristics of patients with and 
without follow-up were compared using Wilcoxon-Mann-Whitney and chi-squared 
tests. The longitudinal pattern of the association between TB and hyperglycemia was 
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assessed for each DM screening test separately a) with two cross-sectional 
comparisons (TB patients at enrolment versus controls and TB patients at follow-up 
versus controls; +/-HIV stratification), b) using a binary GEE-model (+/-HIV 
stratification) to assess the change in the prevalence of hyperglycemia from the time 
of enrolment to follow-up among TB patients. Potential confounding variables were 
included in the final models (age, sex, BMI, SES and HIV status (non-stratified analysis 
only)). Lifestyle variables were not included in the models as they had no influence on 
the reported association.  
Hyperglycemia at enrolment and TB treatment outcome  
Baseline characteristics of patients with and without adverse TB outcome were 
compared using Wilcoxon-Mann-Whitney and chi-squared tests. The association 
between adverse TB outcome and hyperglycemia was assessed for each DM 
screening test separately with logistic regression adjusted for potential confounding 
variables (age, sex, BMI, SES, HIV status, duration of TB symptoms before diagnosis 
and cavity on X-ray). Lifestyle variables were not included in the models as they had 
no influence on the reported association. 
Statistical analyses were performed using Stata software (StataCorp, College Station, 
TX, USA, version 12). 
Ethical considerations 
All participants consented in writing to interview and health examination. The Ifakara 
Health Institute Institutional Review Board and the Medical Research Coordinating 
Committee of the National Institute for Medical Research, Tanzania, gave ethical 
clearance. 
4.4 Results 
Study sample at enrolment  
A total of 539 TB patients and 496 controls were enrolled in the study. Nine TB patients 
and five controls were excluded because of missing FCG, 2-hCG or HbA1c data at 
enrolment (Figure 4-1). Characteristics of the study sample are described in Table 4-
1. TB patients were more often HIV-infected (32 versus 14%), under-weight and 
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anemic. Only 10 TB patients and 2 controls, all HIV-negative, were already diagnosed 
and treated for DM at enrolment. DM prevalence at enrolment was significantly higher 
in TB patients (4.5%, 6.8% and 9.3%) compared to controls (1.2%, 3.1% and 2.2%) for 
FCG, 2-hCG and HbA1c (p<0.01). This was also true for pre-DM, irrespective of HIV 
status. Mean FCG, 2-hCG and HbA1c values were significantly higher in TB patients 
(mean values of 5.6mmol/L, 7.8mmol/L and 6.1%) compared to controls (4.8mmol/L, 
6.7mmol/L and 5.6%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1. Flow chart of study participants. 
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Table 4-1. Characteristics of the case-control sample at enrolment, all subjects and stratified by HIV status. 
 All    HIV-negative    HIV-infected   
 
TB patients 
N=530 
Controls 
N=491 
  
TB patients 
N=355 
Controls 
N=423 
  
TB patients 
N=166 
Controls 
N=66 
 
 N(%) or Mean(sd) p  N(%) or Mean(sd) p  N(%) or Mean(sd) p 
            
Age 35.9 (12) 36.7 (13) 0.75  35.0 (12) 36.0 (14) 0.41  37.0 (9) 41.0 (11) 0.06 
Male sex  341 (64) 255 (52) <0.001  262 (74) 233 (55) <0.001  74 (45) 21 (32) 0.08 
History of smoking 149 (28) 99 (20) 0.003  113 (32) 89 (21) 0.001  34 (21) 10 (15) 0.34 
Alcohol misuse 62 (12) 27 (6) <0.001  47 (13) 24 (6) <0.001  14 (8) 3 (5) 0.31 
Socioeconomic 
status 
  <0.001    <0.001    <0.001 
     Low 170 (32) 85 (18) <0.001  110 (31) 80 (19) <0.001  57 (35) 5 (8) <0.001 
     Medium 253 (48) 243 (50) 0.3  165 (47) 196 (47) 1  83 (51) 46 (71) 0.008 
     High 103 (20) 158 (33) <0.001  79 (22) 143 (34) <0.001  23 (14) 14 (22) 0.17 
Body Mass Index  19.6 (4) 25.4 (5) <0.001  19.3 (4) 25.3 (6) <0.001  20.2 (4) 25.9 (5) <0.001 
High blood pressure 44 (8) 74 (15) 0.001  33 (9) 66 (16) 0.008  10 (6) 8 (13) 0.11 
HIV infection  166 (32) 66 (14) <0.001         
Anemia 425 (81) 172 (35) <0.001  271 (77) 142 (34) <0.001  149 (91) 30 (45) <0.001 
Previously known DM 10 (1.9) 2 (0.4) 0.03  10 (3) 2 (0.5) 0.008  0 (0) 0 (0) - 
FCG   <0.001    <0.001    0.02 
    Normal 459 (86.6) 479 (97.6) <0.001  316 (89.0) 414 (97.9) <0.001  135 (81.3) 63 (95.5) 0.007 
    Pre-diabetes 47 (8.9) 6 (1.2) <0.001  24 (6.8) 5 (1.2) <0.001  23 (13.9) 1 (1.5) 0.004 
    Diabetes 24 (4.5) 6 (1.2) 0.002  15 (4.2) 4 (1.0) 0.004  8 (4.8) 2 (3) 0.73 
2-hCG   <0.001    <0.001    <0.001 
    Normal 365 (68.9) 446 (90.8) <0.001  257 (72.4) 387 (91.5) <0.001  101 (60.8) 57 (86.4) <0.001 
    Pre-diabetes 129 (24.3) 30 (6.1) <0.001  75 (21.1) 26(6.2) <0.001  53 (31.9) 4 (6.1) <0.001 
    Diabetes 36 (6.8) 15 (3.1) 0.006  23(6.5) 10 (2.4) 0.007  12 (7.2) 5 (7.6) 1 
HbA1c   <0.001    <0.001    <0.001 
    Normal 224 (42.3) 329 (67) <0.001  158 (44.5) 283 (66.9) <0.001  62 (37.4) 45 (68.2) <0.001 
    Pre-diabetes 257 (48.5) 151 (30.8) <0.001  164 (46.2) 135 (31.9) <0.001  88 (53.1) 15 (22.7) <0.001 
    Diabetes 49 (9.3) 11 (2.2) <0.001  33 (9.3) 5 (1.2) <0.001  16 (9.6) 6 (9.1) 1 
TB symptoms  
>3months 
97 (18)    69 (19)    25 (15)   
TB            
    Smear positive 385 (73)    269 (76)    111 (67)   
    Smear negative 111 (21)    64 (18)    44 (27)   
    Extrapulmonary 34 (6)    22 (6)    11 (6.6)   
Cavity on X-ray 250 (50)    184 (55)    61 (38)   
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Abbreviations and definitions: FCG: fasting capillary glucose: Normal: <6.1 mmol/L / Pre-diabetes: 6.1-6.9 mmol/L / Diabetes: ≥7 mmol/l  |  2-hCG: 2-hour capillary glucose: Normal: <7.8 
mmol/L / Pre-diabetes: 7.8-11 mmol/L / Diabetes: ≥11.1 mmol/L  |  HbA1c: glycated haemoglobin: Normal:<5.7% / Pre-diabetes: 5.8-6.4% / Diabetes: ≥6.5% 
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Association between TB and DM at enrolment  
Irrespective which DM test was used and whether diabetics previously diagnosed and 
treated were excluded or not, DM and pre-DM were independently associated with TB 
(Table 4-2). The OR for DM criterion based on HbA1c was substantially lower in HIV-
infected participants (interaction p value=0.048). The prevalence of DM among HIV-
infected patients was not different according to the presence or not of cART.  
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Table 4-2. Cross-sectional association of pre-diabetes and diabetes with tuberculosis at enrolment, all subjects and stratified by HIV status. 
 All   HIV-negative  HIV-infected 
 
N=530 Patients with tuberculosis (TB) 
N=491 Healthy controls (HC) 
 
N=355 Patients with tuberculosis (TB) 
N=423 Healthy controls (HC) 
 
N=166 Patients with tuberculosis (TB) 
N=66 Healthy controls (HC) 
 TB HC OR (95% CI) OR (95% CI)  TB HC OR (95% CI) OR (95% CI)  TB HC OR (95% CI) OR (95% CI) 
 N (%) N (%) Unadjusted Adjusted *  N (%) N (%) Unadjusted Adjusted *  N (%) N (%) Unadjusted Adjusted * 
FCG               
Normal 459 (86.6) 479 
(97.6) 
Ref. Ref.  316 
(89.0) 
414 
(97.9) 
Ref. Ref.  135 
(81.3) 
63 (95.5) Ref. Ref. 
Pre-diabetes 47 (8.9) 6 (1.2) 8.2 (3.5-19.3)  8.8 (3.1-25.1)  24 (6.8) 5 (1.2) 6.3 (2.4-16.7) 7.2 (2.1-25.0)  23 (13.9) 1 (1.5) 10.7 (1.4-81.3) 15.5 (1.8-136) 
Diabetes 24 (4.5) 6 (1.2) 4.2 (1.7-10.3)  10.6 (3.2-4.1)  15 (4.2) 4 (1.0) 4.9 (1.6-15.0) 8.8 (2.1-36.6)  8 (4.8) 2 (3.0) 1.9 (0.4-9.1) 17.1 (1.6-179.4) 
               
2-hCG               
Normal 365 (68.9) 446 
(90.8) 
Ref. Ref.  257 
(72.4) 
387 
(91.5) 
Ref. Ref.  101 
(60.8) 
57 (86.4) Ref. Ref. 
Pre-diabetes 129 (24.3) 30 (6.1) 5.3 (3.5-8.0)  8.2 (4.6-14.6)  75 (21.1) 26 (6.2) 4.3 (2.7-7.0) 7.6 (3.9-14.8)  53 (31.9) 4 (6.1) 7.5 (2.6-21.7) 11.1 (3.1-39.9) 
Diabetes 36 (6.8) 15 (3.1) 2.9 (1.6-5.4)  3.7 (1.6-8.3)  23 (6.5) 10 (2.4) 3.5 (1.6-7.4) 3.8 (1.4-10.5)  12 (7.2) 5 (7.6) 1.4 (0.5-4.0) 3.8 (1.0-15.3) 
               
HbA1c               
Normal 224 (42.3) 329 (67) Ref. Ref.  158 
(44.5) 
283 
(66.9) 
Ref. Ref.  62 (37.4) 45 (68.2) Ref. Ref. 
Pre-diabetes 257 (48.5) 151 
(30.8) 
2.5 (1.9-3.3) 3.6 (2.5-5.1)  164 
(46.2) 
135 
(31.9) 
2.2 (1.6-2.9) 3.1 (2.1-4.6)  88 (53.1) 15 (22.7) 4.3 (2.2-8.3) 7.9 (3.1-20.1) 
Diabetes 49 (9.3) 11 (2.2) 6.5 (3.3-12.9) 10.7 (4.5-26)  33 (9.3) 5 (1.2) 11.8 (4.5-31) 19.3 (6.1-61)  16 (9.6) 6 (9.1) 1.9 (0.7-5.3) 4.7 (1.1-20.8) 
               *Adjusted for age, sex, socioeconomic status, body mass index and HIV status (non-stratified models only) 
Adjusted p value of the interaction between pre-diabetes / diabetes and HIV status: FCG: p= 0.66 / p=0.83 ; 2-hCG: p=0.81 / p=0.73; HbA1c: p=0.16 / p=0.048 
Adjusted p value of the interaction between HbA1c based pre-diabetes / diabetes and anemia: in All: p=0.93 / p=0.12; in HIV-negative; p=0.54 / p=0.63; in HIV-infected: p=0.94 / 
p=0.17 
Abbreviations and definitions: TB: tuberculosis; HC: healthy controls; OR: odds ratio / 95% CI: 95% confidence interval 
FCG: fasting capillary glucose: Normal: <6.1 mmol/L / Pre-diabetes: 6.1-6.9 mmol/L / Diabetes: ≥7 mmol/l  |  2-hCG: 2-hour capillary glucose: Normal: <7.8 mmol/L / Pre-diabetes: 
7.8-11 mmol/L / Diabetes: ≥11.1 mmol/L  |  HbA1c: glycated haemoglobin: Normal:<5.7%  / Pre-diabetes: 5.8-6.4% / Diabetes: ≥6.5% 
Statistical significance: in bold if p<0.05 
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Study sample at follow-up  
Of the 530 TB patients, 392 (73%) presented for a follow-up visit; 15 TB patients were 
excluded from the analysis because of missing FCG, 2-hCG or HbA1c at follow-up 
(Figure 4-1). Characteristics and glycemic status of TB patients with and without follow-
up were comparable, except for underweight and extrapulmonary TB being more 
common among subjects without follow-up (Table 4-3). 
Table 4-3. Comparison of TB patients with and without follow-up study visit. 
 TB patients  TB with follow-up TB without follow-up   
 N=530  N=392 (74%) N=138 (26%)   
 N(%) or Mean(sd)   p 
       
Age 35.9 (11.6)  36 (11) 35 (13)  0.27 
Male sex  341 (64)  251 (64) 90 (65)  0.80 
History of smoking 149 (28)  104 (27) 45 (33)  0.15 
Alcohol misuse 62 (11.7)  42 (10.7) 20 (14.5)  0.24 
Socioeconomic status        
     Low 170 (32)  116 (30) 54 (40)  0.04 
     Medium  253 (48)  195 (50) 58 (43)  0.14 
     High 103 (20)  79 (20) 24 (18)  0.53 
Body Mass Index       
     Under-weight 223 (42)  153 (39) 70 (52)  0.02 
     Normal weight 257 (49)  202 (52) 55 (40)  0.02 
     Over-weight 46 (9)  35 (9) 11 (8)  0.86 
High blood pressure 44 (8)  31 (8) 13 (10)  0.56 
HIV infection  166 (32)  125 (32) 41 (31)  0.72 
Anemia 425 (81)  315 (81) 110 (83)  0.66 
Previously known DM 10 (2)  8 (2) 2 (2)  0.78 
FCG       
    Normal 459 (86.6)  342 (87.2) 117 (84.8)  0.47 
     Pre-diabetes 47 (8.9)  33 (8.4) 14 (10.1)  0.60 
     Diabetes 24 (4.5)  17 (4.3) 7 (5.1)  0.81 
2-hCG        
    Normal 365 (68.9)  272 (69.4) 93 (67.4)  0.83 
     Pre-diabetes 129 (24.3)  96 (24.5) 33 (23.9)  1 
     Diabetes 36 (6.8)  24 (6.1) 12 (8.7)  0.33 
HbA1c       
    Normal 224 (42.3)  168 (42.9) 56 (40.6)  0.69 
     Pre-diabetes 257 (48.5)  189 (48.2) 68 (49.3)  0.84 
     Diabetes 49 (9.3)  35 (8.9) 14 (10.1)  0.73 
TB symptoms >3M  97 (18.4)  76 (19.5) 21 (15.4)  0.30 
TB       
    Smear positive 385 (72.6)  286 (73) 99 (71.7)  0.82 
    Smear negative 111 (20.9)  87 (22.2) 24 (17.4)  0.27 
    Extrapulmonary 34 (6.4) 
 19 (4.9) 
15 (10.9) 
 0.02 
       
Abbreviations and definitions: FCG: fasting capillary glucose: Normal: <6.1 mmol/L / Pre-diabetes: 6.1-6.9 mmol/L 
/ Diabetes: ≥7 mmol/l  |  2-hCG: 2-hour capillary glucose: Normal: <7.8 mmol/L / Pre-diabetes: 7.8-11 mmol/L / 
Diabetes: ≥11.1 mmol/L  |  HbA1c: glycated haemoglobin: Normal:<5.7% / Pre-diabetes: 5.8-6.4% / Diabetes: 
≥6.5% 
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Longitudinal evolution of glycemic status and its association with TB 
The value of all three screening tests decreased over time (mean (SD) fall in FCG, 2-
hCG and HbA1c: 0.3mmol/l (1.1), 1.0mmol/l (2.1) and 0.3% (0.5)). 
After exclusion of previously-known DM, most TB patients with glucose levels 
consistent with DM at enrolment were not diabetic at follow-up (75%, 64% and 71%, 
using FCG, 2-hCG and HbA1c, respectively). Irrespective of HIV status, most TB 
patients diagnosed with pre-DM at enrolment had a normal glycemic status at follow-
up (100%, 90% and 59% using FCG, 2-hCG and HbA1c, respectively) (Figure 4-2). 
There was a tendency for HbA1c based DM and pre-DM to more likely persist as 
hyperglycemia at follow-up. More than 99% of TB patients without DM at enrolment 
using any of the three screening methods did not have DM at follow-up. 
 
Figure 4-2. Longitudinal evolution of pre-diabetes (left 2 bars) and diabetes (right 2 bars) among 
tuberculosis patients from enrolment (left bar) to follow-up (right bar) using a.) Fasting capillary glucose 
(FCG), b.) 2-hours capillary glucose (2-hCG), c.) Glycated hemoglobin (HbA1c). Each screening test is 
compared to itself between enrolment and follow-up. Diabetics known and treated for the disease at 
baseline are excluded. 
Prevalence of newly diagnosed DM at follow-up was similar in TB patients (0.8%, 1.4% 
and 2.2%) and controls (0.8%, 2.7% and 1.8%) for FCG, 2-hCG and HbA1c (p>0.1). 
Based on epidemiological data, these patients present probably type 2 DM (Hall et al., 
2011, Swai et al., 1993). Irrespective of HIV status and of previous DM status, the 
adjusted ORs of the association between TB and hyperglycemia at enrolment 
consistently reverted to the null value (OR 1) during follow-up for all three DM 
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screening tests (Figure 4-3). The changes in TB-hyperglycemia association between 
enrolment and FUP were significant for all DM tests. 
None of DM patients newly diagnosed at baseline was treated for DM. Hypoglycemic 
drugs were proposed only to two patients with FCG >10mmol/l, which is usual practice 
in Tanzania. One was lost to follow-up and the other did not start hypoglycemic 
treatment and still had high glycemia at follow-up. 
 
Figure 4-3. Longitudinal evolution of the association between TB and hyperglycemia, adjusted for age, sex, 
body mass index and socioeconomic status. Diabetics known and treated for the disease at baseline are 
excluded. Abbreviations: FCG: fasting capillary glucose; 2-hCG: 2-hours capillary glucose; HbA1c: 
glycated hemoglobin. 
Hyperglycemia at enrolment and TB treatment outcome  
Information on TB treatment outcome was available for patients with and without 
follow-up through NTLP (Figure 4-4). FCG and 2-hCG values in the range of DM or 
pre-DM at enrolment were significantly associated with adverse TB outcome (lost to 
follow-up, treatment failure or death) (Table 4-4). Hyperglycemia detected by FCG at 
enrolment was the only test significantly associated with an increased risk of failure or 
death (adjusted OR (95% CI): 3.32 (1.20-9.14)). 
 Transient Hyperglycemia and Tuberculosis  
34 
Table 4-4. Association of hyperglycemia with adverse tuberculosis outcome (lost to follow-up, treatment 
failure or death) and with failure or death 
 
All patients with tuberculosis 
N=530 
   
 Adverse outcome of tuberculosis  Failure or death 
 OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI) 
 Unadjusted Adjusted *  Unadjusted Adjusted * 
      
FCG Hyperglycemia 2.29 (1.10-4.76) 2.46 (1.08-5.57)  3.33 (1.38-8.06) 3.32 (1.20-9.14) 
      
2-hCG Hyperglycemia 2.29 (1.24-4.24) 2.26 (1.12-4.54)  1.88 (0.83-4.24) 2.08 (0.84-5.18) 
      
HbA1c Hyperglycemia 0.50 (0.27-0.94) 0.57 (0.28-1.14)  0.46 (0.20-1.04) 0.58 (0.23-1.45) 
      
* Adjusted for age, sex, socioeconomic status, body mass index, HIV, duration of TB symptoms before diagnosis, 
cavity. 
Abbreviations and definitions: Adverse outcome of tuberculosis: lost to follow-up, failure or death 
FCG Hyperglycemia: fasting capillary glucose ≥6.1 mmol/L  |  2-hCG Hyperglycemia: 2-hour capillary glucose ≥7.8 
mmol/L  |  HbA1c Hyperglycemia: glycated haemoglobin ≥5.8-6.4% (40-46 mmol/mol) 
Statistical significance: in bold if p<0.05 
Diagnostic discordance of DM screening tests at enrolment  
Using any of the three screening tests, 68 TB patients were diagnosed as DM at 
enrolment and 19 at follow-up. DM screening tests gave concordant results among 
22% of TB patients at enrolment and 53% at follow-up. 
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Figure 4-4. Flow chart of patients with tuberculosis and their outcome. 
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4.5 Discussion 
In this sub-Saharan Africa urban setting, both DM and pre-DM at enrolment were more 
prevalent in TB patients than in controls irrespective of HIV status. But, in this 
environment with low DM prevalence, new hyperglycemia at the level of DM or pre-DM 
seem to be the consequence rather than the cause of TB and DM diagnosis must be 
confirmed after TB treatment.  Testing for the presence of transient hyperglycemia with 
FCG detects TB patients at higher risk of adverse TB outcome and gives the 
opportunity to manage hyperglycemia, but the impact of such intervention on TB 
outcome needs to be confirmed. 
TB and hyperglycemia at enrolment 
The positive cross-sectional associations between TB and hyperglycemia, irrespective 
of the type of DM test, are in agreement with the literature (Jeon and Murray, 2008). 
Previous data from Africa suggests that the associations may be weaker in HIV-
infected persons (Faurholt-Jepsen et al., 2011, Kibirige et al., 2013). In this study, this 
was only true for an HbA1c-based DM which is difficult to interpret due to a high 
prevalence of anemia particularly among HIV-infected patients. The complex interplay 
between HIV-related immunosuppression, the immunosuppressive effect of pre-
existing DM, and the hyperglycemia subsequent to TB infection cannot be 
disentangled cross-sectionally.   
TB and transient hyperglycemia 
Among TB patients with glucose levels consistent with DM at enrolment, 58-80% 
(depending on the screening test) had newly-diagnosed DM (which is similar to the 
study conducted in Mwanza, 77%), but different from studies in India or China where 
>50% are known for DM before the onset of clinical TB (Viswanathan et al., 2012, 
Wang et al., 2013). Most patients with newly-diagnosed DM had a moderately 
increased glycemia. 
Hyperglycemia was transient in the large majority of TB patients with newly diagnosed 
pre-DM and DM at the time of TB diagnosis. This transient hyperglycemia is well known 
in patients with sepsis (Dungan et al., 2009). The normalization of glycemic status 
during TB treatment has already been described in small study samples (N=20-50) 
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using oral glucose tolerance tests (Oluboyo and Erasmus, 1990, Singh et al., 1984). A 
larger study conducted in Iran also reported that one third of patients with high HbA1c 
at TB diagnosis returned to a normal concentration after three months of TB treatment 
(Tabarsi et al., 2014). The cause of this transient hyperglycemic status is likely 
multifactorial and might reflect inflammation induced by TB, the hyperglycemic effect 
of TB treatment and patient predisposition. Stress hyperglycemia results from a 
complex interplay between disturbed cytokine and hormone production leading to 
excessive hepatic glucose production and insulin resistance (Dungan et al., 2009). 
This high frequency of transient hyperglycemia in untreated TB patients raises the 
question of reverse causality between TB and DM and highlights the necessity to 
repeat DM screening later in the course of TB treatment. Furthermore, studies are 
needed to assess if TB patients with transient hyperglycemia are at increased risk to 
develop DM later (Chen et al., 2012). 
Hyperglycemia testing for improved TB treatment  
Hyperglycemia testing and control at TB diagnosis may have clinical utility in improving 
TB treatment outcome. A recent review showed that DM at TB diagnosis increases risk 
of failure and death during TB treatment and a large study conducted in Mwanza, 
Tanzania showed an increased risk of death among patients with TB and DM, 
particularly among HIV-negative patients (Baker et al., 2011, Faurholt-Jepsen et al., 
2012).  In our study, patients with fasting hyperglycemia at TB diagnosis had a higher 
risk of TB treatment failure or death while patients with elevated HbA1c were not at 
higher risk as previously described (Baker et al., 2011, Tabarsi et al., 2014). Short-
term glycemic control with insulin has been linked to better outcome in septic patients, 
but only when using non intensive glycemic targets (Dungan et al., 2009). This 
evidence indirectly suggests that short-term management of glycemia might also 
improve TB outcome. A recent study pointed to metformin as a potentially useful 
adjunct antituberculosis therapy. In mice, it enhances Mycobacterium tuberculosis-
specific host immunity and reduces inflammation. In TB-DM patients metformin, but 
not other DM drugs, improved TB outcome (Singhal et al., 2014). The effect of 
controlling transient hyperglycemia, particularly with metformin, during TB treatment 
was not yet studied in a randomized trial (Riza et al., 2014).  
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DM screening algorithm in TB patients 
The concordance between the three DM tests used in this study is imperfect as 
previously described (2015, Kumpatla et al., 2013). A number of factors may be 
involved. The diagnostic cut-offs of the DM tests may need to be adapted in different 
populations as they were defined in non-African people. HbA1c appears to 
overestimate DM prevalence in iron-deficient populations (Hardikar et al., 2012). The 
fact that HbA1c, despite its longer half-life, does not capture long term DM better than 
other tests among TB patients, might be related to the long duration of the disease 
before TB diagnosis and to prevalent anemia in these patients (Hardikar et al., 2012, 
Roy, 2010). According to our study, FCG testing at the time of TB diagnosis is 
preferable to HbA1c testing, which, in contrast to FCG, failed to detect patients at risk 
of adverse TB outcome. Finally, glucose based tests are less expensive than HbA1c, 
which is a main consideration in low and middle income countries. 
Our study has several strengths. We evaluated three recommended DM tests side-by-
side and the HbA1c test was non sensitive to prevalent hemoglobinopathies 
(Mwakasungula et al., 2014). The study population was well defined and the patients 
categorized according to WHO recommendations. Its limitation was that TB diagnosis 
was based on NTLP guidelines and smear results rather than culture or GenXpert. 
However, the study was conducted under the real case scenario of TB treatment in 
this population. We did not screen for the presence of multidrug resistant M. 
tuberculosis, but their prevalence is still low (incidence of 1.1% in 2014) in Tanzania 
and have probably not affected the association between TB and DM (WHO, 2015). 
Fasting and 2-h glucose were assessed on capillary whole blood using a point-of-care 
test and not in venous blood. However, we used a plasma-calibrated glucometer which 
accuracy conformed to the International Standardization Organization guidelines 
(Essack et al., 2009). Our study was under-powered to investigate the DM course 
according to HIV status. TB patients and controls were not matched by SES and TB 
patients had a lower SES. However, SES variable was included in every multivariate 
analysis.  Thirty percent of TB patients had no glycemic follow-up, but they are unlikely 
to have biased the observed results to a relevant degree as sensitivity analyses using 
inverse probability weighting and multiple imputation gave similar results than the one 
presented in the paper.  
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In conclusion, our study showed that mild hyperglycemia is very common in TB 
patients, but, in most of them, the glucose status is normalized with TB treatment. For 
the setting of sub-Saharan Africa, the clinical implications of this first study describing 
the longitudinal evolution of the three recommended DM tests during TB treatment are 
twofold. First, a new diagnosis of DM in TB patients must be confirmed after TB 
treatment. Larger studies using point-of-care DM tests that are insensitive to infection-
induced hyperglycemia need to assess the role of DM as a risk factor for active TB in 
low DM prevalence-high TB burden settings like Sub-Saharan Africa.  Second, FCG 
testing at enrolment best captures TB patients at risk of treatment failure and death. 
This may give the opportunity to manage hyperglycemia, but the effect of such 
interventions on TB outcome requires confirmation through randomized controlled 
trials including both HIV-infected and HIV-negative patients.  
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5.1 Summary 
Background 
Vitamin D concentration is inversely associated with TB and DM. So, vitamin D could 
mediate the known increased risk of TB associated with DM. We aim to describe the 
associations between vitamin D, TB and DM.  
Methods 
Consecutive adults with TB and sex- and age-matched volunteers were included in a 
case-control study between February-December 2013 in Dar es Salaam, Tanzania. 
Glycemia and 25-hydroxyvitamin D (25(OH)D) were measured at enrolment and after 
TB treatment in cases. Association between 25(OH)D and TB was evaluated by linear 
and logistic regression adjusted for age, sex, body mass index, socioeconomic status, 
sunshine exposure and HIV.  
Findings 
Prevalence of 25(OH)D insufficiency (<75nmol/l) was not different between TB patients 
and controls (25.9 versus 31.0%; p=0.26). But the association between 25(OH)D 
insufficiency and TB was modified by hyperglycemia (pinteraction=0.01). 25(OH)D 
insufficiency was associated with TB risk in the presence of underlying hyperglycemia 
(OR(95%CI): 4.94(1.16-21.0)), but not in the case of normoglycemia (OR(95%CI): 
0.68(0.39-1.17)) when compared to participants without hyperglycemia and 25(OH)D 
insufficiency.  
Interpretation 
25(OH)D insufficiency seams to increase TB risk only if associated with hyperglycemia. 
Diabetic patients living in high TB burden settings might benefit from preventive vitamin 
D supplementation. 
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5.2 Background 
Diabetes mellitus (DM) triples the risk of tuberculosis (TB) and the global increase of 
DM in developing countries is expected to have a strong impact on TB incidence 
(Stevenson et al., 2007b, Wild et al., 2004, Jeon and Murray, 2008). Several studies 
have shown an association of low vitamin D with both, TB as well as DM (Martineau, 
2012, Pilz et al., 2013, Xuan et al., 2013). Vitamin D is generated in the skin after sun 
exposure and, to a lower extent, trough the diet (Rosen, 2011). Vitamin D is usually 
measured as total blood level of 25 hydroxyvitamin D (25(OH)D) which is the major 
circulating form of vitamin D, for a large part protein-bound, but is less than one percent 
as potent as the free vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D), the most active 
form of vitamin D. Unfortunately, measurement of the free biological active vitamin D 
is not yet easily available and epidemiological studies must rely, for the time being, on 
total levels of 25(OH)D which can be affected by the level of binding proteins (Powe et 
al., 2013). 
Vitamin D deficiency was first described as the cause of rickets and osteomalacia. 
However, the vitamin D receptor is expressed in most cells in the body and vitamin D 
seems to have an effect on a number of other health outcomes (Rosen, 2011). The 
association between type 2 DM and poor vitamin D status has been described in 
several cross-sectional and prospective studies and a metaanalysis of 21 prospective 
studies showed an inverse association between level of vitamin D and risk of type 2 
DM (Song et al., 2013). Vitamin D affects pancreatic β-cell function, boosts the 
antimicrobial activity of human macrophages against Mycobacterium tuberculosis, and 
modulates adaptive response (Hawn et al., 2015). Building on these findings, it was 
suggested that vitamin D insufficiency could mediate some of the association between 
DM and TB (Handel and Ramagopalan, 2010). A cross-sectional Indian study 
confirmed the association between vitamin D deficiency, TB and DM while another 
study conducted in China did not show any association (Chaudhary et al., 2013, Zhan 
and Jiang, 2015). 
It has been shown that vitamin D supplementation accelerates the resolution of 
inflammatory responses during TB treatment and may be used as a host-directed 
therapy (Coussens et al., 2012). However, the role of adjunctive vitamin D on TB 
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outcome remains uncertain as randomized clinical trials of vitamin D supplementation 
did not show a beneficial effect on TB outcome or mortality (Kota et al., 2011, 
Martineau et al., 2011b, Nursyam et al., 2006, Wejse et al., 2009, Daley et al., 2015).  
Vitamin D supplementation might have a role in the prevention and treatment of TB in 
targeted subgroups of patients with low vitamin D levels, such as diabetic patients. In 
this study, we aimed to describe the association between vitamin D insufficiency and 
TB according to DM status in an African equatorial population. 
5.3 Methods 
Study design and setting 
This case-control study with longitudinal follow-up of cases was part of a study on the 
association between TB and DM (Boillat-Blanco et al.). TB patients were recruited 
between February and December 2013 and followed up for a median time of 5.8 
months (IQR 4.7-9.9) after the start of anti-TB treatment. Controls were recruited 
between March and September 2013 and did not have follow-up visits. Glucose and 
vitamin D were measured in blood collected at baseline from cases (88% before onset 
of TB treatment) and controls and in blood collected at follow-up from cases (54% still 
under TB treatment). The study was carried out in Kinondoni, the most populated 
District of Dar es Salaam. Patients were recruited in Mwananyamala Regional Hospital 
and connected health facilities (Sinza Hospital, Magomeni Health Centre, Tandale 
Dispensary). Dar es Salaam is located at a latitude of -6.81° and longitude of 39.28° 
which ensures a good ability of sunlight to synthesize vitamin D (Rosen, 2011). 
Study participants 
At enrolment, 280 TB patients and 358 controls had blood sampled for vitamin D and 
glucose measurement. Of the 280 TB patients, 205 (73%) presented for a follow-up 
visit after ≥5 months of TB treatment. The final study sample consisted of 167 TB cases 
with follow-up information and 358 controls, all of whom had complete information on 
fasting glucose, 25(OH)D and relevant covariates (Figure 5-1). 
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Figure 5-1. Flow chart of study participants. 
Cases  
Consecutive adult patients (age ≥ 18 years; living in Kinondoni District) presenting in 
the participating hospitals with new active TB diagnosed by the National TB and 
Leprosy Control Programme (NTLP) were screened for study inclusion.  
TB diagnosis was based on sputum smear microscopy, chest X-ray (read by an 
experienced radiologist), clinical evidence of TB and decision by the clinician to treat 
with a full-course of anti-TB therapy (2013). TB patients were treated for 6 months with 
a standard regimen or longer if necessary (2013, WHO, 2010). Sputum microscopy 
was repeated after two-three months and again after five months of TB treatment by 
NTLP to evaluate the response to treatment in pulmonary smear-positive TB patients 
(2013, WHO, 2010). TB treatment outcome was defined according to WHO guidelines 
as treatment success (cure, treatment completed) or adverse outcome (failure, death, 
lost to follow-up) (WHO, 2010). 
Controls  
Tuberculosis, Diabetes and Vitamin D 
47 
 
We used frequency matching on sex and age (10-year age groups) to select controls 
among adults accompanying patients, other than the one included in the study, to the 
outpatient departments and living in Kinondoni District. Exclusion criteria were a 
biological relationship to case, TB history, symptoms or signs of TB, other acute 
infection or major trauma within the last three months.  
Study procedures 
Demographic characteristics, health history (DM and HIV) and symptoms, 
socioeconomic status (SES; indicators of education, occupation, wealth using factor 
analysis), smoking (ever daily smoking), and alcohol misuse (≥three drinks per day or 
≥six drinks per occasion) were obtained. Daily sunshine hours data were provided by 
the Tanzanian meteorological agency and month at enrolment was classified as high 
sunshine exposure if the monthly mean number of daily sunshine hours was ≥8 hours. 
Data were entered directly into an open data kit in a personal digital assistant with real-
time error, range and consistency checks (Hartung et al., December 2010). Participants 
were screened for HIV infection according to the national algorithm (rapid immune-
chromatographic test (Alere DetermineTM HIV-1/2) confirmed by a second rapid test 
(Trinity Biotech Uni-goldTM Recombigen® HIV-1/2)).  
Total 25 hydroxyvitamin D measurement 
Serum was kept at -80°C within 6 hours of blood withdrawal and total 25(OH)D level 
was assessed by electrochemoluminescence immunoassay (Cobas® 8000, Roche 
Diagnostics) in Switzerland. Vitamin D deficiency was defined as a 25(OH)D <50nmol/l 
and insufficiency as vitamin D <75nmol/l as suggested by the Endocrine Society 
clinical practice guidelines (Holick et al., 2011, Rosen, 2011). 
Hyperglycemia screening 
Blood glucose testing was conducted after an overnight fast of ≥8 hours (fasting 
capillary glucose, FCG) and 2-hour glucose in an oral glucose tolerance test (2-hCG; 
standard 75-gram OGTT; GlucoPlusTM, Diabcare, plasma-calibrated glucometer which 
accuracy conformed to the International Standardization Organization guidelines) 
(Essack et al., 2009). Abnormal glycemic result (FCG ≥5.6 mmol/l or 2-hCG ≥7.8 
mmol/l) were confirmed by repeat testing two to five days later. 2-hCG testing was 
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omitted if FCG was ≥11.1 mmol/l. Hyperglycemia refers to patients with repeated 
FCG≥6.1 mmol/l and/or 2-hCG≥7.8 mmol/l according to WHO (WHO, 2006). 
Participants diagnosed with DM (FCG>7 mmol/l or 2-hCG>11 mmol/l) were referred to 
the local DM clinic, but none was started on DM treatment. 
Data analysis 
Characteristics of TB patients were compared to controls. Differences were tested with 
Wilcoxon-Mann-Whitney and chi-square tests. To identify factors associated with 
25(OH)D insufficiency, study participants with 25(OH)D insufficiency were compared 
to those without insufficiency using Wilcoxon-Mann-Whitney and chi-square tests.  
The independent association of 25(OH)D level and insufficiency at enrolment and 
follow-up with TB status was evaluated by linear and logistic regression, respectively. 
Covariates included in the final models were age, sex, body mass index (BMI), SES, 
sunshine exposure at enrolment and HIV status. To assess the combined effect of 
25(OH)D insufficiency and hyperglycemia on TB risk, a 4-level categorical variable 
reflecting the combination of glycemic and 25(OH)D status was used as predictor 
variable in the logistic regression models. Interaction between 25(OH)D and 
hyperglycemia in linear regression models was assessed by adding each predictor as 
well as their interaction term to the model. Hyperglycemia status was defined based 
on glucose measured at follow-up as a proxy for pre-existing DM because 
hyperglycemia at enrolment is more likely to reflect stress hyperglycemia as a result of 
TB (Boillat-Blanco et al.). 
Statistical analyses were performed using Stata software (StataCorp, College Station, 
TX, USA, version 12). 
Ethical considerations 
All participants gave written informed consent prior to interview and health 
examination. The Ifakara Health Institute Institutional Review Board and the Medical 
Research Coordinating Committee of the National Institute for Medical Research, 
Tanzania, gave ethical clearance. 
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Role of funding source 
No involvement. 
5.4 Results 
Study sample  
Characteristics of the study sample are described in Table 5-1. Compared to controls, 
TB patients were more often HIV-infected, had a lower BMI, higher 25(OH)D level and 
therefore, less often 25(OH)D insufficiency, particularly at follow-up. At enrolment, 
hyperglycemia was more common in TB patients than controls, but there was no longer 
a difference at follow-up after resolution of TB, probably because of stress 
hyperglycemia secondary to TB infection (Boillat-Blanco et al.). The level of 25(OH)D 
increased during TB treatment (mean increase 6.5 nmol/L (SD+21)) independently of 
whether TB treatment was still ongoing at the time of measurement. Correspondingly, 
the prevalence of vitamin D insufficiency decreased (24.6 versus 20.4%, p<0.001). 
Glycemic and vitamin D status of TB patients with and without follow-up data were 
comparable, but males, patients with alcohol misuse, smoking and lower weight were 
more common among subjects without follow-up (data not shown). 
 
 
 
 
 
 
 
 
Table 5-1. Characteristics of the case-control sample 
  TB patients Healthy Controls  
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  N=167 N=358  
  N(%) or Mean(sd) p 
     
Age  33.7 (10.7) 36.1 (13.0) 0.05 
Male sex   95 (56.9) 191 (53.4) 0.45 
History of smoking  25 (15.0) 90 (25.3) 0.008 
Alcohol misuse  16 (9.6) 22 (6.2) 0.16 
Socioeconomic status     
     Low  41 (24.6) 71 (19.9) 0.25 
     Medium  82 (49.1) 185 (52.0) 0.64 
     High  44 (26.4) 100 (28.1) 0.75 
High sunshine exposure  105 (62.9) 214 (59.8) 0.50 
Body Mass Index  (kg/m2)  22.5 (4.2) 25.1 (5.1) <0.001 
HIV infection   51 (30.7) 51 (14.3) <0.001 
Previously known DM  5 (3.0) 2 (0.6) 0.02 
     
VALUES AT ENROLMENT     
Hyperglycemia  38 (22.8) 37 (10.3) <0.001 
Vitamin D deficiency  3 (1.8) 21 (5.9) 0.04 
Vitamin D insufficiency  43 (25.8) 111 (31.0) 0.22 
Vitamin D level (nmol/l)  94.0 (26.9) 89.6 (26.9) 0.08 
     
VALUES AT FOLLOW-UP     
Hyperglycemia  19 (11.4) 37 (10.3) 0.72 
Vitamin D deficiency  7 (4.2) 21 (5.9) 0.43 
Vitamin D insufficiency  34 (20.4) 111 (31.0) 0.01 
Vitamin D level (nmol/l)  100.5 (29.8) 89.6 (26.9) <0.001 
     
TB CHARACTERISTICS     
TB symptoms >3M   21 (12.6)   
TB     
    Smear positive  136 (81.4)   
    Smear negative  27 (16.2)   
    Extrapulmonary  4 (2.4)   
Cavity on X-ray  86 (52.8)   
     
Vitamin D and glycemia have been measured at follow-up only in TB patients. 
Abbreviations and definitions: Alcohol misuse: ≥3 drinks per day or ≥6 drinks per occasion / Socioeconomic status: 
assessed with indicators of scholar education, occupation and wealth ownership using factor analysis / High 
sunshine exposure: monthly mean number of daily sunshine hours ≥8 hours 
Hyperglycemia: fasting capillary glucose: ≥6.1 mmol/l and/or 2-hCG hyperglycemia:≥7.8 mmol/l  
TB symptoms >3M: >3 month duration of tuberculosis symptoms before diagnosis 
Correlates of vitamin D level and vitamin D insufficiency 
In the control group vitamin D insufficiency was more common in women, but less 
common in HIV infected persons. The only other variable associated with vitamin D 
insufficiency was underlying DM (assessed as either a previous DM diagnosis or as 
hyperglycemia measured at follow-up), but only in TB patients and not in controls 
(Boillat-Blanco et al.). Vitamin D insufficiency was more frequent among TB patients 
previously known for DM (9.3% versus 0.8%; p=0.005) and those with hyperglycemia 
at follow-up (18.6% versus 8.9%; p=0.08) (Table 5-2). Indeed, 25(OH)D was lower 
among TB patients previously known for DM (mean 76.1 nmol/l (SD+29.3) versus 94.5 
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(+26.7); p=0.13) and those with hyperglycemia at follow-up (mean 81.5 nmol/l (+21.1) 
versus 95.6 (+27.2); p=0.03) (Table 5-3). 
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Table 5-2. Factors associated with vitamin D insufficiency among healthy controls and tuberculosis patients at enrolment. 
 TB patients (N=167)  Healthy Controls (N=358) 
 Insufficient vitamin D No insufficient vitamin  D   Insufficient vitamin D No insufficient vitamin D  
 N=43 (25.7%) N=124 (74.3)   N=111 (31.0%) N=247 (69.0%)  
 N(%) or Mean(sd) N(%) or Mean(sd) p  N(%) or Mean(sd) N(%) or Mean(sd) p 
        
Age 35.1 (12.0) 33.3 (10.2) 0.53  35.5 (12.4) 36.4 (13.3) 0.79 
Male sex  20 (46.5) 75 (60.5) 0.11  46 (41.4) 144 (58.8) 0.002 
History of smoking 4 (9.3) 21 (16.9) 0.23  25 (22.5) 65 (26.8) 0.40 
Alcohol misuse 0 (0) 7 (5.7) 0.11  3 (2.7) 19 (7.7) 0.07 
Socioeconomic status        
     Low 11 (25.6) 30 (24.2) 0.84  17 (15.3) 54 (22.2) 0.2 
     Medium 22 (51.2) 60 (48.4) 0.86  57 (51.4) 127 (52.3) 1 
     High 10 (23.3) 34 (27.4) 0.84  37 (33.3) 62 (25.5) 0.13 
High sunshine exposure 29 (67.4) 76 (61.3) 0.47  64 (57.7) 150 (60.7) 0.58 
Body mass index (kg/m2) 19.8 (3.1) 20.4 (3.9) 0.54  25.8 (5.5) 24.9 (4.8) 0.11 
HIV infection  12 (27.9) 39 (31.7) 0.64  6 (5.4) 45 (18.4) 0.001 
Previously known for DM 4 (9.3) 1 (0.8) 0.005  0 (0) 2 (0.8) 0.34 
Enrol. Hyperglycemia 9 (20.9) 29 (23.4) 0.74  11 (9.9) 26 (10.5) 0.86 
Follow-up Hyperglycemia 8 (18.6) 11 (8.9) 0.08     
TB symptoms >3M 8 (18.6) 13 (10.5) 0.17     
TB        
    Smear positive 36 (83.7) 100 (80.7) 0.82     
    Smear negative 6 (14.0) 21 (16.9) 1     
    Extrapulmonary 1 (2.3) 3 (2.4) 1     
Cavity on X-ray 20 (48.8) 66 (54.1) 0.56     
        
Abbreviations and definitions: Alcohol misuse: ≥3 drinks per day or ≥6 drinks per occasion / Socioeconomic status: assessed with indicators of scholar education, occupation and 
wealth ownership using factor analysis / High sunshine exposure: monthly mean number of daily sunshine hours ≥8 hours / DM: d iabetes 
Hyperglycemia: fasting capillary glucose: ≥6.1 mmol/l and/or 2-hCG hyperglycemia:≥7.8 mmol/l  
TB symptoms >3M: >3 month duration of tuberculosis symptoms before diagnosis 
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Table 5-3. Factors associated with vitamin D level among TB patients and healthy controls. 
 TB patients   Healthy Controls  
 N=167    N=358   
 N(%) 25(OH) D (nmol/L) P  N(%) 25(OH) D (nmol/L) p 
        
Age (years)   0.47    0.42 
     <45 156 (93.4) 94.4 (26.9)   321 (89.7) 90.0 (27.4)  
     ≥45 11 (6.6) 88.3 (27.4)   37 (10.3) 86.2 (22.6)  
Sex   0.002    <0.001 
     Female 72 (43.1) 86.6 (24.2)   167 (46.6) 84.3 (25.9)  
     Male 95 (56.9) 99.6 (27.6)   191 (53.4) 94.3 (27.0)  
Smoking   0.16    0.41 
     No 145 (86.8) 92.9 (26.9)   271 (75.7) 88.9 (27.8)  
     Yes 22 (13.2) 101.5 (26.1)   85 (23.7) 91.7 (24.3)  
Alcohol   0.31    0.007 
     No misuse 160 (95.8) 93.5 (27.0)   336 (93.9) 88.6 (26.7)  
     Misuse 7 (4.2) 104.1 (24.2)   22 (6.1) 104.6 (26.9)  
Socioeconomic 
status 
  0.59 
   1 
     Low 41 (24.6) 90.3 (25.2)   71 (19.9) 89.4 (25.7)  
     Medium 82 (49.1) 94.7 (28.9)   185 (52.0) 89.7 (25.7)  
     High 44 (26.3) 96.0 (24.8)   100 (28.1) 89.5 (30.4)  
Sunshine exposure    0.86    0.85 
     <8 hours/day 62 (37.1) 94.5 (25.8)   144 (40.2) 90.5 (27.7)  
     ≥8 hours/day 105 (62.9) 93.7 (27.6)   214 (59.8) 89.0 (26.5)  
BMI (kg/m2)   0.79    0.006 
     <18.5 52 (31.1) 95.2 (28.8)   14 (4.0) 75.4 (25.4)  
     18.5-24.9 94 (56.3) 92.8 (26.7)   189 (53.4) 93.3 (28.0)  
     ≥25 21 (12.6) 96.4 (23.6)   151 (42.6) 85.9 (24.8)  
HIV infection    0.74    0.005 
     No 115 (69.3) 93.6 (26.7)   306 (85.7) 88.0 (26.7)  
     Yes 51 (30.7) 95.1 (27.9)   51 (14.3) 99.5 (26.5)  
Known for DM   0.13    0.87 
     No 162 (97.0) 94.5 (26.7)   356 (99.4) 89.6 (27.0)  
     Yes 5 (3.0) 76.1 (29.3)   2 (0.6) 86.5 (2.5)  
Enrol. 
Hyperglycemia  
  0.90 
   0.83 
     No 129 (77.2) 94.1 (28.1)   344 (96.1) 89.5 (27.1)  
     Yes 38 (22.8) 93.5 (22.8)   14  (3.9) 91.1 (24.7)  
FUP Hyperglycemia   0.03     
     No 148 (88.6) 95.6 (27.2)      
     Yes 19 (11.4) 81.5 (21.1)      
TB symptoms 
duration  
  0.23 
    
     <3 months 146 (87.4) 94.9 (26.6)      
     >3 months 21 (12.6) 87.4 (28.9)      
TB   0.16     
    Smear positive 136 (81.4) 92.2 (25.6)      
    Smear negative 27 (16.2) 103.1 (32.7)      
    Extrapulmonary 4 (2.4) 94.4 (20.5)      
Cavity on X-ray   0.78     
     No 77 (47.2) 93.6 (87.9)      
     Yes 86 (52.8) 94.8 (28.7)      
        
Abbreviations and definitions: Alcohol misuse: ≥3 drinks per day or ≥6 drinks per occasion / High sunshine exposure: 
monthly mean number of daily sunshine hours ≥8 hours / DM: diabetes / Enrol.: enrolment / FUP: follow-up / 
Hyperglycemia: fasting capillary glucose: ≥6.1 mmol/l and/or 2-hCG hyperglycemia:≥7.8 mmol/l 
TB symptoms >3M: >3 month duration of tuberculosis symptoms before diagnosis 
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Association between TB and 25(OH)D level in all subjects and according to 
hyperglycemia at follow-up 
In all subjects combined, 25(OH)D levels at baseline and follow-up were slightly higher 
in TB patients compared to controls (baseline: mean 94.0 nmol/l (SD 26.0) vs. 89.6 
(26.9); follow-up: 100.5 (29.8) vs. 89.6 (26.9). However the association between 
25(OH)D level and particularly vitamin D insufficiency with TB depended on the 
presence of hyperglycemia at follow-up as a proxy for DM.  In the absence of DM, 
vitamin D levels were higher in TB patients than in controls, irrespective of the time 
point of vitamin D measurement.  In the presence of DM, though, circulating 25(OH)D 
concentrations were not higher in TB patients. In fact, when assessing the joint 
associations of vitamin D insufficiency and hyperglycemia status with TB status, we 
observed the risk for TB to be highest in participants with a combination of vitamin D 
insufficiency and hyperglycemia. This associations was stronger for vitamin D 
insufficiency at baseline than at follow-up (OR 4.94 (95% CI 1.16-21.0 vs. 3.68 (0.77-
17.70)). In contrast, vitamin D insufficiency at follow-up in the absence of 
hyperglycemia was protective against TB (OR 0.56 (0.31-0.99)) (Table 5-4). 
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Table 5-4. Joint association of vitamin D and hyperglycemia at follow-up with tuberculosis 
 TB patients Healthy Controls    
 N=167 N=358 OR (95% CI) OR (95% CI)  
 N (%) or mean(SD) Unadjusted Adjusted ■ 
p-
interaction 
      
VITAMIN D AT ENROLMENT      
Vitamin D (nmol/l)      
Normal glycemia 95.6 (27.2) 89.7 (26.7) 1.01 (1.00-1.02) 1.01 (1.00-1.02)  
Hyperglycemia 81.5 (21.1) 88.8 (29.3) 0.99 (0.97-1.01) 0.98 (0.94-1.04) 0.07 
      
Vitamin D Insufficiency      
No Insufficiency and Normal glycemia 113 (67.7) 221 (61.7) Ref. Ref.  
No Insufficiency and Hyperglycemia 11 (6.6) 26 (7.3) 0.83 (0.39-1.74) 0.80 (0.31-2.07)  
Insufficiency and Normal glycemia 35 (21.0) 100 (27.9) 0.68 (0.44-1.07) 0.68 (0.39-1.17)  
Insufficiency and Hyperglycemia 8 (4.8) 11 (3.1) 1.42 (0.56-3.64) 4.94 (1.16-21.0) 0.01 
      
VITAMIN D AT FOLLOW-UP      
Vitamin D (nmol/l)      
Normal glycemia 102.0 (29.9) 89.7 (26.7) 1.02 (1.01-1.02) 1.01 (1.01-1.02)  
Hyperglycemia 88.7 (27.4) 88.8 (29.3) 1.00 (0.98-1.02) 1.01 (0.96-1.05) 0.18 
      
Vitamin D Insufficiency      
No Insufficiency and Normal glycemia 121 (72.5) 221 (61.7) Ref. Ref.  
No Insufficiency and Hyperglycemia 12 (7.2) 26 (7.3) 0.84 (0.41-1.73) 0.98 (0.41-2.37)  
Insufficiency and Normal glycemia 27 (16.2) 100 (27.9) 0.49 (0.31-0.80) 0.56 (0.31-0.99)  
Insufficiency and Hyperglycemia 7 (4.2) 11 (3.1) 1.16 (0.44-3.08) 3.68 (0.77-17.70) 0.04 
      
■ Adjusted for age, sex, body mass index, socioeconomic status, sunshine exposure and HIV status  
p-interaction: adjusted p value of the interaction between hyperglycemia at follow-up and vitamin D  
Statistical significance: in bold if p<0.05 
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Vitamin D status and TB treatment outcome  
Information on TB treatment outcome was available for patients with and without study 
follow-up through NTLP. Vitamin D level at baseline was not associated with adverse 
TB outcomes (lost to follow-up, treatment failure or death), but power for this analyses 
was limited as the number of adverse TB outcomes was small (5%; data not shown). 
5.5 Discussion 
In this sub-Saharan Africa equatorial setting, we provide novel evidence for the 
association between low 25(OH)D and TB to depend on underlying hyperglycemia and 
DM, irrespective of HIV status. In normoglycemic participants, 25(OH)D levels were 
higher in TB cases compared to controls. Only in the presence of DM, we observed 
lower levels of 25(OH)D and higher prevalence of vitamin D insufficiency in TB cases 
compared to controls. Furthermore, DM was a determinant of vitamin D insufficiency 
among TB patients. The longitudinal blood sampling in TB cases allowed to have a 
better estimation of vitamin D insufficiency and hyperglycemia in TB cases after 
treatment and therefore, after the time point of acute inflammatory reactions related to 
active TB.   
The associations between vitamin D insufficiency and DM, vitamin D insufficiency and 
TB as well as TB and DM have been demonstrated in many studies. These data point 
to vitamin D as a potential mediator in the link between DM and TB which is in line with 
our results (Handel and Ramagopalan, 2010). Our data are concordant with an Indian 
study showing that the prevalence of vitamin D insufficiency is higher among TB 
patients with DM compared to those without DM (Chaudhary et al., 2013). The absence 
of link between DM and 25(OH)D level among healthy controls may be explained by 
the low number of controls with previously known DM. Our results from a longitudinal 
study underline the limitations of studying the combined impact of circulating glucose 
and 25(OH)D on TB in a cross-sectional manner. At the time of diagnosis of active TB, 
the inflammation status influences both hyperglycemia and likely also 25(OH)D. Cross-
sectional studies may miss the importance of DM in the association between TB and 
vitamin D when only considering the results of baseline glycemic screening at the time 
of active TB that most likely represent stress hyperglycemia (Boillat-Blanco et al.). 
Consistent with two other studies, 25(OH)D level increased during TB treatment, 
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despite the described lowering effect of isoniazid and rifampicin (Brodie et al., 1982, 
Friis et al., 2013, Koo et al., 2012, Sloan et al., 2015). The improved vitamin D status 
during TB treatment may be related to increased exercise, sun exposure and food 
consumption during recovery. However, 25(OH)D results have to be interpreted 
carefully particularly during active TB. Indeed, as previously discussed, 25(OH)D is 
mainly protein-bound and does not represent the free active form of vitamin D. During 
inflammation, the concentration of VDBP which is an acute-phase reactant is probably 
affected and therefore, the level of active or “free” serum 1,25(OH)2D is modified. So, 
the measured total 25(OH)D might not be a suitable marker of vitamin D status during 
infection. Studies showed inconsistent results regarding changes in VDBP 
concentration during inflammation. Lower levels of VDBP were observed in critically ill 
children whereas an increase of VDBP was shown after allergen-induction of 
endobronchial inflammation (Bratke et al., 2014, Madden et al., 2015).  
The importance of vitamin D for active TB development was demonstrated in a 
prospective study conducted among HIV-infected adults in Tanzania where a 
significant association between vitamin D deficiency and incident pulmonary TB was 
identified (Sudfeld et al., 2013). In keeping with this study, most case control studies 
reported a lower 25(OH)D in TB patients compared to the control group (Martineau et 
al., 2011a, Nnoaham and Clarke, 2008). However, consistent with a large study 
conducted in Mwanza, Tanzania, we observed a higher 25(OH)D and lower prevalence 
of vitamin D insufficiency among TB patients compared to healthy controls, particularly 
after treatment of TB (Friis et al., 2013). Contrasting with most studies, the prevalence 
of vitamin D deficiency was low and mean 25(OH)D was in the normal range in the 
Tanzanian studies which may have restricted the impact of low 25(OH)D on TB to 
diabetic patients who had lower 25(OH)D levels.  
There is a high variability in vitamin D deficiency between studies conducted in Africa, 
ranging from 4.3% in Tanzania to 62.7% in South Africa (Martineau et al., 2011a).  
Highly different vitamin D levels between countries are likely explained by the distance 
of the studies sites to the Equator and perhaps also to differences in food composition, 
prevalence of comorbidities such as DM, laboratory techniques, as wells as possibly 
genetic polymorphisms (Powe et al., 2013). 
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In keeping with a recent study from Malawi, lower vitamin D was not associated with 
adverse TB treatment outcome in our study (Sloan et al., 2015) which contrasts with 
other studies conducted in setting where vitamin D levels at baseline were lower. 
However, this is in line with results of randomized control studies of adjunctive vitamin 
D that failed to detect an improvement of TB outcome (Daley et al., 2015, Davies and 
Martineau, 2015, Martineau et al., 2011b). 
Our study has several strengths. First, the longitudinal design allows assessing the 
association between TB, DM and vitamin D after resolution of the inflammation status 
which influences vitamin D level and glycemic status. The study population was well 
defined and the patients categorized according to WHO recommendations. Its main 
limitation is the measurement of total 25(OH)D and not bioavailable “free” serum 
25(OH)D which represents the active form of vitamin D. VDBP binds 85-90% of 
25(OH)D and makes it unavailable to act on target cells (Powe et al., 2013). This might 
have been even more important during the course of an infection which modifies the 
levels of protein. The measurement of “free” 25(OH)D is only available in few 
laboratories, it is not routinely used and thresholds to define vitamin D sufficiency have 
been based on total serum 25(OH)D levels. TB diagnosis was based on NTLP 
guidelines and smear results rather than culture or GenXpert. However, the study was 
conducted under the real case scenario of TB treatment in this population. Fasting and 
2-h glucose were assessed on capillary whole blood using a point-of-care test and not 
in venous blood. However, we used a plasma-calibrated glucometer which accuracy 
conformed to the International Standardization Organization guidelines (Essack et al., 
2009). Our study was under-powered to investigate vitamin D levels among 
hyperglycemic patients.  
In this equatorial population with a low prevalence of vitamin D deficiency, vitamin D 
insufficiency seems to increase the risk of TB only if associated with hyperglycemia 
suggestive of underlying DM and may even be inversely associated with active TB 
otherwise. Diabetic patients might be an appropriate target for vitamin D 
supplementation to improve TB outcome or prevent active TB, but the effect of such 
interventions requires confirmation through randomized controlled trials. 
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6.1 Abstract 
Background 
Diabetes mellitus (DM) constitutes a risk factor for development of active tuberculosis 
(TB). Hyperglycaemia affects negatively innate immune functions. The recent increase 
of type 2 DM in developing countries with high TB endemicity poses novel challenges 
to these health systems. The impact of DM on TB specific adaptive immune responses 
remains poorly addressed.  
Methods 
Latent and active TB patients with or without DM were recruited in Dar es Salaam, 
Tanzania. Peripheral blood mononuclear cells were restimulated in vitro with ESAT-6 
and CFP10 peptide pools or live M. bovis BCG. We analysed by polychromatic flow 
cytometry the intracellular cytokine expression of Th1, Th2, Th9 and Th17 in different 
T cell subsets. Cell culture supernatants harvested after antigen stimulation were 
analysed by Luminex. 
Results 
Our results show a lower frequency of INF-γ CD4+ T cells and a lower proportion of 
CD4+ T cells producing both TNF-α and IFN-γ in patients with active TB and DM after 
live M. bovis BCG but not after peptide pools stimulation. An inverse correlation 
between INF-γ or TNF-α CD4+ T cell frequencies and poor glycaemic control after live 
M. bovis BCG stimulation was observed.  
Conclusions 
DM negatively affects IFN-γ and TNF-α producing CD4+ T cell response in active TB 
after live BCG but not Mtb peptide re-stimulation indicating that antigen processing 
and/or presentation is primarily affected. 
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6.2 Introduction 
Diabetes mellitus (DM) increases the risk of active tuberculosis (TB) development by 
about threefold (Jeon and Murray, 2008). The recent and rapid increase of type 2 DM 
prevalence in countries suffering already from high TB burden is expected to negatively 
impact TB control efforts (Corbett et al., 2003, Stevenson et al., 2007b). The observed 
interaction between active TB and DM suggests that host defence mechanisms for 
control of Mycobacterium tuberculosis (Mtb) infection are impaired. Hyperglycaemia 
affects innate immune functions of neutrophil granulocytes, macrophages and Natural 
Killer cells (Delamaire et al., 1997, Gan, 2013, Schuetz et al., 2011). T cell-mediated 
immune responses are clearly critical in the outcome of an Mtb infection (Jasenosky et 
al., 2015) as demonstrated by the marked susceptibility and reactivation of TB in HIV-
co-infected persons (Sester et al., 2010). Defects in pro-inflammatory T Helper 1 (Th1) 
cellular polarization and cytokine production, particularly IFN-γ, are well-defined risk 
factors for mycobacteriosis (Bustamante et al., 2014). CD4 T+ cell poly-functionality, 
i.e. the ability to produce simultaneously different combinations of IFN-γ, TNF-α and 
IL-2 correlates with improved effector and proliferative functions (Jasenosky et al., 
2015). These responses can be substantially influenced by treatment and disease 
status and could therefore play a role in determining outcome of natural infection.  
The immunological consequences of DM co-morbidity on TB specific adaptive 
immunity has been evaluated in different human studies but a defect in protective 
immunity has not yet been identified (Martinez and Kornfeld, 2014). A mouse model 
study provided interesting data showing a delayed but unimpaired cellular immune 
response to Mtb among mice with DM (Vallerskog et al., 2010). The conclusions of 
several human studies gave conflicting results. A higher production of Th1 cytokines 
following PPD stimulation among diabetic patients with active TB compared to non-
diabetic patients with active TB has been reported but not reproduced in an Indonesian 
setting (Kumar et al., 2013b, Restrepo et al., 2008, Stalenhoef et al., 2008).  
To our knowledge, the immunological features underlying TB and DM comorbidity have 
not been analysed in sub-Saharan Africa and the hypothesis of delayed adaptive 
immune response has not been tested in humans. We performed a broad phenotypic 
and functional characterisation of T cells in subjects with active or latent Mtb infection 
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stratified by their diabetic status following stimulation with either live M. bovis BCG or 
Mtb-specific peptide pools that respectively requires or not antigen processing by 
antigen presenting cells to recall antigen-specific T cell responses in vitro.  
6.3 Methods 
Study design and setting 
This prospective case-control study was part of a study on the association between TB 
and DM (Boillat-Blanco et al.). Patients with active TB were recruited between April 
and December 2013 and controls between May and October 2013. Patients were 
recruited in Kinondoni District in Dar es Salaam (Mwananyamala Regional Hospital, 
Sinza Hospital, Magomeni Health Centre and Tandale Dispensary). Controls were 
recruited among adults accompanying patients, other than the one included in the 
study, to the outpatient departments of the same hospitals and living in Kinondoni 
District. 
Study participants 
Cases  
Active TB patients (≥ 18 years) with new smear positive pulmonary TB were screened 
for study inclusion. Patients were eligible if they were not on TB treatment and sputum 
Xpert MTB/RIF (Cepheid, Sunnyvale, USA) assay was positive, HIV screening (Alere 
DetermineTM HIV-1/2 and Trinity Biotech Uni-goldTM Recombigen® HIV-1/2) was 
negative. Exclusion criteria were pregnancy (positive urinary pregnancy screening test) 
and first week of lactation, any kind of immunosuppression during the last 6 months 
and severe anaemia (<5g/dL).  
 
Controls 
Healthy volunteering adults and diabetic patients attending the diabetes clinic in 
Mwananyamala hospital were screened for inclusion. Eligibility criteria for healthy 
controls were: HIV negative, no past TB history, absence of symptoms or signs of 
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active TB or other acute infection or major trauma within the last three months. 
Exclusion criteria were identical to TB cases. 
Diabetes status 
Blood glucose testing was conducted before the start of TB treatment after an overnight 
fast of ≥8 hours (fasting capillary glucose-FCG; GlucoPlusTM, Diabcare); two-hours 
capillary glucose (2-hCG; standard 75-gram OGTT); glycated hemoglobin HbA1c 
(venipuncture whole blood; immuno-assay certified by the National Glycohemoglobin 
Standardization Program and insensitive to hemoglobinopathies (Tina-quant HbA1c 
Gen. 2 Cobas Integra 400, Roche Diagnostics)) (ADA, 2014, Essack et al., 2009, 
NGSP). DM was defined as repeated measurements ≥7.0 mmol/l for FCG, ≥11.1 
mmol/l for 2-hCG and ≥6.5% for HbA1c and/or in the presence of history and treatment 
for DM according to the standard ADA and WHO criteria (2014, WHO, 2006, WHO, 
2011a). Normal glycaemia was defined as FCG<6.1 mmol/l and 2-hCG<7.8 mmol/l. 
The capillary glucose values were confirmed by plasma testing (Cobas Integra 400 
plus). DM status was confirmed after 5 months of TB treatment to avoid including 
patient with transient stress hyperglycemia (Boillat-Blanco et al.). Patients with pre-DM 
were excluded. 
Latent TB 
Healthy controls were classified as latently infected by Mycobacterium tuberculosis 
(Mtb) based on positive Mtb-specific Interferon-Gamma enzyme-linked immunospot 
assay (ELISPOT) or positive flow cytometry result (frequency of IFN-γ, TNF-α or IL-2 
CD4+ T cells after Mtb-specific stimulation >0.03% and >2 times higher than negative 
control) or positive Luminex results (defined as IFN-γ, TNF-α or IL-2 after Mtb-specific 
stimulation >5 times higher than negative control). Immunologically irrelevant, healthy 
control samples that did not show evidence of latent TB infection were excluded from 
the analysis. 
Study procedures 
Data and sample collection 
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Demographic characteristics, health history and symptoms, socioeconomic status 
(indicators of education, occupation, and wealth using factor analysis) were obtained. 
Complete blood count was performed (Sysmex XS-800i automated haematology 
analyzer). Data were entered directly into an open data kit in a personal digital assistant 
with real-time error, range and consistency checks (Hartung et al., December 2010). 
Before TB treatment initiation, Peripheral Blood Mononuclear cells (PBMC) were 
isolated within five hours of phlebotomy and cryopreserved in temperature monitored 
liquid nitrogen tanks. 
Immunological assays 
Immunological assays were performed after thawing and 5-6 hours resting of 
cryopreserved PBMCs. For flow cytometry assays, PBMC (1x106) were cultivated 
overnight in the presence of Brefeldin A (BD GolgiPlug, Becton Dickinson) either 
untouched (negative control), or stimulated with Staphylococcal enterotoxin B (SEB; 
Sigma; 200 ng/ml−1; positive control), or live M. bovis bacilli Calmette-Guérin vaccine 
(20µl BCG Vaccine solution, Staten Serum Institute) or Mtb specific peptide pools 
covering the 10-kDa culture filtrate antigen (CFP10) and the 6-kDa early secretory 
antigen target (ESAT6) protein sequences as described previously (Harari et al., 
2011). 
IFN-γ ELISPOT assays 
Rested PBMCs were stimulated for 16 hours with Mtb-specific peptide pools or SEB 
(positive control). Only cell samples with >80% viability were analysed. Assays with 
<50 SFU for negative control and >500 SFU per 106 cells after SEB stimulation were 
considered as valid. ELISPOT result was defined positive when Mtb-specific 
stimulation led to ≥55 SFU per 106 cells and fourfold higher than negative control. 
Intracellular cytokine staining and flow cytometry analyses 
Rested PBMCs were incubated in 100 µl PBS containing 1 µl Aqua solution 
(LIVE/DEAD kit, Invitrogen), and then stained with antibodies specific for CD3 (APC-
H7, SK7, BD Biosciences), CD4 (PE-CF594, RPA-T4, BD Biosciences), CD8 
(eFluor625NC, RPA-T8, eBioscience) and CD45RA (BV711, 92430, Biolegend) before 
fixation, and permeabilization with BD Cytofix/Cytoperm kit (BD Biosciences). PBMCs 
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were then stained with antibodies directed against IFN-γ (AF700, B27, BD 
Biosciences), TNF-α (PECy7, Mab11, BD Biosciences), IL-2 (PerCpCy5.5, MQ1-
17H12, Biolegend), IL-10 (BV 421, JES3-9D7, Biolegend), IL-17 (FITC, BL168, 
Biolegend), IL-4 (PE, 3010.211, BD Bioscienecs), IL-5 (PE, TRFK5, Biolegend), IL-13 
(PE, JES10-5A2, Biolegend) and IL-9 (Alexa647, MH9A4, BD Biosciences). Cells were 
fixed, acquired on a BD LSRII apparatus equipped with 405, 488, 532 and 633 nm 
lasers and data analysed with FlowJo version 8.8.6 (Tree Star Inc.) and SPICE version 
5.1 (Roederer et al., 2011). Gating strategy is shown on Figure 6-1. Only samples with 
a cytokine response to SEB at least twice higher than unstimulated control were 
considered valid. A positive flow cytometry response was considered when the 
frequency of cytokine-specific cells after live M. bovis BCG vaccine or Mtb-specific 
peptide pools stimulation was above 0.03% and twice higher than the unstimulated 
specimen for any of the investigated cytokine. 
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Figure 6-1. Gating strategy for the flow cytometry analysis of CD4+ T cell cytokine responses  
Cytokine quantification with Luminex assay 
After overnight stimulation as described above but in the absence of BrefeldinA, cell 
culture supernatants were harvested and stored at -20°C before analysis with 
ProcartaPlex Human Cytokine & Chemokine Panel (Affymetrix ebioscience) and a Bio-
Plex 200 analyzer (Biorad). Data were processed using Hmisc, nCal, rjags, 
gWidgetstcltk R packages. Luminex response was defined as a cytokine or chemokine 
concentration after Mtb-specific peptide pools stimulation fivefold higher than the 
unstimulated specimen. 
Data analysis 
Frequencies of CD4+ T cells producing cytokines as well as quantitative cytokine 
responses were adjusted by subtracting the background level (negative control).  
Frequency of responders based on flow cytometry of the tested cytokines was 
compared between the 4 study groups with Fischer’s exact test. Only cytokines with a 
flow cytometry responder’s frequency ≥50% in at least one study group were kept in 
subsequent analyses.     
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Frequencies of CD4+ T cells producing cytokines after live M. bovis BCG vaccine and 
Mtb-specific peptide pools stimulation were compared between the different study 
groups by Wilcoxon-Mann-Whitney test using GraphPad Prism 6. 
SPICE analysis of CD4+ T cells frequencies was compared between the different study 
groups by unpaired two-tailed Student’s t test. 
Frequencies of CD4+ T cells producing cytokines were analysed according to fasting 
glycaemia by linear regression after adjustment for age and sex. HbA1c results were 
not considered as they appeared to overestimate DM prevalence in this TB population 
with a high prevalence of anemia and hemoglobinopathies (Boillat-Blanco et al.).  
Frequency of responders per cytokine and cytokine concentration level after live M. 
bovis BCG vaccine and Mtb-specific peptide pools stimulation were compared 
between the study groups by Wilcoxon-Mann-Whitney test. Statistical analyses were 
performed using Stata software (StataCorp, College Station, TX, USA, version 12). 
Ethical considerations 
All participants consented in writing to interview and health examination. The Ifakara 
Health Institute Institutional Review Board and the Medical Research Coordinating 
Committee of the National Institute for Medical Research, Tanzania, gave ethical 
clearance. 
6.4 Results 
Study sample  
In total, 26 latent and 28 active TB cases with and without DM were enrolled into this 
immunological study with their anthropometric and glycemic status summarized in 
Table 6-1. Participants suffering from DM were significantly older than the one with 
normal glycemia while gender and body mass index did not differ between the study 
groups. Figure 6-2 depicts the distribution of participants with latent TB, active TB or 
no TB in the two groups according to their glycaemic status (DM versus normal plasma 
glucose). Among patients with active TB and DM co-morbidity, 5/8 received already 
DM treatment prior to TB diagnosis (4/8 were treated with metformin and 1/8 with 
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insulin). All volunteers with latent TB and DM comorbidity were under DM treatment at 
the time of blood collection (11/12 received metformin and 1/12 received insulin). 
Clearly, glycaemia was uncontrolled with values in the DM range, most likely due to 
poor treatment adherence.  
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Figure 6-2. Flow chart of study participants and immunological tests. 
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Table 6-1. Study population. 
 Latent Mtb Latent Mtb DM   Active TB Active TB DM  
 N=14 N=12   N=20 N=8  
 N (%) / median (IQR) p  N (%) / median (IQR) p 
        
Age 35 (10) 45 (27) <0.001 28 (11) 57 (7) <0.001 
Male sex 10 (71) 5 (42) 0.13  17 (85) 7 (88) 0.86 
Low socio-economic status 3 (23) 2 (17) 0.69  7 (37) 3 (43) 0.78 
Body mass index (kg/m2) 23.4 (5.5) 26.3 (8.8) 0.96  18.4 (4.3) 18.7 (3.6) 0.57 
Under treatment for diabetes - 12 (100) -  - 5 (63) - 
TB symptom duration>1month - - -  15 (79) 6 (86) 0.70 
Fasting capillary gluc. (mmol/L) 4.8 (0.7) 10.1 (4.6) <0.001 5.0 (0.5) 18.3 (12) <0.001 
Fasting plasma gluc. (mmol/L) 5.1 (1.1) 16.4 (4.6) <0.001 5.1 (0.6) 20.7 (6.2) <0.001 
Glycated Hemoglobin (%) 5.4 (0.6) 11.2 (3.4) <0.001 5.8 (0.7) 13.6 (4.5) <0.001 
        
Abbreviations and definitions:  
Latent Mtb: Mycobacterium tuberculosis latent infection defined as positive Mtb-specific Interferon-Gamma enzyme-
linked immunospot assay or positive Mtb-specific flow cytometry response or positive Mtb-specific cytokine release 
assay / TB: tuberculosis / DM: diabetes mellitus 
P value calculated with two-sided Wilcoxon-Mann-Whitney or chi-square tests when appropriate. 
Mtb peptide and BCG specific responses  
We determined the intracellular expression of the cytokines IFNγ, IL-2, TNFα, IL-4, IL-
9, IL-10 and IL-17 by CD4+ T cells using multi-parameter flow cytometry following 
stimulation of PBMCs with Mtb-specific peptide pools or live BCG. The percentage of 
volunteers responding to Mtb-specific peptide pools or live BCG did not vary 
significantly amongst study groups for any of these cytokines (Table 6-2). Participants 
with latent Mtb showed a trend towards lower frequency of Mtb-specific TNF-α CD4+ T 
cell responses compared to patients with active TB (p=0.08). After live BCG 
stimulation, patients with active TB and DM had a lower frequency of IFN-γ CD4+ T cell 
responses compared to participants with latent Mtb infection (p=0.07). Positive staining 
for cytokines IL-4, IL-9, IL-10 or IL-17 was low and was not evaluated further (Table 6-
2).  
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Table 6-2. Percentage of responding volunteers per cytokine and per study group. 
 Mtb-specific peptide pools stimulation  Live M. bovis BCG stimulation 
 All Latent Mtb Latent Mtb DM Active TB Active TB DM  All Latent Mtb Latent Mtb DM Active TB Active TB DM 
 N=50 N=12 N=12 N=19 N=7  N=50 N=12 N=12 N=19 N=7 
            
Any 881  92 75 89 100  92 92 100 89 86 
Th1 84 75 75 89 100  88 92 92 84 86 
IFN-γ 70 67 75 74 57  62 75 75 58 29¥ 
TNF-α 80 58§ 75 89 100  82 83 92 79 71 
IL-2 60 50 67 53 86  36 58 33 26 29 
IL-4 8 8 8 11 0  2 0 0 5 0 
IL-9 4 8 0 5 0  4 0 0 11 0 
IL-10 6 17 0 0 14  12 0 17 21 0 
IL-17 0 0 0 0 0  2 0 0 5 0 
            
Abbreviations and definitions:  
Mtb-specific stimulation: Mycobacterium tuberculosis antigens (CFP-10 and ESAT-6) / Latent Mtb: defined as positive Mtb-specific Interferon-Gamma enzyme-linked immunospot 
assay or positive Mtb-specific flow cytometry response or positive Mtb-specific cytokine release assay / TB: tuberculosis / DM: diabetes mellitus / Th1: IFN-γ, TNF-α or IL-2. 
§: P value=0.08 compared to active TB group under same stimulation condition; ¥: P value=0.07 compared to latent TB group under same stimulation condition (Fischer’s exact 
test). 
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Frequencies of CD4+ T cells producing Th1 cytokines  
<Following live BCG stimulation, we observed lower absolute frequency of CD4+ T 
cells producing IFN-γ (p=0.04; Figure 6-3a) and a similar trend in CD4+ T cells 
producing TNF-α among patients with active TB and DM compared to normo-
glycaemic  patients with active TB. In contrast, after Mtb-specific peptide pools 
stimulation, no difference in cytokine producing CD4+ T cells frequencies was observed 
between study groups (Figure 6-3b). As positive control documenting comparable 
PBMC viability polyclonal SEB stimulation was performed. No difference in frequencies 
of IFN-γ or TNF-α producing CD4+ T cells was measured (Figure 6-3c). 
 
 
 
 
 
Figure 6-3. Frequencies of CD4+ T cells producing cytokines between the different study groups after: a)  
live M. bovis BCG stimulation; b) Mtb-specific peptide pools stimulation; c) SEB stimulation 
CD4 T cells poly-functionality  
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We next investigated the representation of the CD4+ T cell subset producing different  
combinations of cytokines. After live M. bovis BCG stimulation, we observed a lower 
proportion of CD4+ T cells producing both TNF-α and IFN-γ in the group of patients 
with active TB and DM compared to normoglyacemic participants with latent Mtb 
infection (p=0.06, Figure 6-4a). There was a lower proportion of BCG-specific CD4+ T 
cells producing IFN-γ only in the group of participants with latent Mtb infection and DM 
compared to normo-glycaemic  patients with active TB (p=0.08; Figure 6-4a). The 
proportion of Mtb-specific CD4+ T cells double positive for TNF-α and IFN-γ was lower 
among participants with latent Mtb infection compared with all other study groups 
(Figure 6-4b).  
 
Figure 6-4. Representation of mono/polyfunctional CD4+ T cell subset responses between the different 
study groups after a) live M. bovis BCG stimulation; b) Mtb-specific peptide pools stimulation. Bars 
represent the median, lines the interquartile range. 
Frequencies of CD4+ T cells producing cytokines according to glycaemia 
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We next sought to investigate whether the intensity of the cytokines responses 
detected by flow cytometry would correlate with DM disease severity irrespectively of 
TB disease status. An increase in glycaemia was found negatively correlated with INF-
γ and TNF-α CD4+ T cells frequency under live M. bovis BCG stimulating condition 
(p=0.02 and 0.03 respectively) while there was no difference under Mtb-specific 
peptide pools or SEB control stimulation (Figure 6-5).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-5. Dot-plot graphs of the frequencies of CD4+ T cells producing cytokines against fasting capillary 
glucose levels after: a) live M. bovis BCG stimulation; b) Mtb-specific peptide pools stimulation; c) SEB 
stimulation. Linear regression was adjusted for age and sex. The horizontal line represents the median 
value of the logarithmic frequency of CD4+ T cells producing cytokines and the vertical line represents the 
fasting glucose level cut-off used for diabetes mellitus disease classification 
Cytokine and chemokine release assay response per study groups 
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Finally, we measured the secretion of cytokines and chemokines in cell culture 
supernatant after stimulation with Mtb-specific peptide pools (Table 6-3) or live M. bovis 
BCG (Table 6-4). Overall, Mtb-specific stimulation did not elicit substantial cytokine 
and chemokine production. Inflammatory mediators detected in BCG stimulated 
samples for more than 50% of patients in at least one arm and for which the production 
could statistically discriminate between two arms is summarized in Table 6-5). We 
observed a significantly lower frequency of responders for IL-9 and IL-22 among 
participants with latent Mtb infection and DM compared to those with a normal 
glycaemic status (p=0.005 and p=0.03). The production of IL-6 and MIP-1α was 
significantly higher among participants with latent Mtb infection and DM when 
compared to those with a normal glycaemic status (p=0.03 and p=0.007). In return, the 
level of IL-21 was lower among in participants with latent Mtb infection and DM 
compared to those with a normal glycaemic status (p=0.05). Among patients with 
active TB and DM and compared to those with a normal glycaemic status, the IL-18 
frequency of responders was found significantly reduced (p=0.02).  
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Table 6-3. Frequency of responders based on Luminex data analysis per cytokine and per study group, and 
cytokine level in all participants per study group after Mtb-specific peptide pool stimulation. 
 All  Latent Mtb Latent Mtb DM  Active TB Active TB DM 
 N=46  N=12 N=10  N=17 N=7 
 %  % Median (IQR) % Median (IQR)  % Median (IQR) % Median (IQR) 
            
IFN-γ 83  75 23(85) 70 24(603)  94 10(36) 86 55(346) 
TNF-α 28  33 1.2(4.9) 40 0.8(4.5)  29 0(1.3) 10 0.6(9.1) 
IL-2 46  50 11(21) 30 9.8(66)  53 2.5(9.3) 43 7.7(81) 
IL-4 30  17 2(14) 30 2.4(15)  41 0(9.1) 29 14(23) 
IL-5 13  8 0(0) 20 0(0)  12 0(0) 14 0(0) 
IL-13 46  58 0.9(4.5) 60 3.5(5.4)  29 0(2.1) 43 0(22) 
IL-9 20  25 0(24) 0 0(5.8)  24 0(5.8) 29 2.5(17) 
IL-10 9  0 0(1.4) 10 0(1)  12 0(0) 14 0(1.6) 
IL-17A 15  25 0(1.2) 10 0(1.3)  6 0(0) 29 0(3) 
IL-6 20  17 15(83) 30 180(362)  12 24(59) 29 20(668) 
IL-7 4  8 0(0) 10 0(0)  0 0(0) 0 0(0) 
IL-8 0  0 209(673) 0 472(605)  0 1892(3357) 0 258(384) 
IL-12p70 2  0 0(0) 10 0(0)  0 0(0) 0 0(0) 
IL-15 20  25 0(2.3) 20 0(3.6)  18 0(1.7) 14 0(2.6) 
IL-18 15  17 0(0) 30 0(14)  6 0(0) 14 0(0) 
IL-21 15  17 0(13) 10 1.8(7.1)  12 0(2) 29 4.6(11) 
IL-22 15  17 37(100) 20 25(131)  12 0(66) 14 12(167) 
IL-23 100  100 0(5.2) 100 0(7)  100 0(7) 7 3.2(8.5) 
IL-27 13  25 43(66) 10 0(45)  12 0(0) 0 0(0) 
IL-31 9  8 0(48) 0 0(27)  12 0(29) 14 4.5(37) 
IP-10 85  83 185(1398) 70 425(823)  88 183(669) 100 164(1318) 
MCP-1 4  8 498(1147) 0 146(795)  6 447(690) 0 173(1191) 
MIP-1 α 39  50 196(587) 40 402(290)  29 58(451) 43 125(281) 
MIP-1 β 15  17 448(1536) 10 974(1612)  18 354(1382) 14 498(1363) 
RANTES 4  0 1.3(37) 10 3.6(34)  0 16(54) 14 0(4.3) 
SDF-1 α 4  8 123(378) 0 167(320)  6 359(790) 0 109(199) 
TNF-β 9  8 0(8.4) 0 9.2(31)  0 0(21) 43 0(12) 
INF-α 28  50 0.2(0.8) 30 0.4(0.6)  18 0(0) 14 0(0.8) 
Eotaxin 33  50 0.6(0.8) 20 0.4(1)  29 0(0.5) 29 0(1) 
GM-CSF 28  42 4.2(19) 20 0(22)  12 0(0) 57 8.7(42) 
IL-1RA 17  25 300(1757) 20 150(1126)  18 371(933) 0 24(861) 
IL-1α 7  0 0.2(0.8) 0 0.4(0.6)  18 0(0) 0 0(0.8) 
IL-1β 41  42 1.2(4) 50 8(20)  35 1.6(4.1) 43 0.9(12) 
GROα 11  8 77(152) 0 229(262)  18 87(216) 14 47(175) 
            
P value<0.05 in bold. P values calculated with Wilcoxon-Mann-Whitney. 
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Table 6-4. Frequency of responders based on Luminex data analysis per cytokine and per study group, and 
cytokine level in all participants per study group after stimulation with live M. bovis BCG. 
 All  Latent Mtb Latent Mtb DM  Active TB Active TB DM 
 N=46  N=12 N=10  N=17 N=7 
 %  % Median (IQR) % Median (IQR)  % Median (IQR) % Median (IQR) 
            
IFN-γ 89  83 576(1908) 100 792(2277)  94 209(279) 71 84(7057) 
TNF-α 96  92 214(658) 90 200(193)  100 317(226) 100 244(699) 
IL-2 76  67 28(34) 60 45(35)  88 37(20) 86 34(48) 
IL-4 85  75 57(61) 80 79(58)  94 74(32) 86 74(51) 
IL-5 78  83 6.5(11) 60 9.4(16)  88 4.5(11) 71 5.7(11) 
IL-13 93  92 5.4(23) 100 9.5(12)  100 3.9(9) 71 5.4(60) 
IL-9 30  58 18(38) 0 0(35)  29 0(11) 29 0(37) 
IL-10 91  92 39(85) 80 39(36)  100 71(78) 86 33(186) 
IL-17A 41  58 1.1(3.1) 30 1.2(5)  29 0(2.1) 57 1.6(10) 
IL-6 72  67 2665(1528) 60 6802(5655)  76 3617(1565) 86 3672(3732) 
IL-7 15  17 0(0) 10 0(0)  12 0(0) 29 0(0.4) 
IL-8 0  0 159(895) 0 664(1620)  0 1469(1688) 0 367(7715) 
IL-12p70 41  58 7.6(24) 50 2.1(21)  29 0(5.1) 29 0(8.6) 
IL-15 48  67 7.9(7.6) 40 3.6(8)  35 0(1.7) 57 3.6(12) 
IL-18 85  75 13(23) 90 17.3(15)  100 12(8.6) 57 10(35) 
IL-21 30  50 14(11) 10 2.5(9.6)  24 1.9(8.9) 43 8.6(18) 
IL-22 50  75 249(649) 29 183.5(316)  47 106(106) 57 165(766) 
IL-23 15  8 22(96) 9 20.2(8.7)  29 39(73) 14 42(80) 
IL-27 24  42 150(215) 10 13.1(76)  24 11(30) 14 18(215) 
IL-31 15  17 41(87) 10 8(55)  18 4.4(43) 14 32(106) 
IP-10 28  50 10(49) 10 19.6(46)  29 15(29) 14 10(24) 
MCP-1 2  0 0(194) 0 0(0)  6 42(558) 0 0(0) 
MIP-1 α 43  50 1069(779) 30 1684(205)  35 1747(715) 43 1781(1497) 
MIP-1 β 43  50 8730(14356) 30 13384(23089)  35 16154(26790) 43 37571(185385) 
RANTES 7  0 35(120) 0 62(80)  18 100(411) 0 19(251) 
SDF-1 α 9  8 205(656) 0 456(953)  18 889(787) 0 105(458) 
TNF-β 9  8 0(34) 10 0(7.6)  6 0(12) 14 0(1.6) 
INF-α 30  58 0.7(0.9) 30 0(0.3)  18 0(0) 14 0(0.8) 
Eotaxin 41  58 2(1.4) 20 1.2(1.3)  47 1.3(0.9) 29 0.7(1.7) 
GM-CSF 98  92 453(654) 100 432(208)  100 559(571) 100 532(1231) 
IL-1RA 28  33 1021(2117) 10 604(1664)  35 1780(2539) 29 401(629) 
IL-1α 33  25 0.7(0.9) 20 0(0.3)  47 0(0) 29 0(0.8) 
IL-1β 93  92 751(1186) 90 1275(1198)  94 1028(1144) 100 800(1366) 
GROα 30  25 249(494) 20 560(344)  24 434(230) 71 450(4519) 
            
P value<0.05 in bold. P values calculated with two-sided Wilcoxon-Mann-Whitney 
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Table 6-5. Frequency of responders based on Luminex data analysis per cytokine and per study group, and 
cytokine level in all participants per study group after stimulation with live M. bovis BCG vaccine. 
 All  Latent Mtb Latent Mtb DM  Active TB Active TB DM 
 N=46  N=12 N=10  N=17 N=7 
 %  % 
Median 
(IQR) 
% 
Median 
(IQR) 
 % 
Median 
(IQR) 
% 
Median 
(IQR) 
            
IL-9 30  58 18(38) 0 0(35)  29 0(11) 29 0(37) 
IL-6 72  67 2665(1528) 60 6802(5655)  76 3617(1565) 86 3672(3732) 
IL-18 85  75 13(23) 90 17.3(15)  100 12(8.6) 57 10(35) 
IL-21 30  50 14(11) 10 2.5(9.6)  24 1.9(8.9) 43 8.6(18) 
IL-22 50  75 249(649) 29 183.5(316)  47 106(106) 57 165(766) 
MIP-1 α 43  50 1069(779) 30 1684(205)  35 1747(715) 43 1781(1497) 
            
P value<0.05 in bold. P values calculated with two-sided Wilcoxon-Mann-Whitney 
6.5 Discussion 
Under live M. bovis BCG stimulation, we observed a lower frequency of responders 
and reduced frequencies of IFN-γ CD4+ T cells as well as lower proportion of CD4+ T 
cells producing both TNF-α and IFN-γ in patients with active TB and DM compared to 
normo-glycaemic  TB patients. 
This study presented here has the strengths that our study population is well 
characterized and that DM diagnosis is based on three currently recommended 
screening tests that were repeated after TB treatment to avoid inclusion of patients 
with stress hyperglycaemia (2014). Patients with with pre-DM were excluded from the 
immunological study. PBMC collection was performed prior initiation of TB treatment 
since it is well known that cellular immune responses change rapidly under TB 
treatment (Jasenosky et al., 2015). We have studied PBMC instead of whole blood to 
circumvent potential bias linked to the extent of hyperglycaemia present in a whole 
blood assay set up. Importantly, we compared PBMC stimulation using whole live BCG 
side by side with peptide pools stimulation assuming that live BCG bacteria require 
steps of antigen processing and presentation for T cell stimulation while peptides can 
readily be loaded onto MHC class II molecules and presented to CD4+ T cells. Finally, 
we have used one of the most exhaustive Luminex cytokine detection panels available 
to compare the production of immune mediators in the different study groups. The 
study limitation mainly resides in the small sample size. Despite systematic screening 
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of TB patients for DM comorbidity, the recruitment of patients with active TB and DM 
has been greatly impeded by the exclusion of individuals with HIV co-infection. Also, 
only volunteers showing hyperglycaemia in all three screening tests used were 
included which allowed to select DM patients with persistent hyperglycaemia at the 
end of TB treatment rather than transient stress-induced hyperglycaemia (Boillat-
Blanco et al.). 
To our knowledge, only one study previously examined by using multiparameter flow 
cytometry the influence of DM on CD4+ T cells responses from patients with active TB 
after stimulation with various Mtb antigens including PPD, ESAT-6 and CFP-10. 
Contrasting to our observations, higher frequencies of CD4+ T cells expressing single 
or combinations of IFN-γ, IL-2 and TNF-α was found in active TB patients with DM 
compared to non-diabetic TB patients, suggesting a sustained, strong adaptive 
immune response in the presence of DM co-morbidity (Kumar et al., 2013b). However, 
Kumar et al. reported higher frequencies of CD4+ T cell producing cytokines at baseline 
than under antigen specific stimulation while our gating strategy used the signals 
detected among negative controls to solely detect T cell signals specifically induced by 
the stimuli after minimal background subtraction. Another study used ELISA to assess 
PBMC cytokine responses after stimulation with a battery of mycobacterial antigens 
and whole-mycobacteria and did not detect significantly different responder 
frequencies due to DM among patients with active TB (Al-Attiyah and Mustafa, 2009). 
These results suggested that adaptive immunity is not affected by DM or that TB 
specific CD4+ T cells may develop excessively. Different factors related to the host and 
pathogen genetics and to the selection of the study participants make comparison of 
the published results difficult. The study of Kumar et al. was conducted in India and 
DM diagnosis was based on glycated haemoglobin or random blood glucose measured 
at TB diagnosis while Al-Attiyah et al. included TB patients in Kuwait and defined DM 
using two blood glucose measurements (Al-Attiyah and Mustafa, 2009, Kumar et al., 
2013b). In our study, DM stratification was the most stringent using repeated fasting 
glucose, an oral glucose tolerance test and glycated haemoglobin that were further 
confirmed to be high after 5 months of TB treatment to avoid inclusion of patients with 
transient stress-induced hyperglycemia rather than DM (Boillat-Blanco et al.).   In 
addition, pre-DM patients were excluded. Furthermore, most our diabetic participants 
Diabetes and Impaired Tuberculosis Immunity 
81 
 
 
were previously known and treated for DM and did not take their treatment the day 
before study inclusion while this information is not available in other studies. For 
instance, Metformin, which is frequently used for DM treatment, facilitates phagosome-
lysosome fusion and enhances Mtb-specific immune response. This could improve 
antigen presentation and bias the interpretation of assay result (Singhal et al., 2014).  
We report an extensive multiplex cytokine/chemokine Luminex based detection, 
highlighting notably or the first time a lower frequency of responders of IL-9 and IL-22 
producing cells among diabetic participants with latent TB compared to normo-
glycaemic  volunteers. We also observed a lower response frequency of IL-18 
producing cells and a trend towards lower IFN-γ producing cells among patients with 
TB and DM compared to normo-glycaemic  active TB patients. 
The lower response frequency of IL-9 in patients with latent TB and DM is in line with 
previous results showing that IL-9 was significantly reduced in patients with DM 
compared to normo-glycaemic patients (Vasanthakumar et al., 2015). The higher IL-6 
release in patients with latent TB and DM following BCG stimulation also supports the 
generally elevated levels of circulating IL-6 described in type 2 DM and in patients with 
TB and high HbA1c level or in TB patients with DM and severe hyperglycemia (Kumar 
et al., 2013a, Restrepo et al., 2008, Stalenhoef et al., 2008). IL-22 has an important 
function in regulating metabolism including hyperglycaemia and insulin resistance 
(Wang et al., 2014, Wilson et al., 2010). Consistent with some of the findings of Kumar 
et al, we found a lower frequency of IL-22 responders among patients with latent TB 
and DM which is produced by macrophages and stimulating T cells to release INF-γ 
(Kumar et al., 2013a, Maartens and Wilkinson, 2007, Okamura et al., 1995). IL-18 has 
a decisive role in Mtb protective immunity (Schneider et al., 2010). The observed lower 
IL-18 response among patdiabetic patients with active TB and DM has not been 
previously documented.  
The lower frequency of IFNγ or IFNγ/TNFα CD4+ T cells among diabetic patients with 
active TB that is observed solely when PBMCs were stimulated with live M. bovis BCG 
but not with peptide pools, points to an antigen processing defect in this population. 
Our interpretation of a delayed T cell recall in live M. bovis BCG stimulated samples is 
in line with human experimental studies showing a defective function of antigen-
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presenting cells among diabetics and with the diminished interaction of Mtb with 
monocytes among patients with TB and DM (Delamaire et al., 1997, Gomez et al., 
2013, Jansen et al., 1995). Our results also go along with experimental data in mice 
showing that although the adaptive immune response against Mtb among diabetic 
mice is conserved, a delayed priming of CD4+ T cells to produce IFN-γ was observed 
and further sustained by the late migration of antigen presenting cells to the lung 
(Martens et al., 2007, Vallerskog et al., 2010). 
Of note, we observed a significant negative correlation between increasing levels of 
hyperglycaemia and the ability to measure antigen-specific CD4+ T cells following live 
M. bovis BCG stimulation in both, latent and active TB cases. This observation 
highlights the negative impact of high blood glucose levels on antibacterial immunity 
and has not been assessed in this way before. 
In conclusion, an impaired function of antigen presenting cells supported by other 
reports strongly reconcile the different CD4+ T cell recall responses observed between 
BCG and Mtb-specific peptide pools stimulation. These findings suggest that DM may 
not quantitatively affect T-cell mediated immunity in Tanzanian TB patients, but would 
rather delay its priming by affecting antigen processing and presentation. This 
undoubtedly warrants further investigation notably in the context of Metformin adjunct 
therapy during TB treatment that may specifically compensate for this defect and 
explain the benefits observed when Metformin was administered together with regular 
TB treatment regimen (Singhal et al., 2014).  
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7 Discussion 
The main purpose of this PhD thesis was to analyze the epidemiological and 
immunological backgrounds underlying the association between DM and TB in 
Tanzania, a setting with high HIV prevalence.  
The main findings of these studies are the following. Irrespective of HIV status, 
hyperglycemia was very common in TB patients, but, in most of them, the glucose 
status was normalized with TB treatment. Fasting hyperglycemia screening at TB 
diagnosis captured patients at risk of adverse TB outcome. In this equatorial African 
setting, vitamin D insufficiency seemed to increase the risk of TB only if associated 
with hyperglycemia measured after TB treatment. The immunological analyses 
suggested that DM does not quantitatively affect Mtb-specific T-cell mediated immunity 
in TB patients based on in vitro stimulation using ESAT-6 and CFP-10 peptide pools. 
However, poor glycemic control correlated with reduced in vitro IFN-γ secretion after 
live M. bovis BCG stimulation most likely reflecting impaired antigen processing or 
presentation. 
In this section we will discuss questions that have arisen throughout the project on 
comorbidity between communicable and non-communicable diseases. We will present 
how our studies contributed to generation of new knowledge on (i) the real burden of 
DM / low vitamin D and TB (7.1), (ii) the optimal methods of DM screening during TB 
(7.2), and (iii) the management of comorbid patients with DM and TB (7.3) 
7.1 Assessment of tuberculosis risk related to hyperglycemia and 
vitamin D: Advantage of a longitudinal study design 
Most studies assessed the link between TB and DM with a cross-sectional design and 
reported an increased risk of TB in the presence of DM (Jeon and Murray, 2008, 
Stevenson et al., 2007a). It is highly plausible that DM predisposes to TB as 
hyperglycemia leads to an impaired innate immune response which is the cornerstone 
of TB resistance, but TB also induces hyperglycemia through inflammation-driven 
insulin resistance and neoglucogenesis. Similarly, many cross-sectional studies 
reported that low vitamin D is a risk factor for TB which is compatible with the biological 
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activity of vitamin D as a booster of the innate antimicrobial activity. However, the 
inflammation induced by TB can possibly alter vitamin D metabolism and affect the 
concentration of the free active vitamin D by modifying the concentration of vitamin D-
binding proteins that are acute phase reactants (Bratke et al., 2014, Madden et al., 
2015). 
Therefore, cross-sectional study designs are limited by the reverse causality between 
TB and DM / vitamin D and quantification of the increased risk of TB attributable to DM 
based on the available evidence is questionable. The dynamic nature of these 
diseases calls for different study designs to understand the real burden of the 
association between TB and DM / vitamin D as well as the long term effect of each 
disease on the other. 
Ideally, a longitudinal population-based study with blood collected for DM screening / 
vitamin D measurement before the onset of active TB would provide the best evidence. 
However, such studies would need a very large sample size as the incidence of active 
TB is rather low. Registry-based studies could be an interesting alternative providing a 
large sample size, but mostly lack of access to prospective blood to allow DM and 
Vitamin D screening. So, given the challenges associated with an appropriate cohort 
or population-based study with prospectively sampled blood, the second best way to 
evaluate the real dual burden of TB and DM / vitamin D is to conduct a longitudinal 
study with glycemic and vitamin D measurements after treatment and resolution of 
active TB as we did in our study. By measuring these parameters after TB has been 
treated, we assumed that they were the best representation of the situation before the 
onset of TB. We used post-treatment blood levels as surrogate markers of the baseline 
situation. 
We will discuss below how our longitudinal study has advanced understanding of the 
correlation between hyperglycemia / low vitamin D and the risk to develop active TB. 
7.1.1 Hyperglycemia and risk of active TB and impact on TB outcome 
We observed a high frequency of transient hyperglycemia during active TB which 
highlighted the necessity to repeat DM screening later in the course of TB treatment to 
confirm DM and understand better the potential impact of DM on the burden of TB. As 
a result of the normalization of glycemic status during TB treatment, the observed 
Discussion 
86 
 
 
association between TB and DM at baseline disappeared after TB treatment. So, in 
cross-sectional studies, the impact of DM on active TB may be overestimated due to 
capture of stress hyperglycemia. However, detection of stress hyperglycemia was 
useful in predicting adverse TB outcome. 
Most studies evaluating the link between TB and DM have been conducted in settings 
with low HIV prevalence and only few studies have been conducted in the African 
region where HIV is the leading cause of TB. Our results suggest that DM may not be 
a major contributor to TB risk in this African setting. A study conducted in Mwanza, 
Tanzania showed that DM was a risk factor for TB only in HIV-negative patients.  
HIV is contributing to both, high TB and high DM prevalence as these diseases were 
both more common in HIV-infected individuals. While the contribution of HIV to these 
diseases independently is well known and was confirmed in our study, we did not 
observe a synergistic effect of HIV and DM on the risk of TB or the course of TB.  
7.1.2 Low vitamin D and risk to develop active TB 
We observed that vitamin D was lower among TB patients with underlying DM 
(assessed as either a previous DM diagnosis or as hyperglycemia measured at follow-
up) when compared to TB patients with a normal glycemia at follow-up. Vitamin D level 
was not affected by baseline hyperglycemia. Furthermore, we identified an increased 
risk of TB linked to vitamin D insufficiency only in the presence of hyperglycemia at 
follow-up. 
Considering the above, it is easy to understand how cross-sectional studies may miss 
the importance of DM in the association between TB and vitamin D when only 
considering the results of baseline glycemic screening at the time of active TB and its 
diagnosis. 
7.1.3 Importance of longitudinal glycemic evaluation in immunological studies 
We observed a lower frequency of IFN-γ or IFN-γ/TNF-α CD4+ T cells among diabetic 
patients with active TB after stimulation with live M. bovis BCG whereas in another 
study using the same methodology, higher frequencies of IFN-γ, IL-2 and TNF-α CD4+ 
T cells were found in active TB patients with DM compared to non-diabetic TB patients. 
The definition of DM was very different between studies. Indeed, we included only 
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patients with previously known DM or persisting DM at the end of TB treatment while 
the other studies categorized their DM patients based on HbA1c and/or glycemia 
measurement done at TB diagnosis. They probably included many TB patients with 
stress hyperglycemia rather than DM. The impact of stress hyperglycemia on TB-
specific immune response might be completely different than the impact of preexisting 
DM. Indeed, stress hyperglycemia results in a new glucose balance that might be 
beneficial for not insulin dependent tissues, like central and peripheral nervous system, 
bone marrow, white and red blood cells for which glucose movements is dependent on 
this concentration gradient. Stress hyperglycemia provides a source of fuel for the 
immune system and the brain at a time of stress (Marik and Bellomo, 2013). In contrast, 
in the presence of chronic hyperglycemia, the innate responses have impaired 
performance with decreased mobilization, chemotaxis, phagocytic activity and cytokine 
expression (Schuetz et al., 2011). So, the complete DM assessment done in our 
immunological study allowed to have comparable DM patients within the TB group as 
well as between the TB and control groups which was a major limitation of previous 
studies. 
Indeed, the recognition of stress hyperglycemia versus DM is of primary importance to 
identify the immunological mechanisms underlying the link between TB and DM. 
7.2 Methods of diabetes screening 
According to WHO and the American Diabetes Association (ADA), DM definition is 
based on three different biomarkers, fasting plasma glucose (FPG), 2-h plasma 
glucose (2-hPG) in an oral glucose tolerance test and, more recently, HbA1c. As shown 
in a recent review of data from several world regions, different biomarkers and 
definitions for DM provide different estimates of DM prevalence (2015). 
Each screening test has advantages and disadvantages (Figure 7-1). FPG is a cheap 
test, widely available and easy to perform. But, the test has to be done in the morning 
after an 8-hour overnight fast which can be challenging in sick patients. 2-hPG is a 
more sensitive test. However, it is not convenient to perform and this particularly in 
very sick people. HbA1c has several advantages over the other tests. Most assays 
have been standardized by the National Glycohemoglobin Standardization Program 
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which has improved precision and accuracy of the tests. It is more convenient for the 
patient as fasting is not required and it can be done at any time during the day. It has 
less day-to-day perturbations during acute illnesses due to its long half-life. So, we 
assumed that it would better capture preexisting DM during stress and illness. 
However, HbA1c is an expensive test which is not affordable and available in many 
low- and medium-income countries. Point of care HbA1c assays have not been 
validated for DM diagnostic. Furthermore, it has a lower sensitivity and Hba1c-based 
definition will not identify a substantial proportion of DM people (2015). HbA1c level 
may vary with patients ethnicity and HbA1c cut-off for DM diagnosis has not been 
validated in some part of the world. It might also be difficult to interpret HbA1c result in 
the presence of anemia and hemoglobinopathies. 
 
Figure 7-1. DM screening tests done during the study a. fasting capillary glucose; b. 2-hour glucose 
measurement after an oral glucose tolerance test; c. glycated hemoglobin in venous blood. 
Most studies assessing the link between TB and DM used one or two different DM 
screening tests and few evaluated Hba1c, while we used the three screening tests in 
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parallel which gives a unique opportunity to compare their performance during active 
TB.  
We will discuss below how using the three recommended DM biomarkers has 
advanced understanding of the optimal DM screening algorithm among TB patients. 
7.2.1 Non-overlap of the three screening tests 
We observed a very low concordance between tests, primarily due to a high number 
of Hba1c-only based DM diagnoses among TB patients (Figure 7-2). 
Figure 7-2. Concordance between DM screening tests for DM diagnosis among TB patients at TB diagnostic 
in the epidemiological study described in Chapter 4. 
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7.2.2 Performance of glycated hemoglobin 
Surprisingly, HbA1c did not perform better than other screening tests in capturing 
preexisting DM. The use of Hba1c for DM diagnosis was never validated in East Africa, 
a setting with a high prevalence of hemoglobinopathies and infectious diseases. 
Patients with active TB have a high prevalence of anemia which probably affects the 
reliability of the assay. Moreover, TB has unique characteristics as most of the patients 
have been sick for several months before diagnosis and the belief that preexisting 
underlying DM can be identified by Hba1c which is not affected by acute disease is 
wrong. This was also shown in a study conducted in Iran and confirmed by our findings 
(Tabarsi et al., 2014). 
HbA1c performed less well than fasting glucose to identify TB patients who will have 
an adverse outcome during TB treatment. Therefore, fasting glucose seems to be the 
optimal DM screening test to identify stress hyperglcycemia and potential associated 
adverse TB outcome. 
7.2.3 Repeated testing 
Most studies on the association between TB and DM based their DM diagnosis on a 
single unrepeated screening test value. We confirmed every elevated result by 
repeated testing as recommended by ADA (ADA, 2014) and observed a high intra-
individual variability particularly for FCG and 2-hCG (Figure 7-3). Part of this variability 
can probably be explained by an inappropriate fasting state. 
Figure 7-3. Intra-individual variability of repeated DM screening tests among TB patients at TB diagnostic 
in the epidemiological study described in Chapter 4. 
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These results highlight the need for repeated testing particularly during an acute 
disease making fasting difficult. They show the potential overdiagnosis of 
hyperglycemia in the absence of diagnosis confirmation. 
7.2.4 Impact for the immunological study 
During our immunological study, the TB group with DM consisted of patients having 
the three confirmed DM screening tests in the DM range. This allowed selecting 
patients with underlying DM as it was confirmed during follow-up. We discussed above 
the importance of DM definition as the expected Mtb-specific immune response is 
probably highly different in the presence of chronic underlying DM and stress 
hyperglycemia. 
7.3 DM management in TB patients 
We observed that fasting hyperglycemia was associated with poor TB outcome. 
Therefore, management of DM during TB treatment might be beneficial. However, all 
studies examining the effect of hyperglycemia management have been conducted in 
intensive care units. In this setting, short-term glycemic control with insulin has been 
linked to better outcome in septic patients, but only when targeting non intensive 
glycemic control and therefore avoiding the occurrence of hypoglycemia (Dungan et 
al., 2009). This evidence indirectly suggests that short-term management of glycemia 
might also improve TB outcome. However, the optimal glucose cutoff for treatment 
introduction and the appropriate drug to be used in the outpatient setting have to be 
defined. Important considerations about the management of hyperglycemia among TB 
patients are that we are dealing with outpatients having limited glucose monitoring and 
having an unpredictable nutritional intake which hamper the use of insulin. In this 
setting, metformin, the most prescribed drug for type 2 DM worldwide, might be a good 
choice. It has the advantage to reduce blood glucose without inducing hypoglycemia. 
Furthermore, metformin is currently being investigated for novel applications as host-
directed therapy for TB (Pryor and Cabreiro, 2015). Our immunological study suggests 
that DM delays the priming of T-cell mediated immunity by affecting antigen processing 
and presentation, a defect that may be specifically compensated by metformin. 
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The optimal glycemic cut-off to decide on hypoglycemic treatment and the benefit of 
such treatments is controversial. The long term DM risk among patients with transient 
hyperglycemia is unknown. However, detection of hyperglycemia is an opportunity to 
raise awareness of lifestyle influence on DM risk. 
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8 Recommendations 
We will now discuss the potential impact of our results on a change in medical practice 
and how NCDs programs can learn from communicable diseases in low- and middle-
income countries. 
Recommendations for policy and care 
 Integration of care between TB and DM programs 
 Screen TB patients for DM with fasting glycemia at TB diagnosis 
 Treat hyperglycemia among TB cases to improve TB  outcome 
 Confirm DM at the end of TB treatment to decide on long-term DM treatment 
 Screen DM patients for TB 
8.1 Integration of care between TB and DM programs 
The new post-2015 Global TB Strategy aims to end the global TB epidemic by 2035. 
To reach this target, there is a need to accelerate the reduction in TB incidence. Given 
the accepted link between TB and DM (increased TB risk and adverse TB outcome) 
and the expected sharp rise in DM during the next decade, it is important to include 
DM in strategic plans to control TB. TB programs could also be used to raise 
awareness of the importance of healthy diet and physical activity in case of 
hyperglycemia. So, there is a need to develop interactions, synergies and integration 
of care between TB and NCDs. These synergies and care integrations can be done at 
low cost through educational tools. These measures are most pressing in low- and 
middle-income countries, precisely those which are least prepared to confront this 
huge-scale DM pandemic. The link between TB and DM and the implementation of the 
collaborative framework for care and control have the potential to stimulate and 
strengthen the scale-up of NCD care and prevention programs, which may help in 
reducing not only the global burden of DM but also the global burden of TB.  
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 Integration of care between TB and DM programs should start without delay and 
address NCDs prevention and treatment in TB clinics as well as education about 
signs and symptoms of TB in diabetic clinics. This could help to reduce the burden 
of both communicable and non-communicable diseases. 
8.2 DM screening algorithm among TB patients 
Fasting hyperglycemia is very common in TB patients and is associated with an 
adverse outcome, but, in most of them, the glucose status is normalized with TB 
treatment. In most countries, there is a high yield from DM screening among TB 
patients at TB diagnosis (Harries et al., 2015). The yield is particularly high in older TB 
patients (>40 years) living in an urban setting and programs could chose to target 
higher risk patients according to their local epidemiology. DM screening at TB 
diagnosis gives the opportunity first, to identify patients at higher risk of adverse TB 
outcome and second, to manage hyperglycemia in these patients. However, DM needs 
confirmation later during TB treatment because of the high prevalence of transient 
hyperglycemia and the poor performance of HbA1c to detect preexisting DM.  
 Systematic fasting glucose screening of patients at the start of anti-TB treatment 
should be implemented. 
 In case of hyperglycemia, it should be treated to improve TB outcome.  
 Because of the high rate of transient hyperglycemia, DM should be confirmed at 
the end of TB treatment. 
 If DM diagnosis is confirmed, long-term DM treatment should be introduced and 
counselling about lifestyle modifications should be done. 
8.3 TB screening in DM clinics 
Systematic TB screening among diabetic people should be considered only in high TB 
burden countries because of very high number of diabetic patients needed to screen 
to detect one TB case in other settings. A recent Danish longitudinal study showed that 
the risk of TB drastically decrease within the first two years after diagnosis of DM 
(Kamper-Jorgensen et al., 2015). This raises some concern in parallel to our own 
observations, namely that at least some of the DM/TB association may be the result of 
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transient hyperglycemia rather than underlying DM. Therefore, at least in the African 
setting that we focused on, screening all DM patients for TB with expensive tests is not 
justified. But a simple and inexpensive TB screening method is to implement an 
education programme for care givers and patients to understand the increased TB risk 
and recognize early TB symptoms. 
 Systematic TB symptoms screening of DM patients should be done and DM 
patients should be able to recognize early signs and symptoms of TB. 
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9 Future research 
Recommendations for future research 
 Large cohorts of DM patients to follow-up for the incidence of TB 
 Cohorts of TB patients to follow-up for the long-term risk of DM after transient 
hyperglycemia 
 Randomized control trials to evaluate the optimal treatment of hyperglycemia 
during TB 
 Randomized control trials to evaluate the benefit of vitamin D supplementation to 
prevent TB among DM patients 
 Immunological studies including TB patients with DM and with transient 
hyperglycemia 
 Studies on the role of DM in other infections 
9.1 Large DM and TB cohorts 
The interaction between TB and DM is a dynamic process leading to difficult 
interpretation of cross-sectional data on the causal association between the two 
diseases. The dynamic nature of these diseases calls for appropriate longitudinal study 
design such as cohorts. Such studies will help to understand the relevance of dual or 
triple disease burden on the global burden of diseases. The integration of such data in 
the prediction models of the Global Burden of Disease rather than assessing the 
contribution of single diseases will improve the accuracy and reliability of the models. 
Cohort studies can also address the long term risk of DM among people having 
experienced transient stress hyperglycemia. Indeed, by analogy with gestational DM, 
the presence of transient hyperglycemia might identify people at higher risk of 
developing type 2 DM. 
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9.2 Randomized control trials to evaluate the optimal treatment of 
hyperglycemia during TB 
There is an urgent need to bring evidence to the management of comorbid patients. 
Intervention studies addressing the optimal glycemic cut-off for hypoglycemic 
treatment start as well as the choice of the appropriate treatment should be performed.  
The clinical benefits of adjunctive therapy with metformin together with regular TB 
treatment regimen were observed in two retrospective cohorts (Singh et al., 1984). The 
use of metformin adjunct therapy undoubtedly warrants further investigation. The 
therapeutic potential of metformin treatment extends far beyond its use as an anti-
hyperglycemic drug. It may be useful as a host-directed therapy for TB. Host-directed 
therapies include drugs that target the host and not the pathogen. They modulate the 
protective innate and adaptive immunity, reduce excess inflammation, repair or prevent 
tissue damage or enhance the effectiveness of TB drug therapy by modulating host 
factors (Hawn et al., 2015, Zumla and Maeurer, 2015). A key virulence mechanism of 
Mtb is its capacity to halt phagosome maturation in macrophages enabling an increase 
in lung bacterial load until adaptive immunity has been primed. Innate immune cells 
such as macrophages and dendritic cells play key roles in sensing infection, 
orchestrating adaptive immune priming and expressing enhanced antimicrobial 
functions once activated or targeted for cytolysis by antigen-specific T cells. Given the 
diversity of diabetic complications and the numerous pathways involved, the immune 
response to Mtb infection is probably affected at different levels (Martinez and Kornfeld, 
2014). Data from mice suggested an impaired function of antigen presenting cells to 
initial infection with a resulting delay in the adaptive immune effector response as a 
key mechanism of susceptibility (Vallerskog et al., 2010). This is consistent with our 
data which suggest that DM may not quantitatively affect T-cell mediated immunity in 
TB patients, but would rather delay its priming by affecting antigen processing and 
presentation. Metformin which enhances macrophage autophagy by promoting 
phagolysosome fusion and increasing mitochondrial ROS production may specifically 
compensate for the observed defect in antigen presenting cells (Singhal et al., 2014).  
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9.3 Randomized control trials to evaluate vitamin D on TB outcome and 
for TB prevention in DM patients 
Vitamin D is another candidate for host-directed therapy. It boosts the antimicrobial 
activity of human macrophages against Mtb. Vitamin D stimulates the vitamin D 
receptor to induce cathelicidin expression which has both immunoregulatory and direct 
antimicrobial activity (Hawn et al., 2015). 
Randomized control trials using vitamin D as adjunct anti-TB therapy did not provide 
detectable improvement in clinical outcome or mortality among patients with TB. 
Patients with DM who have a lower vitamin D level might be an appropriate target for 
a personalized approach for vitamin D supplementation to improve TB outcome. 
On the other hand, vitamin D supplementation is maybe more effective in prevention 
than treatment (Davies and Martineau, 2015). There is an ongoing trial testing the 
effectiveness of vitamin D in preventing pulmonary TB among HIV infected individual 
in Tanzania. Trials of vitamin D to prevent active disease in other high risk groups like 
people with DM are lacking and would provide interesting results. 
9.4 Immunological studies including TB patients with DM and with 
transient hyperglycemia 
For a better understanding of the immunological characteristics of patients with TB and 
DM, it will be important in future studies to differentiate patients with DM from those 
with transient hyperglycemia who will potentially not be affected in the same way. 
9.5 Studies on the role of DM in other infections 
The rising burden of DM in low- and middle-income countries might have a negative 
impact on other infections. The role of stress hyperglycemia and DM should be 
studied in other infections. Thanks to the expertise acquired during this PhD, I could 
bring my knowhow into a study on DM and dengue. Interestingly, we observed that 
DM was associated with an increased risk for a severe clinical presentation of 
dengue (Annex 1).
Conclusions 
101 
 
 
10 Conclusions 
In this sub-Saharan African setting, HIV seems to be a stronger contributor to TB than 
DM when looking at the impact on the risk of active TB. However, screening for 
hyperglycemia at TB diagnosis is still relevant, particularly in HIV positive patients, to 
identify patients at risk of adverse TB outcome who would benefit from appropriate 
management of hyperglycemia. As glycemic status is normalized with TB treatment in 
most patients, DM needs confirmation after TB treatment. The present work highlighted 
the dynamics of glycemic status during TB and the usefulness to screen patients at 
different time points during their disease. 
This work also provides interesting information on the association between low level of 
vitamin D, TB and DM. Low level of vitamin D seams to increase the risk of TB only if 
associated with hyperglycemia. These data move towards a potential use of vitamin D 
supplementation in a targeted diabetic population to prevent the development of active 
TB. 
Furthermore, the findings of the immunological work give new insights in the 
mechanisms underlying the association between TB and DM. These data indicate that 
DM affects live M. bovis BCG-specific CD4+ T cell responses through negative 
interaction with antigen processing or presentation events. This undoubtedly warrants 
further investigation notably in the context of Metformin adjunct therapy which may 
specifically compensate for this defect. 
This observational work was the first step in a better understanding of the interaction 
between TB and DM. It is now time to move to the improvement of the management of 
these comorbid patients, to integration between TB and DM programs, and to the setup 
of intervention studies. 
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Author Summary  
Both, dengue and diabetes have reached epidemic dimensions and pose a joint threat 
to a large proportion of populations in low- and middle-income countries. Dengue is no 
longer a disease primarily affecting children. Therefore the influence of non-
communicable diseases such as diabetes, which are increasingly prevalent in adults, 
on the clinical presentation of a dengue episode becomes a public health priority. We 
conducted a systematic literature review to assess the available evidence on the effect 
of diabetes mellitus (DM) on the clinical presentation of dengue. The meta-analysis of 
published evidence combined with supporting biological evidence point to an increased 
risk for potentially life threatening symptoms of dengue among patients with diabetes. 
The current evidence is limited by statistical power and other study limitations and does 
not allow conclusions about a causal effect of diabetes. Yet, based on the currently 
available evidence, diabetes patients with fever and living in a dengue endemic region 
should seek confirmation of dengue infection as early as possible. Diabetes should be 
considered in the triage of patients for close observation and early intervention, which 
are challenges, particularly during dengue outbreaks. Timeliness of intervention is the 
most important factor averting serious complications and death in patients with acute 
dengue.  
 
This paper has been published in Plos neglected Tropical Diseases 2015; 9: e0003741
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Abstract 
Background 
The mean age of acute dengue has undergone a shift towards older ages. This 
fact points towards the relevance of assessing the influence of age-related 
comorbidities, such as diabetes on the clinical presentation of dengue episodes. 
Identification of factors associated with a severe presentation is of high relevance, 
because timely treatment is the most important intervention to avert complications 
and death. This review summarizes and evaluates the published evidence on the 
association between diabetes and the risk of a severe clinical presentation of 
dengue. 
Methodology/Findings 
A systematic literature review was conducted using the MEDLINE database to 
access any relevant association between dengue and diabetes. Five case-control 
studies (4 hospital-based, 1 population-based) compared the prevalence of 
diabetes (self-reported or abstracted from medical records) of persons with dengue 
(acute or past; controls) and patients with severe clinical manifestations. All except 
one study were conducted before 2009 and all studies collected information 
towards WHO 1997 classification system. The reported odds ratios were formally 
summarized by random-effects meta-analyses. A diagnosis of diabetes was 
associated with an increased risk for a severe clinical presentation of dengue (OR 
1.75; 95% CI: 1.08-2.84, p =0.022).  
Conclusions/Significance 
Large prospective studies that systematically and objectively obtain relevant signs 
and symptoms of dengue fever episodes as well as of hyperglycemia in the past, 
and at the time of dengue diagnosis, are needed to properly address the effect of 
diabetes on the clinical presentation of an acute dengue fever episode. The 
currently available epidemiological evidence is very limited and only suggestive. 
The increasing global prevalence of both, dengue and diabetes, justify further 
studies. At this point, confirmation of dengue infection as early as possible in 
diabetes patients with fever if living in dengue endemic regions seems justified. 
The presence of this co-morbidity may warrant closer observation for glycemic 
Annex1 - Diabetes and Severe Dengue 
 
117 
 
control and adapted fluid management to diminish the risk for a severe clinical 
presentation of dengue.  
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Introduction 
With low- and middle-income countries (LMIC) experiencing a growing chronic 
non-communicable disease (NCD) burden and a continuously high communicable 
disease (CD) incidence rate, understanding the co-morbidity between the two 
disease groups is necessary to properly assess, monitor, evaluate, and control 
their prevalence (Bygbjerg, 2012, Remais et al., 2013). Cardiovascular diseases 
and their risk factors including diabetes mellitus (DM) are major contributors to the 
growing NCD burden (Murray et al., 2012). WHO projects that DM will be the 7th 
leading cause of death in 2030. Today there are 347 million people worldwide who 
have DM (Danaei et al., 2011), around 90% of them type 2 DM (WHO, 2014b). 
More than 80% of DM deaths occur in LMIC(WHO, 2014b). In high income 
countries DM has long been known for its association with increased susceptibility 
to infections such as tuberculosis (Martinez and Kornfeld, 2014). Although these 
associations have been attributed in part to DM associated alterations in innate 
immunity, related evidence is inconsistent and underlying mechanisms remain 
poorly understood. They are likely to vary by type of infection (Knapp, 2013). Yet, 
only few studies investigated the complex associations of diabetes with neglected 
tropical diseases (NTDs).  
Dengue, one of 17 diseases assigned NTD status by WHO, is next to malaria the 
most important arthropo-borne (ARBO) tropical infection caused by the dengue 
virus. It is transmitted by several mosquito species within the genus Aedes, 
principally A. aegypti (Gubler, 1998). The number of Dengue virus infections has 
increased 30fold over the last decades. Today it is a major public health problem 
in tropical and subtropical regions (Who, 2014a). The absence of adequate public 
health awareness, surveillance and control, population growth, globalization and 
urbanization contributed to this increase. An estimated 2.5 billion people are at risk 
of infection in over 100 endemic countries(CDC, 2012). WHO estimates that 
currently between 50 and 100 million dengue infections occur annually. An 
estimated 500’000 dengue patients with potentially life threatening symptoms 
require hospitalization each year and about 2.5% of those affected die (WHO, 
2014c). Dengue ranges from asymptomatic or self-limiting non-severe dengue 
(with or without warning symptoms) to severe dengue, characterized variously by 
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severe plasma leakage, severe bleeding or severe organ involvement (WHO, 
2009).  The studies reviewed in this paper were all except one conducted before 
2009 and therefore routine clinical data was collected according to the WHO 1997 
guidelines. These guidelines group symptomatic dengue virus infections into three 
clinical categories: undifferentiated fever, dengue fever (DF), and dengue 
hemorrhagic fever (DHF). DHF is further subclassified into four severity grades, 
with grades III and IV being defined as dengue shock syndrome (DSS) (WHO, 
1997). The clinical presentation of a dengue infection is difficult to predict, although 
the presence of warning signs occurring within 3 to 7 days after the first symptoms 
warrant strict observation and medical intervention. Intervention, including 
intravenous rehydration as the therapy of choice, can reduce case fatality in severe 
dengue to less than 1 % (Who, 2012). Dengue has long been viewed as a pediatric 
disease, but the average age of dengue cases has been rising and there is a 
suggestion for adults to be at increased risk for dying from dengue. The increase 
of tourism in tropical regions also contributed to the increase in adult dengue cases 
(Tantawichien, 2012) .  
There are five dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, 
DENV-4 and DENV-5), however, serotype 5 seems not to have a sustained 
transmission cycle in humans (Normile, 2013). Infection confers immunity to the 
infecting serotype which is life-long, but not to the remaining three. Subsequent 
infections with a different dengue virus serotype increase the risk of severe 
complications (Ooi et al., 2006). Other than that, factors increasing the risk of 
severe clinical manifestations remain poorly characterized (Cunha et al., 1999, 
Kouri et al., 1989, Malik et al., 2012). Present evidence suggests that beyond viral 
factors age, gender, social status, genetic background, sickle cell anemia, uremia, 
bronchial asthma, allergies, hypertension, chronic renal failure and also DM might 
adversely influence the clinical presentation of an infection (Cunha et al., 1999, 
Huy et al., 2013, Khor et al., 2011, Kouri et al., 1989, Silva et al., 2010, Thomas et 
al., 2010).  
In acknowledging the shift of dengue to older ages and the steep increase in the 
prevalence of DM, the objective of this review is to access the current clinical and 
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epidemiological evidence for this NCD to contribute to a higher risk of a severe 
clinical presentation in dengue fever patients.  
 
Methods 
Search strategy 
We conducted a systematic literature review using MEDLINE database to access 
any relevant publication describing an association between dengue and diabetes 
up to February 28 2014. The search terms used were “("dengue"[MeSH Terms] 
OR "dengue"[All Fields]) AND ("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All 
Fields] AND "mellitus"[All Fields]) OR "diabetes mellitus"[All Fields] OR 
"diabetes"[All Fields]”. 
Inclusion criteria 
We included articles in all languages; articles which reported on epidemiology, 
clinical signs, and laboratory parameters for dengue-infected patients, or on 
severity assessment. There was no restriction in publication dates, place of study, 
study design or age of research participants. As a validity assessment, the 
PRISMA criteria were used (2009, David Moher, 2009). 
For meta-analyses, we included studies that compared the prevalence of DM 
between persons affected by different dengue stages (case-control studies), 
reporting estimates of association and their 95% confidence intervals, or enough 
information to derive this.  
Data extraction 
We extracted the year during which dengue cases were diagnosed (year during 
which the study was conducted), year of the publication, country of the study, study 
design, study definitions of dengue infection and diabetes, and confounder 
adjustments. We extracted data on the sample size of enrolled persons and 
number of cases and controls and on the estimates (unadjusted and adjusted 
models) of the association (and their 95% confidence intervals) between diabetes 
and severe dengue. The transition of the patients data from clinical or hospital 
records to this review was based on published non-individual and non-identifying 
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data. Data were extracted from the published papers independently by two 
reviewers and disagreements were resolved by discussion. 
 
Case Definitions 
Dengue 
The studies included in this review mostly included dengue diagnosed before 2009 
and applied the WHO 1997 dengue classification criteria (WHO, 1997). A 2009 
classification was proposed by the WHO/TDR group and in 2011 the WHO/SEARO 
group also suggested modifications (Who, 2012). We list the classification system 
applied in the respective studies in Table 12-1, which summarizes the available 
evidence. Control status and case status are predominantly defined as DF and as 
DHF or DSS respectively. Cases of DHF/DSS in the studies reviewed were 
hospitalized cases or deaths confirmed serologically, clinically with hemorrhagic 
manifestations or radiographically with a certain extent of plasma leakage. 
According to WHO 1997 classification, DHF is clinically subdivided into grades I-
IV and all 4 grades could have some degree of at least subclinical plasma leakage. 
Grade I is the presence of fever with positive tourniquet test, grade II presents with 
spontaneous bleeding into the skin and elsewhere, grade III shows clinical signs 
of shock or circulatory failure, and grade IV presents with severe shock with 
undetectable blood pressure and pulse. Grade III and IV have also been labeled 
as “dengue shock syndrome” (DSS). The WHO 2009 classification differs from the 
1997 classification scheme in that dengue cases are classified by the levels of 
severity with or without warning signs. Several clinical features specifically listed in 
the WHO 2009 classification were not directly obtained in the reviewed studies, 
e.g. clinical features such as lethargy, restlessness, and severe organ impairment 
or failure. We refer to DHF/DSS as “severe clinical presentation of dengue”. 
In the reviewed publications, laboratory diagnosis methods to confirm dengue virus 
infection as the cause of disease varied across studies and involved detection of 
virus, viral nucleic acid, antigens or antibodies, or a combination of these 
techniques (WHO, 2009). The detection of virus, nucleic acid or antigen in the 
blood is confirmatory for an acute dengue infection. Antibody response to infection 
Annex1 - Diabetes and Severe Dengue 
 
122 
 
differs by the host immune status. In the setting of a primary infection, IgM are the 
first antibodies to appear, but it takes 10 days for them to be detectable in 99% of 
patients. During a secondary dengue infection, anti-dengue IgG are detectable at 
high levels already in the acute phase, whereas IgM levels remain significantly 
lower than in primary dengue infection. A four-fold or greater increase in IgG 
antibody levels in paired sera (sample collected during the acute stage of illness 
and sample collected in the convalescent stage) indicates acute dengue (WHO, 
2009). Identification of virus/viral RNA/viral antigen and antibody response are 
ideally combined for the confirmation of acute dengue. Yet, as specimen collection 
and processing is easier for serology, the laboratory methods applied in the studies 
mostly conducted in LMIC varied broadly. We list the laboratory confirmation 
methods applied in the respective studies in Table 12-1, together with the available 
evidence. 
Diabetes Mellitus 
In studies included in this review, the diagnosis of DM was mostly ascertained by 
self-reported diagnosis in the context of in-person interviews or DM diagnosis listed 
in clinical records. The DM diagnosis was further verified by requesting the 
prescription and/or medication package during the in-person interview in the only 
population-based case-control study (Figueiredo et al., 2010). An oral glucose 
tolerance test was performed in dengue patients in the case series published by 
Hasanat study (Hasanat et al., 2010). 
Meta-analysis 
We used random-effects models for meta-analyses of the association between DM 
and a severe clinical presentation of dengue (Lau et al., 1997). They take into 
consideration the variation between the true effects estimated by included studies 
unlike fixed effect models which assume a common true effect across studies. We 
used odds ratios as measure of association across all studies. We used the 
estimates reported by the authors as “primary model” and the I2 metric and Tau2 to 
describe the between study heterogeneity and variance respectively.  
We conducted sensitivity analyses by using a fixed effect model and excluding a 
study, which was based on non-matched random controls and that only reported 
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unadjusted estimates (Karunakaran et al., 2014). We performed analyses with 
Stata version 12 (Stata Corporation, Texas) and considered p<0.05 as statistically 
significant. 
 
Results 
Our literature search resulted in 32 hits (Fig. 12-1). After excluding duplicates and 
non-relevant articles based on a full text analysis (single case reports, outbreak 
investigation reports, no specific factors studied, narrative overview of dengue 
infections in a specific country or globally), ten articles were retained. Among them, 
five studies were case-control studies (Karunakaran et al., 2014, Mahmood et al., 
2013, Pang et al., 2012, Min-Sheng Lee, 2006)  with one study being population-
based (Figueiredo et al., 2010). The case-control studies compared the prevalence 
of DM in persons with acute or past non severe dengue (controls) to that in persons 
with an acute severe clinical presentation of dengue. Five additional articles (case 
series) characterized DM in mostly dengue patients with severe clinical 
manifestations, including fatal cases (Hasanat et al., 2010, Lahiri et al., 2008, Lye 
et al., 2010, Sam et al., 2013, Wieten et al., 2012). These studies lack a comparison 
group with acute or past non severe of dengue, and are therefore not included in 
the meta-analysis. 
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Figure 12-1. PRISMA Flow diagram of diabetes and dengue 
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Epidemiological evidence from case-control studies on the association 
between DM and a severe clinical presentation of dengue  
Epidemiological studies included in the meta-analysis compared the prevalence of 
DM and other co-morbidities between patients suffering from acute dengue with a 
severe presentation and controls with acute or past dengue without severe clinical 
manifestations (Table 12-1). In the absence of controls without evidence for a 
dengue infection history, studies thereby compared the prevalence of DM in 
dengue patients with different degrees for severity in clinical presentation, rather 
than the risk of being infected with dengue virus.  
The only population-based case-control study (Figueiredo et al., 2010) identified 
was conducted in two Brazilian cities and included both, children and adults. DHF 
cases were ascertained through the national surveillance system. The surveillance 
records were reviewed by two physicians. DHF was defined according to criteria 
used by Brazilian Healthy System, which were very close to WHO 1997 criteria. 
Controls were selected from the same neighborhood as cases. In addition, they 
were tested positive for anti-dengue IgG and matched to cases by age, sex and a 
report of a past dengue-like fever in the same year as the DHF diagnosis of cases. 
Additional information from both, cases and controls was obtained through in-
person interviews. DM was based on a self-reported physician-diagnosis. 
Interviewers also asked for medication intake and verified it by seeing the 
prescription of packaging. DM was statistically significantly associated with DHF 
independent of age, sex skin color, income and educational level (aOR 2.75, 95% 
CI 1.12-6.73). The association of self-reported diabetes with DHF was stronger in 
diabetic patients being treated, especially if treated with insulin or more than 1 drug 
(aOR 3.36; 95% CI 0.72-15.61). In addition, white ethnicity (aOR 4.70, 95% CI 
2.17-10.2), high income (aOR 6.84, 95% CI 4.09-11.43), high educational level 
(aOR 4.67, 95% CI 4.09-11.43) and a self-report of allergy treated with steroids 
(aOR 2.94, 95% CI 1.01-8.54) were also associated with a more severe clinical 
presentation of dengue.  
A hospital-based study including persons aged 15 to 65 in Pakistan (Mahmood et 
al., 2013) compared hospitalized acute DHF patients (cases) to dengue IgG 
positive patients, but hospitalized for unrelated conditions (controls). The study was 
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conducted in two major tertiary care hospitals. A DHF case was defined as 
diagnosis by an experienced clinician applying WHO criteria, although the version 
applied was not specified. The categorization into persons with and without DHF 
points to the use of WHO 1997 criteria. Information was obtained through 
structured record review and in-person interview. Age- and sex-matched DHF 
cases were slightly more likely to report a DM diagnosis than control patients. In 
both groups, the reported prevalence of DM was exceptionally high, 41.8% in 
controls and 43.2% in cases. The association of DM with DHF adjusted for age, 
sex and duration of illness was statistically non-significant (aOR 1.26, 95% CI 0.78-
2.03, p= 0.34).  
In Singapore, a hospital-based study was conducted in the nation’s largest clinic. 
It included all admitted patients with acute dengue without age restriction (Pang et 
al., 2012). Information on case and control status as well as comorbidities was 
exclusively derived from abstracting medical charts. Cases were defined as DHF 
patients, and controls were DF patients. Probable dengue patients had a positive 
acute dengue serology. Confirmed dengue patients had positive dengue 
polymerase chain reaction assays. Clinical diagnosis for DHF was based on WHO 
1997 criteria. The data was analyzed separately for the two epidemic periods of 
2006 (predominantly DENV-1) and 2007/2008 (predominantly DENV-2; larger 
sample size). No association between DM status and DHF was found in the 2006 
dengue outbreak. DM was independently associated with DHF in the 2007/8 
epidemic (aOR 1.78, 95% CI 1.06-2.97). The association was stronger if the 
diabetic patients additionally had hypertension (aOR 2.16, 95% CI 1.18-3.96) or 
asthma (aOR 4.38, 95% CI 0.80-23.85). Mean hospitalization days were longer for 
DM (4.99±3.34days) as compared to non-DM patients (4.04±1.62 days, p =0.001). 
Additional factors associated with DHF were Chinese ethnicity (compared to Malay 
or Indian ethnicity) (aOR 1.90, 95% CI 1.01-3.56 in 2006 epidemic periods and 
aOR 1.67, 95% CI 1.24-2.24 in 2007/2008 epidemic periods) as well as middle age 
in 2007/2008 (aOR 1.41, 95% CI 1.09-1.81 in 30-39 years and aOR 1.34, 95%CI 
1.09-1.81 in 40-49 years of age group).  
In 2002 in Taiwan, all patients with confirmed acute DF treated at the Kaoshiung 
Medical University Hospital during a large outbreak occurring in the southern 
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Taiwan were categorized into groups of DF and DHF/DSS by strictly adhering to 
clinical WHO 1997 criteria and laboratory confirmation under the auspices of the 
Taiwanese Centre of Disease Control (Min-Sheng Lee, 2006). Clinical information 
such as signs and symptoms and the results of blood investigation were abstracted 
from medical records. Cases were mostly adults, only 4.5% were below age 15 
years. The prevalence of DM was 16.8% in DHF/DSS cases compared to 7.6% in 
DF patients (controls). The adjusted OR reported was 1.86 (95%CI 1.04-3.37), 
albeit covariates were not reported. In addition to the independent association of 
DHF/DSS with DM, statistically significant associations with hypertension and renal 
insufficiency, uremia, past history of dengue infection as well as male gender and 
older age were also found. 
A hospital-based study in Southern India (Karunakaran et al., 2014) obtained 
information on patients admitted to the largest multi-specialty hospital in South 
Kerala for acute dengue between 2005 and 2008. The case group consisted of 10 
in-hospital deaths of patients admitted with a clinical diagnosis of probable dengue, 
which was confirmed by either RT-PCR or IgM antibody tests, and review of clinical 
symptoms through medical record review. Forty non-matched controls were 
randomly selected among patients with a confirmed acute dengue, but recovering 
from the illness. The classification of dengue among the controls was not specified. 
Information on co-morbidities and other factors was abstracted from medical 
records. The prevalence of DM in controls was 2.5% compared to 40% in cases. 
DM was a strong predictor of mortality in the bivariate analysis (OR 26.0, 95% CI 
2.47-273.67, p =0.004). In the same study, hypertension was also a strong 
predictor of mortality (OR 44.3, 95% CI 6.2-315.5, p= 0.000). Mortality was much 
higher in patients over 40 years (OR 9.3, 95% CI 1.9-44.4, p= 0.002). No adjusted 
odds ratios, which would facilitate the interpretation of independency in the 
reported associations, were reported. 
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Table 12-1. Summary of case-control studies and case series. 
 
First author 
and 
publication 
date 
Country & 
Year of 
study 
Study design Characteristics of Study population 
Results(Odds ratios (OR) and 95% 
confidence intervals) 
Epidemiological case-control studies 
Figueiredo 
et al.(2010)  
Brazil, 
2002-2003 
(Salvador), 
2003-2005 
(Fortaleza) 
Population-based 
case-control 
study 
Cases:170 acute DHF    Predominantly DENV-3,Association DM 
– acute DHF vs. asymptomatic (IgG) 
(+)ve controls Adjusted OR (age, 
sex,income, neighborhood, skin colour, 
education) 
-registered in the national surveillance systems DM yes vs. no.: aOR 2.75 (1.12-6.73) 
-residents of 2 cities DM according to the number of 
medications: no medication vs. no DM 
:aOR 1.83 (0.18-18.67)                           
-no age restriction 1 medicine vs. no DM: aOR 2.72 (0.86-
8.60)                     
-diagnostic criteria: Insulin/ >1 medicine vs. no DM:aOR 
3.36 (0.72-15.61) 
surveillance record review by 2 physicians;  DM prevalence: 
controls:2.6%,cases:5.3% 
Brazilian Health Service (very similar to WHO 1997) criteria;  
fever & positive serology for anti-dengue IgM and/or viral isolation and 
characterization; 
 
at least two signs or symptoms of dengue fever (headache or retroorbital pain, 
myalgia, arthralgia, prostration, exanthema); 
 
all of the following signs: hemorrhagic manifestations, hemoconcentration with 
an increased haematocrit level; thrombocytopenia; 
 
no consideration of ascites or pleural effusion (rarely recorded)  
Controls: 1175   
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-neighborhood controls   
-sero-positive (anti-dengue IgG)   
-self-report of dengue like illness in same year as matched case   
-no history of DHF  
-matched for age and sex (within 5 years)  
Information on dengue history, confounders, effect modifiers & 
comorbidities: in-person interviews  with cases and controls 
 
DM: self-report of physician diagnosis and verification of prescription 
/packaging of medication 
 
Mahmood et 
al (2013)  
Pakistan 
(2011) 
Hospital-based 
case-control 
study 
Cases: 132 acute DHF Association DM – acute DHF vs. 
asymptomatic IgG positive controls: 
Adjusted OR (sex, age, duration of 
illness) 
-admitted to two major tertiary care hospitals of Lahore DM yes vs. no: aOR 1.26 (0.78-2.03), 
p=0.34 
-age 15-65 DM according to its duration: 
-diagnostic criteria: 5-10 vs. <5 yrs aOR 2.76(0.77-
9.84),p=0.11                 
diagnosed as DHF by a  trained clinician; >10  vs. <5 yrs:aOR 1.86 (0.55-
6.26),p=0.31 
WHO criteria (version not specified) DM prevalence: controls: 42% 
,cases:43% 
Controls: 249 patients without acute dengue  
-random sample of patients from same health facilities admitted for reasons 
other than dengue; 
 
-positive for anti-dengue IgG;  
-matched for age and sex (within 5 years);  
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-Information on dengue history, confounders, effect modifiers & co-moribities: 
in-person interviews  with cases and controls; checklist for clinical record 
review 
 
DM: self-report or clinical record  
Pang et al 
(2010) 
Singapore 
(2006-
2008) 
Hospital-based 
case-control 
study 
2006 epidemic: Cases:149 acute DHF, Controls:326 acute DF 2006 epidemic: predominantly DENV-1 
2007/2008 epidemic: Cases:590 acute DHF, Controls:1141 acute DF 27.6% of patients PCR (+)ve 
-admitted to the largest hospital of Singapore for dengue 72.4% of patients sero-positive & PCR(-
)ve  
-adult Association DM- acute DHF vs. 
acuteDF: Adjusted OR (age, ethnicity) 
-diagnostic criteria: DM yes vs. no: aOR 0.34 (0.06-1.89) 
probable DF: positive acute dengue serology (Dengue Duo IgM & IgG Rapid 
Strip Test) and clinical criteria of DF by WHO1997; 
DM prevalence: controls:  2.2% ,cases: 
1.3%   
confirmed DF: positive dengue PCR and clinical criteria of DF by WHO 1997 2007/8 epidemic: predominantly DENV-
2 
-DHF: presence of all four criteria of fever, hemorrhagic  manifestiations, 
thrombocytopenia, plasma leakage 
32.6% of patients PCR positive 
Information on dengue history, confounders, effect modifiers & 
comoribities: clinical record review 
67.4% of patients sero-positive & PCR 
(-)ve 
DM: clinical records Association DM- acute DHF vs. acute 
DF: aOR (age, ethnicity, gender, 
hypertension) 
 DM  yes vs. no: aOR 1.78 (1.06-2.97)                                               
 DM with hypertension: aOR 2.16  (1.18-
3.96)                                
 DM with hyperlipidemia:aOR 1.62 (0.90-
2.92)                            
 DM with asthma: aOR  4.38 (0.80-
23.85)                                               
 DM prevalence: controls:3.5%, 
cases:6.4% 
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Lee et al.  
(2006) 
Taiwan 
(2002) 
Hospital-based 
case-control 
study 
Cases:232 acute DHF (12 DSS) Association DM- acute DHF/DSS vs. 
acute DF: Adjusted OR( factors not 
reported) 
Controls:412 acute DF DM  yes vs. no: aOR 1.86 (1.04-3.37) 
-all confirmed acute DF treated at Kaohshiung Medical University Hospital in 
2002 
DM prevalence: cases:16.8%, 
controls:7.6% 
-no age restriction Plasma leakage prevalence: Pleural 
effusion: 51% of DHF cases  
-diagnostic criteria for confirmed acute DF: Ascites: 31% of DHF cases 
WHO 1997 criteria, meeting any of:  
positive dengue virus by PCR;  
4-fold increase of dengue virus-specific IgM or IgG in paired serum samples; 
 
 
positive for dengue virus-specific IgM or IgG in a single serum sample; 
 
 
Thrombocytopenia;  
Evidence for hemorrhage and plasma leakage;  
additional diagnostic criteria DSS:  
hypotension, narrow pulse pressure, clinical signs of shock  
Information on dengue history, confounders, effect modifiers & 
comoribities: clinical record review 
 
DM: clinical records  
Karunakaran 
et al (2014) 
 
India 
(2005-
2008) 
Hospital-based 
case-control 
study 
Cases:     10 acute dengue patients, fatal Association DM -  mortality among 
confirmed acute dengue patients 
Controls: 40 acute dengue patients, non-fatal DM yes vs. No: Crude OR 26.0 (2.5-
273.7) 
-confirmed dengue patients admitted to in South Kerala hospital between 
2005-2008 
DM prevalence: controls:2.5%, 
cases:40% 
diagnostic criteria:  
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-confirmation by PCR or IgM antibody  
Information on dengue history, symptoms, confounders, effect modifiers 
& comorbities: semi-structured interview ;assessment of warning signs 
according to WHO 2009 case definition 
 
   DM mellitus: self-report  
Case series 
Lye et al. 
(2009) 
Singapore 
(2004) 
Hospital-based  Cases: 1971 acute DF, DHF, and DSS cases DM prevalence: Age <60:2% ,Age ≥ 60: 
17% 
-all patients admitted to the Tan Tock Seng Hospital in Singapore in 2004   
- fulfilling WHO 1997 criteria for acute dengue   
- positive dengue  diagnostic tests:  
- probable dengue:(+)ve acute dengue serology (Dengue Duo IgM & IgG Rapid Strip 
Test) 
 
- confirmed dengue:   
- positive PCR   
- no age restriction  
Information on dengue history, symptoms, confounders, effect modifiers 
& comoribities:  clinical records 
 
DM: clinical records  
Wieten et al. 
(2012) 
Netherlands 
(2006-
2011) 
Tropical and 
travel-medicine 
based case 
series 
Cases: 132 acute dengue cases  DM prevalence: 8% 
-dengue patients serologically tested at Amsterdam Medical Center between 
2006-2011 
 
-diagnostic criteria:  
serological confirmation:positive anti dengue  IgM or at least fourfold increase  
in dengue specific IgG if possible based on  one sample from the initial phase 
and one from the convalescent phase or else according to WHO 2009 criteria 
for a single sample; 
 
 
 
clinical picture of probable dengue (WHO 1997 and 2009 criteria) or   
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DHF (WHO 1997) or dengue with warning signs (WHO 2009);  
Information on dengue history, symptoms, confounders, effect modifiers 
& comoribities: clinical records 
 
DM: clinical records  
Sam et al  
(2013)     
Malaysia 
(2006-
2007) 
Hospital-based  Cases: 10 acute DF/DHF/DSS patients, fatal DM prevalence: 30% (pre-existing) 
-fatal cases at the University Malaya Medical Center 2006-2007 Plasma leakage prevalence: 78% of all 
cases  
-diagnostic criteria: (67% among diabetic patients) 
laboratory confirmation: acute phase dengue-specific IgM and IgG; RT-PCR;  
disease severity classification WHO 1997 ;  
age range: 11-59;  
Information on dengue history, symptoms, confounders, effect modifiers 
& comoribities: clinical records 
 
DM: clinical records  
Lahiri et al  
(2008)    
Singapore 
(2004-
2005) 
Hospital-based  Cases: 9 acute dengue cases, fatal  DM prevalence: 78% 
-fatal cases of a total of 1235 admissions with acute dengue in 2004-2005 Plasma leakage prevalence: 28% of  DM 
patients 
-all 9 patients had positive laboratory test for dengue (7 by IgM, 3 by PCR)  
-all 9 patients had evidence for capillary leakage and hemorrhagic manifestations  
-7 of  9 patients strictly met DHF WHO 1997 criteria  
- age range: 37-71  
Information on dengue history, symptoms, confounders, effect modifiers 
& comoribities: 
 
clinical records   
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DM: clinical records  
Hasanat et  
al.(2010) 
Bangladesh 
(2009) 
Hospital-based  
(prospective) 
Cases: 133 acute dengue cases  Status on 1st  OGTT (n=133): 
Normal:25% , Glucose intolerant:54% 
,DM:21% 
-patients admitted to Samoritha Hospital in Dakha for dengue Status on 2nd   OGTT (n=40):  
- laboratory confirmation by anti-dengue antibody test 1 week of onset of illness Normal:83% 
-further diagnostic criteria not provided Glucose intolerant:17% 
Information on dengue history, symptoms, confounders, effect modifiers 
& comorbities: interviews 
Repeatedly normal:25%, 
DM: Oral glucose tolerance testing in consenting cases: 1st test between day 
3 and 10 of admission and 2nd test before discharge 
Repeatedly abnormal:18% 
 Reverting to normal:55% 
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Meta-analysis of epidemiological evidence from case-control studies 
We included the results of five above mentioned studies in a meta-analysis. One 
of these studies reported two separate estimates from two independent cross-
sectional assessments; hence, we considered them as separate studies. The 
meta-analysis showed that the presence of a severe clinical presentation of 
dengue was positively associated with the presence of DM.  
A diagnosis of DM was associated with an increased risk for severe clinical 
manifestations of dengue by 75% (95% CI: 1.08-2.84, p =0.022) compared to non-
DM patients (Fig. 12-2). This OR remained robust across sensitivity analyses 
involving fixed effect analysis. We observed some heterogeneity across the 
studies, consistent with the broadly differing study settings. The small number of 
studies included in the meta-analysis did not provide statistical power for formal 
statistical assessment of heterogeneity (Fig. 12-2). 
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Figure 12-2. Meta-analysis of case-control studies on the association between diabetes mellitus and 
severe clinical presentation of dengue. 
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Clinical case series on characteristics of DHF patients 
We additionally identified five case series reporting dengue-related hospitalizations 
and the prevalence of DM in these cases. They are listed in Table 12-1 as 
reference of the prevalence of DM in dengue patients with a severe clinical 
presentation. The studies have been conducted mostly in Asian dengue endemic 
regions such as Malaysia (Sam et al., 2013); Bangladesh (Hasanat et al., 2010); 
Singapore (Lye et al., 2010, Lahiri et al., 2008). In the absence of a control group, 
these studies are of limited value for better understanding of the role of DM on the 
clinical presentation of dengue. In several instances the case definition was 
restricted to just being dengue seropositive. This does not allow differentiating 
between DM influencing the clinical manifestations of dengue infection versus 
dengue infection influencing the clinical presentation of DM. Of interest, in that 
respect is the study by Hasanat et al (Hasanat et al., 2010). Hospitalized DF 
patients underwent oral glucose tolerance testing (OGTT) between 3 and 10 days 
after the start of illness. A subset of these patients agreed to a second OGTT before 
discharge. The authors demonstrated a high rate of glucose intolerance in the early 
phase of disease, which returned though to normal in 55% of the patients.  
Discussion 
The few published studies specifically addressing the role of DM as a risk factor 
for a severe clinical presentation of dengue provide suggestive evidence for an 
adverse effect. This result merits further investigation in the context of study 
designs that overcome the weaknesses of currently available publications as 
addressed below.  
Assigning causality to the modifying effect of diabetes on the clinical presentation 
of dengue is premature. First, the case-control studies conducted to date and 
summarized above are mostly retrospective in nature. The clinical and laboratory 
diagnostic criteria applied in different studies vary broadly, as does the definition 
for the control group. Second, the WHO 1997 dengue classification used in the 
studies reviewed, has itself a number of limitations. For example, the development 
of this classification was based on disease patterns of children in Thailand, 
potentially limiting its generalizability to other geographical regions and to older age 
groups. Furthermore, clinical assessments such as the  Tourniquet test do not 
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differentiate between DF, DHF and other febrile illness (Deen JL, 2006, Rigau-
Perez JG, 2006). It also fails to detect severe dengue manifestations in many 
patients (Balmaseda A, 2005). Third, information on DM was either self-reported 
or record-based and did not systematically allow differentiating between DM 
diagnosed before versus concurrent with the dengue episode. Given the high 
degree of under diagnosis of DM, especially in LMIC, misclassification of DM status 
in the studies is likely substantial. The problem of under diagnosis is not easy to 
overcome, as DM measured at the time of acute dengue is not necessarily 
reflecting the underlying DM status, but rather stress-related hyperglycemia, which 
disappears after recovery from dengue (Hasanat et al., 2010). Longitudinal studies 
of dengue patients are needed that allow studying both, the longitudinal course of 
hyperglycemia and the evolvement of clinical presentation of the dengue infection. 
In addition, whether better control of DM in early stages of dengue will prevent 
severe forms of dengue needs to be assessed in the context of intervention studies. 
The basis should be dengue surveillance programs which registers all dengue 
episodes and which includes routine collection of blood specimens for HbA1c and 
other hyperglycemia parameters and of information regarding diagnosis and 
treatment of DM. A fifth limitation of studies conducted to date is the fact that most 
of them were hospital-based case-control studies with a high potential for selection 
bias. But the results from the only population-based case-control study also point 
to DM increasing the risk for a severe clinical presentation of dengue (Figueiredo 
et al., 2010). Finally, study limitations also include the fact that the modifying effect 
of DM on different dengue serotypes could not be differentiated; that the age range 
of study subjects was not always reported; and that many studies included children 
and adolescents in whom DM is rare.The observed heterogeneity between the 
results of the individual studies is a limitation in the meta-analysis and reflects 
differences in the diagnostic and classification criteria for dengue and DM, 
differences in the controls selected, as well as differences in study design such as 
sample size, population and study setting or confounders considered in the 
analysis. Our systematic and broad search strategy, (not limiting to publication 
dates, place of study, study design or age of research participants) and the novelty 
of this topic are the strengths of our review and should stimulate further research 
into the topic, also in the light of supporting results from experimental studies. 
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Biological evidence exists to support the hypothesis for a high DHF: DF ratio in 
diabetes. One example for a line of reasoning is that the cytokine overload related 
to a Th1 to Th2 shift and a severe manifestation of dengue superimposed by the 
cytokine overload of a diabetic state may be particularly detrimental to the 
endothelium and for subsequent vascular leakage (Sierra et al., 2010, Daniel 
Limonta, 2008, Chaturvedi et al., 2000).  The third space fluid shift such as 
pleural/pericardial effusion or ascites is an important clinical manifestation in 
dengue with severe clinical symptoms, which is a consequence of endothelial 
dysfunction and results in hemoconcentration, hypotension and shock (Lahiri et al., 
2008).  DM shares with a severe clinical presentation of dengue alterations in the 
innate immune response, a pro-inflammatory state and endothelial dysfunction. 
Lee and colleagues infected mononuclear cells from diabetic (n=33) and healthy 
individuals (n=29) with dengue virus. Cells from diabetics produced higher levels 
of IL-4 and of both, IL-4 and IL-10 as well as granulocyte-macrophage colony-
stimulating factor (GM-CSF) on the first and third day post-infection, respectively. 
No differences in viral load were found (Lee et al., 2013). In a post-mortem study 
of DHF/DSS related deaths, the intestinal serosa of 1 DM case with ascites, but 
not of non-DM cases showed apoptosis of microvascular endothelial cells (Daniel 
Limonta, 2008). Microvascular endothelial cells cultured with sera from acute 
dengue infection patients containing high TNF-𝛼 levels exhibited activation and 
apoptosis, a pathophysiological alteration likely related to vascular leakage (Sierra 
et al., 2010). 
Currently available epidemiological studies on the DM/DHF, DSS association do 
not provide sufficient clinical details to specifically address this “cytokine overload” 
hypothesis. For example, the Brazilian study explicitly stated that it did not look into 
ascites or pleural effusion, as these were very rarely recorded (Figueiredo et al., 
2010). The other studies did not mention plasma leakage such as pleural effusion 
or ascites except for the Taiwan study, where 51% of 164 DHF cases showed 
evidence of pleural effusion in X- ray and 31% of DHF cases had ascites in 
ultrasound (Min-Sheng Lee, 2006). Future studies thus need to specifically address 
the issue of plasma leakage in the overlap between severe dengue and DM. 
Clinical reporting of the presence of pleural effusion and ascites as signs of severe 
plasma leakage is essential, as hemoconcentration and shock symptoms in the 
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absence of plasma leakage can also arise from poorly controlled DM. The direct 
hypovolemic effect of hyperglycemia and the associated elevated hematocrit may 
even lead to misclassification of diabetics as DHF in the absence of objective 
evidence of plasma leakage. While recognition of hemoconcentration irrespecitive 
of its reason is of primary clinical importance for the provision of appropriate fluid 
therapy, currently available studies on the DM and DHF/DSS association do not 
provide sufficient clinical details to differentiate between effects of DM vs. 
DHF/DSS.   
The potential role of altered innate immunity in mediating the association between 
DM and a severe clinical presentation of dengue obtains indirect support by 
observations that the latter may also have a higher prevalence of asthma and 
allergies. Patients with asthma and allergy also exhibit altered Th1 and Th2 
responses (Figueiredo et al., 2010, Mahmood et al., 2013). But in DM, factors 
beyond the altered cytokine profile may additionally put people at risk. Diabetic 
patients express high rates of hypertension and impaired renal function which are 
both themselves associated with endothelial dysfunction (Dharmashankar and 
Widlansky, 2010, Lin et al., 2010). Hypertension was also observed to be more 
common in patients with dengue (Figueiredo et al., 2010, Mahmood et al., 2013, 
Pang et al., 2012, Karunakaran et al., 2014, Lye et al., 2010), but often exhibited 
no independent effect in regression models adjusting for diabetes (Mahmood et al., 
2013, Pang et al., 2012). Pang and colleagues (2012) reported a higher risk for a 
severe clinical presentation of dengue in hypertensive when compared to non-
hypertensive diabetic patients (Pang et al., 2012).  
 
 
 
 
Conclusion 
Understanding factors increasing the likelihood of dengue patients with severe 
clinical symptoms would help the physician to decide in a timely fashion on the 
need for close observation, adequate treatment, or hospitalization. The available 
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evidence points to DM as a potentially important co-factor. Additional prospective 
studies among DM and non-DM patients are needed to assess the impact of pre-
existing DM as well as of hyperglycemia at the time of dengue diagnosis on the 
risk of a severe clinical presentation of dengue and of related deaths. Even in the 
absence of causal inference, it seems justified that fever episodes in patients with 
DM and living in a dengue endemic region are confirmed for dengue as soon as 
possible and that they remain under close surveillance if an acute dengue infection 
is confirmed. Future studies need to also address whether better control of 
glycemia level in dengue patients with DM can improve the outcome of the patient 
and decrease the risk of a severe clinical presentation. As the fluid management 
in diabetic patients with a severe clinical presentation of dengue poses a particular 
challenge, this issue should be taken into consideration by these studies. Diabetic 
patients in dengue endemic regions should consistently receive recommendations 
to protect against dengue infection by taking preventive measures against indoor 
mosquito breeding and against mosquito bites.  
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